b'<?xml version="1.0" encoding="utf-8"?>\n<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">\n<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">\n    \n    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />\n        <!-- AppResources meta begin -->\n        <script type="text/javascript">var ncbi_startTime = new Date();</script>\n        <!-- AppResources meta end -->\n        \n        <!-- TemplateResources meta begin -->\n        <meta name="paf_template" content="" />\n\n        <!-- TemplateResources meta end -->\n        \n        <!-- Logger begin -->\n        <meta name="ncbi_db" content="pmc" /><meta name="ncbi_pdid" content="article" /><meta name="ncbi_acc" content="" /><meta name="ncbi_domain" content="jbb" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/articles/PMC2846346/" /><meta name="ncbi_app" content="pmc" />\n        <!-- Logger end -->\n        \n        <title>DNA Vaccines: Developing New Strategies against Cancer</title>\n        \n        <!-- AppResources external_resources begin -->\n        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>\n\n        <!-- AppResources external_resources end -->\n        \n        <!-- Page meta begin -->\n        <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2846346/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="citation_journal_title" content="Journal of Biomedicine and Biotechnology" /><meta name="citation_title" content="DNA Vaccines: Developing New Strategies against Cancer" /><meta name="citation_authors" content="Daniela Fioretti, Sandra Iurescia, Vito Michele Fazio, Monica Rinaldi" /><meta name="citation_date" content="2010" /><meta name="citation_volume" content="2010" /><meta name="citation_doi" content="10.1155/2010/174378" /><meta name="citation_abstract_html_url" content="/pmc/articles/PMC2846346/?report=abstract" /><meta name="citation_pmid" content="20368780" /><meta name="DC.Title" content="DNA Vaccines: Developing New Strategies against Cancer" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="Hindawi Limited" /><meta name="DC.Contributor" content="Daniela Fioretti" /><meta name="DC.Contributor" content="Sandra Iurescia" /><meta name="DC.Contributor" content="Vito Michele Fazio" /><meta name="DC.Contributor" content="Monica Rinaldi" /><meta name="DC.Date" content="2010" /><meta name="DC.Identifier" content="10.1155/2010/174378" /><meta name="DC.Language" content="en" /><meta property="og:title" content="DNA Vaccines: Developing New Strategies against Cancer" /><meta property="og:type" content="article" /><meta property="og:description" content="Due to their rapid and widespread development, DNA vaccines have entered into a variety of human clinical trials for vaccines against various diseases including cancer. Evidence that DNA vaccines are well tolerated and have an excellent safety profile ..." /><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2846346/" /><meta property="og:site_name" content="PubMed Central (PMC)" /><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbi" /><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc_extras_prnt.min.css" type="text/css" media="print" /><script type="text/javascript" src="/corehtml/pmc/js/common.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js">//</script><meta name="citationexporter" content="backend:\'https://api.ncbi.nlm.nih.gov/lit/ctxp/v1/pmc/\'" /><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/jquery.citationexporter.min.js">//</script><link rel="stylesheet" href="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/citationexporter.css" type="text/css" /><script type="text/javascript">window.name="mainwindow";</script><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-jbb.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style><style type="text/css">\n        div.pmc_para_cit li.highlight,\n        div.pmc_para_cit li.highlight .one_line_source\n        { background: #E0E0E0; }\n        a.bibr.highlight { background: #E0E0E0; } \n      </style><meta name="cited_in_systematic_reviews" content="" /><link rel="alternate" type="application/epub+zip" href="/pmc/articles/PMC2846346/epub/" /><link rel="alternate" type="application/pdf" href="/pmc/articles/PMC2846346/pdf/JBB2010-174378.pdf" />\n\n        <!-- Page meta end -->\n    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="8A1A129CE9A405F10000000004F604F1.m_8" />\n<meta name=\'referrer\' content=\'origin-when-cross-origin\'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4048120/3846471/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4128070/9685/3549676/3609192/3609193/3609213/3395586/4143404.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3411343/3882866/4157116.css" media="print" /></head>\n    <body class="article">\n        <div class="grid">\n            <div class="col twelve_col nomargin shadow">\n                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->\n                <div class="sysmessages">\n                    <noscript>\n\t<p class="nojs">\n\t<strong>Warning:</strong>\n\tThe NCBI web site requires JavaScript to function. \n\t<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>\n\t</p>\n\t</noscript>\n                </div>\n                <!--/.sysmessage-->\n                <div class="wrap">\n                    <div class="page">\n                        <div class="top">\n                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main\n                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to\n                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>\n                            <div class="header">\n    <div class="res_logo">\n  <h1 class="img_logo"><a href="/pmc/" class="pmc_logo offscreen">PMC</a></h1>\n  <div class="NLMLogo">\n    <a href="https://www.nlm.nih.gov/" title="US National Library of Medicine">US National Library of Medicine</a>\n    <br />\n    <a href="https://www.nih.gov/" title="National Institutes of Health">National Institutes of Health</a>\n  </div>\n</div>\n    <div class="search"><form method="get" action="/pmc/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="pmc" selected="selected" class="last" data-ac_dict="pmc-search-autocomplete">PMC</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search PMC. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:\'pmc-search-autocomplete\',disableUrl:\'NcbiSearchBarAutoComplCtrl\'" autocomplete="off" data-sbconfig="ds:\'no\',pjs:\'no\',afs:\'yes\'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>\n                        <a href="/pmc/advanced/">Advanced</a>\n                    </li><li>\n                        <a href="/pmc/journals/">Journal list</a>\n                    </li><li class="help">\n                        <a target="_blank" href="/books/NBK3825/">Help</a>\n                    </li></ul></div>\n</div>\n\n                            \n                            \n                        <!--<component id="Page" label="headcontent"/>-->\n                            \n                        </div>\n                        <div class="content">\n                            <!-- site messages -->\n                            <div class="container">\n    <div id="maincontent" class="content eight_col col">\n        <div class="navlink-box">\n            <ul class="page-breadcrumbs inline_list small"><li class="journal-list"><a href="/pmc/journals/" class="navlink">Journal List</a></li><li class="archive"><a class="navlink" href="/pmc/journals/94/">J Biomed Biotechnol</a></li><li class="issue-page"><a class="navlink" href="/pmc/issues/181617/">v.2010; 2010</a></li><li class="accid">PMC2846346</li></ul>\n        </div>\n\n        <!-- Journal banner -->\n        <div class="pmc-page-banner whole_rhythm"><div><img src="/corehtml/pmc/pmcgifs/logo-jbb.gif" alt="Logo of jbb" usemap="#logo-imagemap" /><map id="logo-imagemap" name="logo-imagemap"><area shape="rect" coords="0,0,500,57" alt="Journal\'s Home" title="Journal\'s Home" href="http://www.hindawi.com/journals/jbb/" ref="reftype=publisher&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext" /><area shape="rect" coords="370,58,500,75" alt="Manuscript Submission" title="Manuscript Submission" href="http://mts.hindawi.com" ref="reftype=publisher&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext" /><area shape="rect" coords="264,58,369,75" alt="Aims and Scope" title="Aims and Scope" href="http://www.hindawi.com/journals/jbb/aims.html" ref="reftype=publisher&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext" /><area shape="rect" coords="148,58,263,75" alt="Author Guidelines" title="Author Guidelines" href="http://www.hindawi.com/journals/jbb/guidelines.html" ref="reftype=publisher&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext" /><area shape="rect" coords="49,58,147,75" alt="Editorial Board" title="Editorial Board" href="http://www.hindawi.com/journals/jbb/editors.html" ref="reftype=publisher&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext" /><area shape="rect" coords="0,58,48,75" alt="Home" title="Home" href="http://www.hindawi.com/journals/jbb/" ref="reftype=publisher&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext" /></map></div> </div>\n        \n        <!--component id=\'MainPortlet\' label=\'search-reference\'/-->\n        \n        <!-- Book content -->\n        <div class="">\n            \n        \n            \n            <div class="hide-overflow article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: [\'h2\'], headingExclude: \':hidden\'"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-citation half_rhythm no_top_margin clearfix"><div class="inline_block eight_col va_top"><div><div><span class="cit"><span id="pmcmata">J Biomed Biotechnol</span>. 2010; 2010: 174378. </span></div><div><span class="fm-vol-iss-date">Published online 2010 Mar 28. </span>  <span class="doi">doi:\xc2\xa0<a href="//dx.doi.org/10.1155%2F2010%2F174378" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1155/2010/174378</a></span></div></div></div><div class="inline_block four_col va_top show-overflow align_right"><div class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC2846346</span></div><div class="fm-citation-pmid">PMID: <a href="/pubmed/20368780">20368780</a></div></div></div></div><h1 class="content-title">DNA Vaccines: Developing New Strategies against Cancer</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="/pubmed/?term=Fioretti%20D%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20368780" class="affpopup" co-rid="_co_idm139857071638912" co-class="co-affbox">Daniela Fioretti</a>,<sup>1</sup> <a href="/pubmed/?term=Iurescia%20S%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20368780" class="affpopup" co-rid="_co_idm139857075802512" co-class="co-affbox">Sandra Iurescia</a>,<sup>1</sup> <a href="/pubmed/?term=Fazio%20VM%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20368780" class="affpopup" co-rid="_co_idm139857077389664" co-class="co-affbox">Vito Michele Fazio</a>,<sup>2, 3</sup><sup></sup> and  <a href="/pubmed/?term=Rinaldi%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20368780" class="affpopup" co-rid="_co_idm139857071634656" co-class="co-affbox">Monica Rinaldi</a><sup>1,</sup><sup>*</sup></div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm139857071638912"><h3 class="no_margin">Daniela Fioretti</h3><p><sup>1</sup>Institute of Neurobiology and Molecular Medicine, Department of Medicine, National Research Council (CNR), Via Fosso del Cavaliere 100, 00133 Rome, Italy</p><div>Find articles by <a href="/pubmed/?term=Fioretti%20D%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20368780">Daniela Fioretti</a></div></div><div id="_co_idm139857075802512"><h3 class="no_margin">Sandra Iurescia</h3><p><sup>1</sup>Institute of Neurobiology and Molecular Medicine, Department of Medicine, National Research Council (CNR), Via Fosso del Cavaliere 100, 00133 Rome, Italy</p><div>Find articles by <a href="/pubmed/?term=Iurescia%20S%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20368780">Sandra Iurescia</a></div></div><div id="_co_idm139857077389664"><h3 class="no_margin">Vito Michele Fazio</h3><p><sup>2</sup>Section of Molecular Medicine and Biotechnology, Interdisciplinary Center for Biomedical Research, University Campus Bio-Medico, Via &#x000c1;lvaro del Portillo 21, 00128 Rome, Italy</p><p><sup>3</sup>Unit&#x000e0; Operativa Oncologia, Istituto di Ricovero e Cura a Carattere Scientifico Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, Foggia, Italy</p><div>Find articles by <a href="/pubmed/?term=Fazio%20VM%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20368780">Vito Michele Fazio</a></div></div><div id="_co_idm139857071634656"><h3 class="no_margin">Monica Rinaldi</h3><p><sup>1</sup>Institute of Neurobiology and Molecular Medicine, Department of Medicine, National Research Council (CNR), Via Fosso del Cavaliere 100, 00133 Rome, Italy</p><div>Find articles by <a href="/pubmed/?term=Rinaldi%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20368780">Monica Rinaldi</a></div></div></div></div><div class="fm-panel half_rhythm"><div class="togglers"><a href="#" class="pmctoggle" rid="idm139857077411952_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm139857077411952_an">Article notes</a> <a href="#" class="pmctoggle" rid="idm139857077411952_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/">Disclaimer</a></div><div class="fm-authors-info fm-panel hide half_rhythm" id="idm139857077411952_ai" style="display:none"><div class="fm-affl" lang="en" id="I1"><sup>1</sup>Institute of Neurobiology and Molecular Medicine, Department of Medicine, National Research Council (CNR), Via Fosso del Cavaliere 100, 00133 Rome, Italy</div><div class="fm-affl" lang="en" id="I2"><sup>2</sup>Section of Molecular Medicine and Biotechnology, Interdisciplinary Center for Biomedical Research, University Campus Bio-Medico, Via &#x000c1;lvaro del Portillo 21, 00128 Rome, Italy</div><div class="fm-affl" lang="en" id="I3"><sup>3</sup>Unit&#x000e0; Operativa Oncologia, Istituto di Ricovero e Cura a Carattere Scientifico Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, Foggia, Italy</div><div id="cor1">*Monica Rinaldi: <a href="mailto:dev@null" data-email="ti.rnc.mmni.votra@idlanir.acinom" class="oemail">ti.rnc.mmni.votra@idlanir.acinom</a></div><div id="idm139857078115456">Academic Editor: Soldano Ferrone</div></div><div class="fm-article-notes fm-panel hide half_rhythm" id="idm139857077411952_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2009 Nov 20; Accepted 2010 Feb 5.</div></div><div class="permissions fm-panel half_rhythm hide" id="idm139857077411952_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright</a>  &#x000a9; 2010 Daniela Fioretti et al.</div><div class="license half_rhythm">This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</div></div></div><div id="pmclinksbox" class="links-box whole_rhythm"><div class="fm-panel"><div>This article has been <a href="/pmc/articles/PMC2846346/citedby/">cited by</a> other articles in PMC.</div></div></div></div><div class="sec"></div><div id="idm139857113524160" lang="en" class="tsec sec"><h2 class="head no_bottom_margin" id="idm139857113524160title">Abstract</h2><!--article-meta--><div><p id="__p2" class="p p-first-last">Due to their rapid and widespread development, DNA vaccines have entered into a variety of human clinical trials for vaccines against various diseases including cancer. Evidence that DNA vaccines are well tolerated and have an excellent safety profile proved to be of advantage as many clinical trials combines the first phase with the second, saving both time and money. It is clear from the results obtained in clinical trials that such DNA vaccines require much improvement in antigen expression and delivery methods to make them sufficiently effective in the clinic. Similarly, it is clear that additional strategies are required to activate effective immunity against poorly immunogenic tumor antigens. Engineering vaccine design for manipulating antigen presentation and processing pathways is one of the most important aspects that can be easily handled in the DNA vaccine technology. Several approaches have been investigated including DNA vaccine engineering, co-delivery of immunomodulatory molecules, safe routes of administration, prime-boost regimen and strategies to break the immunosuppressive networks mechanisms adopted by malignant cells to prevent immune cell function. Combined or single strategies to enhance the efficacy and immunogenicity of DNA vaccines are applied in completed and ongoing clinical trials, where the safety and tolerability of the DNA platform are substantiated. \nIn this review on DNA vaccines, salient aspects on this topic going from basic research to the clinic are evaluated. Some representative DNA cancer vaccine studies are also discussed.</p></div></div><div id="sec1" class="tsec sec"><h2 class="head no_bottom_margin" id="sec1title">1. Introduction</h2><p id="__p3" class="p p-first">Spontaneous tumour regression has followed bacterial, fungal, viral, and protozoal infections. Intratumoral infections may reactivate defensive functions, causing tumour regression.</p><p id="__p4">These phenomena inspired the development of numerous rudimentary cancer immunotherapies, starting with nonspecific immunostimulatory approaches first used by William Coley [<a href="#B1" rid="B1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872864">1</a>] and leading to the concept of therapeutic vaccination against cancer. The recent identification and characterization of genes coding for tumour antigens (Ag) has enabled the design of antigen-specific cancer vaccines based on plasmid DNA and recombinant viral vectors. Gene therapy can be used to manipulate the immune system to help body\'s natural defences to recognise and target cancer cells.</p><p id="__p5">In the last few years, it is estimated that in Europe there were almost 3&#x02009;000&#x02009;000 cancer cases diagnosed (excluding non melanoma skin cancers) and more than 1&#x02009;500&#x02009;000 deaths from cancer each year [<a href="#B2" rid="B2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872870">2</a>]. Standard therapeutic procedures currently in practice, including surgery, radiation, and chemotherapy have not greatly impacted the spread and recurrence of progressive malignancies [<a href="#B3" rid="B3" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872839">3</a>], reducing the ability of the immune system to provoke &#x0201c;spontaneous&#x0201d; regressions. Newer strategies are needed to improve upon the current treatment success rate.</p><p id="__p6">Historically, Wolff and colleagues [<a href="#B4" rid="B4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872759">4</a>] first demonstrated that long-term gene expression in mouse skeletal muscle could be achieved with direct intramuscular injection of plasmid DNA. This and other early studies, demonstrating the feasibility of direct intramuscular gene transfer for DNA vaccination purpose, propelled the first vaccination studies utilizing plasmid DNA in protection scenarios involving influenza    [<a href="#B5" rid="B5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872791">5</a>] and HIV-1    [<a href="#B6" rid="B6" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872807">6</a>]. Cellular and humoral immune responses have been demonstrated after the injection of naked plasmid DNA vaccines into the dermis or muscle tissue of mice    [<a href="#B5" rid="B5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872739">5</a>, <a href="#B7" rid="B7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872755">7</a>]. Such responses have induced protection in preclinical models of infectious disease and malignancies (for review, see Donnelly et al.    [<a href="#B8" rid="B8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_321350097">8</a>]).</p><p id="__p7">The DNA vaccine is a prime example of a modern genetic vaccine. The use of naked plasmid DNA as vaccine to elicit the immune system against disease provides a variety of practical benefits for large-scale vaccine production that are not as easily manageable with other forms of vaccines including recombinant protein or whole tumor cells    [<a href="#B9" rid="B9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872776">9</a>, <a href="#B10" rid="B10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872782">10</a>]. </p><p id="__p8">The effectiveness to screen for antigens rapidly and to design specific types of expression constructs has made the study of DNA vaccines a valuable field for immunotherapy of cancer.</p><p id="__p9">New technologies including gene-expression profiling has increased the list of candidate tumor antigens. Investigators have focused on targets which are either tumour-specific, including idiotypic antigens of B-cell tumours [<a href="#B11" rid="B11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872826">11</a>] or tumour-associated antigens    [<a href="#B12" rid="B12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872853">12</a>] that are also expressed by the normal cell of origin [<a href="#B13" rid="B13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872873">13</a>] and that include the so-called cancer-testis antigens [<a href="#B14" rid="B14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872846">14</a>].</p><p id="__p10">Examples under intensive investigation are the antigens of melanoma (<a href="http://www.cancer.gov/cancertopics/types/melanoma" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">http://www.cancer.gov/cancertopics/types/melanoma</a>), prostate cancer (<a href="http://www.cancer.gov/cancertopics/types/prostate" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">http://www.cancer.gov/cancertopics/types/prostate</a>), and other epithelial cancers (<a href="http://www.cancer.gov/cancertopics/types/skin" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">http://www.cancer.gov/cancertopics/types/skin</a>).</p><p id="__p11">DNA vaccines offer the opportunity to incorporate additional genes encoding molecules aimed at overcoming the weak immunogenicity of tumor antigens and the patients\' tolerized immune repertoire. </p><p id="__p12" class="p p-last">This paper briefly summarizes findings and key technologies that have contributed to the rapid progress of DNA vaccines (mode of action, design, and optimization of DNA vaccines) as well as the state of the art of some of the more encouraging clinical studies using or against tumor antigens.</p></div><div id="sec2" class="tsec sec"><h2 class="head no_bottom_margin" id="sec2title">2. Cancer Antigens</h2><p id="__p13" class="p p-first">Scientists have identified a large number of cancer-associated antigens, many of which are now being used to perform cancer treatment vaccines both in basic research and in clinical trials. The list of candidate tumor antigens grows daily, largely because of expanding genetic technology including human genome sequencing and gene-expression profiling. Tumor antigens have been classified into two broad categories: tumor-specific shared antigens and tumor-specific unique antigens [<a href="#B15" rid="B15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872852">15</a>]. Shared antigens or tumor-associated antigens (TAAs) are expressed by more than one type of tumor cells. A number of TAA are also expressed on normal tissues, albeit in different amounts. As reported in the official National Cancer Institute website (NCI, <a href="http://www.cancer.gov/" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">http://www.cancer.gov/</a>), representative examples of such shared antigens are the cancer-testis antigens [<a href="#B14" rid="B14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872787">14</a>], human epidermal growth factor receptor 2 (HER2)/neu protein (reviewed in [<a href="#B16" rid="B16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872734">16</a>]), and carcinoembryonic antigen (CEA) [<a href="#B17" rid="B17" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872840">17</a>]. Unique tumor antigens result from mutations induced through physical or chemical carcinogens; they are therefore expressed only by individual tumors. Tumor-specific unique antigens encompass melanocyte/melanoma differentiation antigens, such as tyrosinase [<a href="#B18" rid="B18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872817">18</a>], MART1    [<a href="#B19" rid="B19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872838">19</a>] and gp100    [<a href="#B20" rid="B20" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872815">20</a>], prostate-specific antigen (PSA) (reviewed in    [<a href="#B21" rid="B21" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872834">21</a>]) and Idiotype (Id) antibodies [<a href="#B11" rid="B11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872878">11</a>]. Optimally designed cancer vaccines should combine the best tumor antigens with the most effective immunotherapy agents and delivery strategies to achieve positive clinical results. An important dilemma for vaccination against overexpressed tumor-associated antigens is how to induce effective immunity against the chosen target without leading to damaging autoimmunity. The precision offered by DNA vaccines will induce focused immunity against selected antigens, and, as they become more powerful, targets will have to be selected carefully to avoid autoimmunity. Recently, an NCI pilot prioritization study produced a well-vetted, priority-ranked list of cancer antigens [<a href="#B22" rid="B22" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_668105731">22</a>]. Antigen prioritization involved developing a list of &#x0201c;ideal&#x0201d; cancer antigen criteria/characteristics and assigning relative weights to those criteria using pairwise comparisons. The result of criteria weighting was as follows: (a) therapeutic function, (b) immunogenicity, (c) role of the antigen in oncogenicity, (d) specificity, (e) expression level and percent of antigen-positive cells, (f) stem cell expression, (g) number of patients with antigen-positive cancers, (h) number of antigenic epitopes, and (i) cellular location of antigen expression [<a href="#B22" rid="B22" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_668105732">22</a>]. Such an effort to prioritize cancer antigens represents the logical next step in attempting to focus translational efforts on cancer vaccine regimens with the highest potential for success. </p><p id="__p14" class="p p-last">A biological issue limiting the efficacy of cancer vaccines is the low immunogenicity of cancer antigens. Strategies to enhance antigen immunogenicity are discussed in a later section.</p></div><div id="sec3" class="tsec sec"><h2 class="head no_bottom_margin" id="sec3title">3. Priming the Immune System</h2><p id="__p15" class="p p-first">DNA vaccines are simple vehicles for in vivo transfection and antigen production. A DNA vaccine is composed of a plasmid DNA that encodes the antigen of interest under the control of a mammalian promoter (i.e., CMV-intA, CMV immediate/early promoter, and its adjacent intron A sequence) and can be easily produced in the bacteria [<a href="#B23" rid="B23" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872777">23</a>].</p><p id="__p16">The optimized gene sequence of interest is delivered to the skin (intradermally), subcutaneum or to the muscle by one of several delivery methods. Using the host cellular machinery, the plasmid enters the nucleus of transfected local cells (such as myocytes or keratinocytes), including resident antigen presenting cells (APCs). Here, gene expression from plasmid is followed by generation of foreign antigens. Although the elucidation of all immunological components involved following DNA immunization has not been entirely achieved, the mode of action of plasmid DNA vaccines appears twofold. DNA plasmids, which are derived from bacteria, stimulate the innate immune system by interacting with Toll-like receptor 9 (TLR9) [<a href="#B24" rid="B24" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872785">24</a>]), a receptor found on APCs, although the differential expression of TLR9 in mice and primate immune cells makes more complex their role as adjuvants in primates. This nonspecific immune response augments the antigen-specific immune response, where the direct and indirect presentations of antigen to APCs are involved. Two overarching models have been proposed. The antigen encoded by the plasmid is produced in host cells, either in professional APCs leading to direct priming of immune responses or in nonprofessional cells from where the antigen can be transferred to APCs leading to cross-priming.</p><p id="__p17">A series of studies intended to determine how such vaccines could work investigated the source of Ag presentation, the immunological properties of the DNA itself, and the role of cytokines in eliciting the immune responses. </p><p id="__p18">Early studies showed that DNA delivery method affected the cell types that were transfected. Gene Gun (bombardment of the epidermis with plasmid coated onto gold microbeads) tended to directly transfect epidermal keratinocytes and also Langerhans cells, which were shown to migrate rapidly to regional lymph nodes    [<a href="#B25" rid="B25" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872794">25</a>]. In this case, professional APCs were transfected directly and behave as the source of Ag presentation.</p><p id="__p19">Alternatively, intramuscular injection of plasmid predominantly led to transfection of myocytes. Myocytes lack expression of major histocompatibility complex class (MHC) II and costimulatory molecules and thus would not be expected to prime T lymphocytes directly. Instead, immune priming likely occurs by dendritic cells (DCs)    [<a href="#B26" rid="B26" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872733">26</a>, <a href="#B27" rid="B27" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_321350100">27</a>] that presumably migrate to the site of DNA inoculation in response to inflammatory or chemotactic signals following vaccination    [<a href="#B28" rid="B28" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_321350104">28</a>, <a href="#B29" rid="B29" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_321350125">29</a>]. These DCs are thought to present antigen by cross-presentation of extracellular antigen or following direct transfection of plasmid DNA    [<a href="#B26" rid="B26" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872875">26</a>, <a href="#B30" rid="B30" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_321350098">30</a>].</p><p id="__p20">Thus, in terms of induction of immunity, there is an influence of the site and procedure used for injection, with muscle and skin cells clearly able to act as antigen depots but unable to prime the immune response. It is likely that cross-presentation from these sites to APCs is the major route to priming    [<a href="#B26" rid="B26" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872752">26</a>], but there is also evidence for direct transfection of APCs, especially when delivery is to skin sites through a gene gun    [<a href="#B25" rid="B25" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872796">25</a>]. The host-synthesized antigen is then processed and presented by APCs in the context of both MHC I and MHC II.</p><p id="__p21">Antigen-loaded APCs travel to the draining lymph nodes, where they present peptide antigens to na&#x000ef;ve T cells, thereby eliciting both humoral and cellular immune responses. Although plasmid DNA vaccines vectors can induce antibody and CD4<sup>+</sup>&#x02009;&#x02009;T cell helper responses, they are particularly suited to induce CD8<sup>+</sup>&#x02009;&#x02009;T cell responses because they express antigens intracellularly, introducing them directly into the MHC I antigen processing and presentation pathway [<a href="#B31" rid="B31" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872810">31</a>].</p><p id="__p22">Whatever, the process that conveys antigens to the APC seems highly efficient since DNA vaccines, that produce only very low levels of antigen, can induce all arms of the immune response [<a href="#B32" rid="B32" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_321350112">32</a>].</p><p id="__p23" class="p p-last"> One lesson learned in the last years is that the development of plasmid DNA as cancer vaccine raises key issues such as the need to break immunological tolerance, gradual loss of MHC and antigen in tumour cells, regulatory T cells that could negatively influence the induction of antitumour responses, systemic defects in dendritic cells, secretion of immunosuppressive cytokines, resistance to apoptosis    [<a href="#B33" rid="B33" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872822">33</a>, <a href="#B34" rid="B34" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872857">34</a>] as is discussed elsewhere.</p></div><div id="sec4" class="tsec sec"><h2 class="head no_bottom_margin" id="sec4title">4. Advantages and Disadvantages of DNA Vaccines</h2><p id="__p24" class="p p-first">The use of DNA vectors represents an important platform for clinical applications, in which large-scale vaccine production is not easily manageable with other forms of vaccine including recombinant protein, whole tumor cells, or viral vectors [<a href="#B35" rid="B35" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872798">35</a>].</p><p id="__p25">Although viral mediated gene transfer by genetically modified lentiviruses, adenoviruses, adeno-associated viruses, and retroviruses is advantageous because of its high transfection efficiency and stability [<a href="#B36" rid="B36" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872836">36</a>], the largest hurdles using viral vectors are to overcome the immunogenicity of the viral packaging proteins. Furthermore, viral methods are disadvantageous because of their high expense, toxic side effects, limits on transgene size, and potential for insertional mutagenesis    [<a href="#B37" rid="B37" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872856">37</a>].</p><p id="__p26">On the one hand, nonviral vectors are highly flexible, are capable of encoding a number of immunological components, are associated with a lower cytotoxicity, are relatively more stable, and are potentially more cost-effective for manufacture and storage (<a href="/pmc/articles/PMC2846346/table/tab1/" target="table" class="fig-table-link figpopup" rid-figpopup="tab1" rid-ob="ob-tab1" co-legend-rid=""><span>Table 1</span></a>).</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="tab1"><h3>Table 1</h3><!--caption a7--><div class="caption"><p id="__p103">DNA vaccines main features.</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139857113860320" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th align="left" rowspan="1" colspan="1"></th><th align="left" rowspan="1" colspan="1">Advantage</th><th align="center" rowspan="1" colspan="1">Drawback</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><em>Design</em></td><td align="left" rowspan="1" colspan="1">Allowing the introduction of several immunological components; synthetic and PCR methods for simple modifications</td><td align="center" rowspan="1" colspan="1">Low transfection efficiency</td></tr><tr><td align="center" colspan="3" rowspan="1"><hr /></td></tr><tr><td align="left" rowspan="1" colspan="1"><em>Manufacture</em></td><td align="left" rowspan="1" colspan="1">Rapid production and formulation; easily engineered, reproducible, large-scale production and isolation</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="center" colspan="3" rowspan="1"><hr /></td></tr><tr><td align="left" rowspan="1" colspan="1"><em>Safety</em></td><td align="left" rowspan="1" colspan="1">No pathogenic infection in vivo; no significant adverse events in any clinical trial; neutralizing immune responses rarely observed; boost strategy is possible</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="center" colspan="3" rowspan="1"><hr /></td></tr><tr><td align="left" rowspan="1" colspan="1"><em>Stability</em></td><td align="left" rowspan="1" colspan="1">Long shelf life; relative temperature insensitivity; lack necessity of a cold chain stored on a large scale</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="center" colspan="3" rowspan="1"><hr /></td></tr><tr><td align="left" rowspan="1" colspan="1"><em>Immunogenicity</em></td><td align="left" rowspan="1" colspan="1"> &#x02003;</td><td align="center" rowspan="1" colspan="1">Lower immunogeni-city in larger animals and human compared to mice</td></tr></tbody></table></div><div id="largeobj_idm139857113860320" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2846346/table/tab1/?report=objectonly">Open in a separate window</a></div></div><p id="__p27">Their safety in terms of adverse reactions after injection has been demonstrated in animal models    [<a href="#B38" rid="B38" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872867">38</a>, <a href="#B39" rid="B39" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872850">39</a>] as well as in human clinical trials.</p><p id="__p28">The first clinical trail, initiated to monitor the safety and efficacy of a DNA vaccine against HIV-1 infection    [<a href="#B40" rid="B40" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872854">40</a>], demonstrated that  DNA plasmid vaccines were safe and were capable of inducing detectable immune cellular and antibody responses    [<a href="#B40" rid="B40" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872757">40</a>&#x02013;<a href="#B42" rid="B42" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872829">42</a>].</p><p id="__p29">The simple plasmid backbone coupled with the technology of gene manipulation allows incorporation of genes, which are then expressed by cells transfected in vivo. Although the transfection process is inefficient and varies with the target tissue and means of delivery, sufficient DNA is generally taken up to prime the immune response [<a href="#B32" rid="B32" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_321350120">32</a>].</p><p id="__p30">DNA vaccines are free of the problems associated with producing recombinant protein vaccines, and they are also safer than live attenuated which can cause pathogenic infection in vivo. Additionally, studies with DNA vaccines have shown that even after multiple immunizations, anti-DNA antibodies are not produced [<a href="#B43" rid="B43" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872869">43</a>].</p><p id="__p31">The ability to introduce antigen to the host immune system, thus enabling it to elicit strong Th1 type CD4<sup>+</sup> T cells and CD8<sup>+</sup> cytotoxic T cells, is a unique feature of DNA vaccines which makes them distinct from conventional protein or peptide vaccines. Because of this feature, they can readily induce humoral as well cellular immune responses [<a href="#B44" rid="B44" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_848523567">44</a>].</p><p id="__p32" class="p p-last">Plasmid-based gene transfer can also deliver oligonucleotides that can alter gene splicing or gene expression, for example, siRNA    [<a href="#B35" rid="B35" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872865">35</a>, <a href="#B45" rid="B45" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872830">45</a>].</p></div><div id="sec5" class="tsec sec"><h2 class="head no_bottom_margin" id="sec5title">5. Enhancing Efficacy and Immunogenicity of DNA Vaccines</h2><p id="__p33" class="p p-first">Despite immunogenicity of DNA vaccines has been well established in animal models, low immunogenicity has been the major deterrent towards the development of DNA vaccines in large animal models and human. In order to overcome this hurdle, several approaches have been investigated including plasmid design, immunomodulatory molecules, delivery techniques, and prime-boost strategy (<a href="/pmc/articles/PMC2846346/table/tab2/" target="table" class="fig-table-link figpopup" rid-figpopup="tab2" rid-ob="ob-tab2" co-legend-rid=""><span>Table 2</span></a>).</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="tab2"><h3>Table 2</h3><!--caption a7--><div class="caption"><p id="__p104">DNA Vaccine Enhancing Strategies.</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139857076070800" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th align="left" rowspan="1" colspan="1">Strategy</th><th align="left" rowspan="1" colspan="1"><em>Approach</em></th><th align="left" rowspan="1" colspan="1"><em>Indication</em></th><th align="center" rowspan="1" colspan="1"><em>References</em></th></tr></thead><tbody><tr><td align="left" rowspan="7" colspan="1">Routes of administration</td><td align="left" rowspan="1" colspan="1">intramuscular/EP</td><td align="left" rowspan="1" colspan="1">prostate cancer; B-cell lymphoma</td><td align="center" rowspan="1" colspan="1">   [<a href="#B46" rid="B46" class=" bibr popnode">46</a>&#x02013;<a href="#B48" rid="B48" class=" bibr popnode">48</a>]</td></tr><tr><td align="left" rowspan="1" colspan="1">intradermal/EP</td><td align="left" rowspan="1" colspan="1">prostate cancer; colon cancer</td><td align="center" rowspan="1" colspan="1">   [<a href="#B49" rid="B49" class=" bibr popnode">49</a>, <a href="#B50" rid="B50" class=" bibr popnode">50</a>]</td></tr><tr><td align="left" rowspan="1" colspan="1">gene gun</td><td align="left" rowspan="1" colspan="1">cervical cancer</td><td align="center" rowspan="1" colspan="1">   [<a href="#B51" rid="B51" class=" bibr popnode">51</a>, <a href="#B52" rid="B52" class=" bibr popnode">52</a>]</td></tr><tr><td align="left" rowspan="1" colspan="1">tattoo perforating needle</td><td align="left" rowspan="1" colspan="1">melanoma</td><td align="center" rowspan="1" colspan="1">[<a href="#B53" rid="B53" class=" bibr popnode">53</a>]</td></tr><tr><td align="left" rowspan="1" colspan="1">intratumor</td><td align="left" rowspan="1" colspan="1">melanoma; renal carcinoma</td><td align="center" rowspan="1" colspan="1">   [<a href="#B54" rid="B54" class=" bibr popnode">54</a>, <a href="#B55" rid="B55" class=" bibr popnode">55</a>]</td></tr><tr><td align="left" rowspan="2" colspan="1">high-pressure liquid delivery</td><td align="left" rowspan="1" colspan="1">B-cell lymphoma;</td><td align="center" rowspan="2" colspan="1">   [<a href="#B50" rid="B50" class=" bibr popnode">50</a>, <a href="#B56" rid="B56" class=" bibr popnode">56</a>]</td></tr><tr><td align="left" rowspan="1" colspan="1">colon cancer</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr /></td></tr><tr><td align="left" rowspan="5" colspan="1">Genetic immunomodulators as Adjuvants</td><td align="left" rowspan="1" colspan="1">cytokine</td><td align="left" rowspan="1" colspan="1">liver cancer; prostate cancer; melanoma; B-cell lymphoma</td><td align="center" rowspan="1" colspan="1">   [<a href="#B56" rid="B56" class=" bibr popnode">56</a>&#x02013;<a href="#B62" rid="B62" class=" bibr popnode">62</a>]</td></tr><tr><td align="left" rowspan="1" colspan="1">chemokine</td><td align="left" rowspan="1" colspan="1">B-cell lymphoma</td><td align="center" rowspan="1" colspan="1">[<a href="#B63" rid="B63" class=" bibr popnode">63</a>]</td></tr><tr><td align="left" rowspan="1" colspan="1">T cell helper epitopes</td><td align="left" rowspan="1" colspan="1">prostate cancer;  follicular lymphoma; colon carcinoma</td><td align="center" rowspan="1" colspan="1">   [<a href="#B46" rid="B46" class=" bibr popnode">46</a>, <a href="#B47" rid="B47" class=" bibr popnode">47</a>, <a href="#B64" rid="B64" class=" bibr popnode">64</a>, <a href="#B65" rid="B65" class=" bibr popnode">65</a>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Toll-receptor ligands</td><td align="left" rowspan="1" colspan="1">lung carcinoma</td><td align="center" rowspan="1" colspan="1">   [<a href="#B66" rid="B66" class=" bibr popnode">66</a>]</td></tr><tr><td align="left" rowspan="1" colspan="1">heat shock proteins</td><td align="left" rowspan="1" colspan="1">cervical cancer</td><td align="center" rowspan="1" colspan="1">[<a href="#B67" rid="B67" class=" bibr popnode">67</a>] </td></tr><tr><td align="center" colspan="4" rowspan="1"><hr /></td></tr><tr><td align="left" rowspan="4" colspan="1">Prime-boost strategy</td><td align="left" rowspan="1" colspan="1">plasmid DNA/plasmid DNA+EP</td><td align="left" rowspan="1" colspan="1">prostate cancer; colon cancer</td><td align="center" rowspan="1" colspan="1">   [<a href="#B46" rid="B46" class=" bibr popnode">46</a>, <a href="#B47" rid="B47" class=" bibr popnode">47</a>, <a href="#B50" rid="B50" class=" bibr popnode">50</a>]</td></tr><tr><td align="left" rowspan="1" colspan="1">plasmid DNA/recombinant protein</td><td align="left" rowspan="1" colspan="1">prostate carcinoma; breast cancer</td><td align="center" rowspan="1" colspan="1">   [<a href="#B68" rid="B68" class=" bibr popnode">68</a>] <a id="__tag_544253160" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT00363012" ref="reftype=extlink-clinical-trial&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT00363012","term_id":"NCT00363012"}}</span>NCT00363012</a></td></tr><tr><td align="left" rowspan="1" colspan="1">plasmid DNA/viral vector</td><td align="left" rowspan="1" colspan="1">liver cancer; melanoma; prostate carcinoma</td><td align="center" rowspan="1" colspan="1">   [<a href="#B58" rid="B58" class=" bibr popnode">58</a>, <a href="#B60" rid="B60" class=" bibr popnode">60</a>, <a href="#B69" rid="B69" class=" bibr popnode">69</a>]</td></tr><tr><td align="left" rowspan="1" colspan="1">viral vector/plasmid DNA</td><td align="left" rowspan="1" colspan="1">prostate cancer</td><td align="center" rowspan="1" colspan="1">   [<a href="#B59" rid="B59" class=" bibr popnode">59</a>]</td></tr></tbody></table></div><div id="largeobj_idm139857076070800" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2846346/table/tab2/?report=objectonly">Open in a separate window</a></div></div><div id="sec5.1" class="sec"><h3 id="sec5.1title">5.1. Plasmid Design</h3><p id="__p34" class="p p-first">Early in the development of DNA vaccines, it became clear that maximizing the expression of the encoded Ag was critical to the induction of potent immune responses. Strong viral promoters, such as CMV-intA, are generally favoured over regulated or endogenous eukaryotic promoters [<a href="#B70" rid="B70" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872803">70</a>]. Furthermore nuclear targeting sequence (NTS) could be introduced to increase the efficiency of nuclear plasmid uptake from cytoplasm after intramuscular injection    [<a href="#B48" rid="B48" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872788">48</a>, <a href="#B71" rid="B71" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_500657276">71</a>].</p><p id="__p35">The utilization of codon-optimized sequences instead of the wild-type coding sequences is a general and potent method to improve vaccination. An optimal coding sequence is determined back from the amino acid sequence of the antigen by algorithms that take into account the abundance of specific tRNAs in the cytosol of human cells and the predicted structure of the mRNA. Thereafter the selected gene sequence is constructed in vitro using synthetic oligonucleotides. Adverse rare codons are avoided and secondary structures in the mRNA are minimized. Thereby, the synthetic gene is optimal for expression and consequently for the induction of an immune response [<a href="#B72" rid="B72" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872855">72</a>].</p><p id="__p36">The flexibility of plasmid design coupled with the technology of gene manipulation allows also &#x0201c;gene optimization.&#x0201d; Indeed, the variable regions of the heavy (<em>V</em><sub><em>H</em></sub>) and light chain (<em>V</em><sub><em>L</em></sub>) of the tumor immunoglobulin, specific for the B-cell malignancies, can be readily cloned and combined into single-chain variable fragment (scFv) format, encoding a single polypeptide consisting of <em>V</em><sub><em>H</em></sub> and <em>V</em><sub><em>L</em></sub> genes linked together in frame by a short 15-amino acid linker [<a href="#B73" rid="B73" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872814">73</a>].</p><p id="__p37">As already discussed, the backbone of bacterial DNA includes cytosine-phosphate-guanine (CpG) unmethylated regions as sequence motifs that stimulate innate immunity, creating an inflammatory milieu for triggering the adaptive immune response [<a href="#B74" rid="B74" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872844">74</a>]. The role of CpG motifs as adjuvants of immune response to DNA vaccines is well documented in mice    [<a href="#B75" rid="B75" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872783">75</a>]. Preclinical studies showed that the addition of CpG motifs in the plasmid can result in the induction of proinflammatory cytokines, for example, IL-12 or IFN-I    [<a href="#B75" rid="B75" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872874">75</a>]. CpGs are recognized by TLR9, a receptor found on APCs, helping cytotoxic T-lymphocyte (CTL) differentiation and priming. The coadministration of genes encoding ligands for Toll-like receptors (TLRs) or their signaling molecules has been shown to improve the immunogenicity of DNA vaccines    [<a href="#B66" rid="B66" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872811">66</a>, <a href="#B76" rid="B76" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_321350128">76</a>].</p><p id="__p38">Engineering DNA vaccine design for maximizing epitope-specific immunity has allowed  epitope enhancement by sequence modification. The recent molecular understanding of the immune response is leading to new strategies to induce more effective immune responses. Self-tolerance might lead to deletion of T cells specific for the most effective epitopes, leaving only low-avidity T cells    [<a href="#B77" rid="B77" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_321350119">77</a>, <a href="#B78" rid="B78" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_321350109">78</a>]. Therefore, not all sequences are optimal antigenic epitopes. A process termed epitope enhancement is expected to make the sequences of many epitopes of cancer more immunogenic [<a href="#B79" rid="B79" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872770">79</a>]. Epitope sequences can be modified to increase the affinity of the epitope peptide for the MHC molecule. The knowledge of sequence motifs for peptide binding is the key to improve the primary and/or secondary &#x0201c;anchor residues&#x0201d; that provide much of the specificity of binding to the MHC molecule    [<a href="#B80" rid="B80" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872795">80</a>, <a href="#B81" rid="B81" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872823">81</a>]. This strategy can greatly increase the potency of a vaccine and can convert a subdominant epitope into a dominant one by making it more competitive for available MHC molecules, thereby increasing the level of specific peptide&#x02014;MHC complexes on the antigen presenting cell surface    [<a href="#B82" rid="B82" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872818">82</a>]. Epitope enhancement has been used to increase the affinity for both MHC class I and class II molecules (reviewed in [<a href="#B83" rid="B83" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_321350118">83</a>]).</p><p id="__p39">To enhance the immunogenicity of DNA, vaccines encoding immunostimulatory RNA, such as double-stranded RNA or replicon RNA, were also generated [<a href="#B84" rid="B84" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872738">84</a>].</p><p id="__p40">Engineering vaccine design for manipulating antigen presentation and processing pathways is one of the most important aspect that can be easily handled in the DNA vaccine technology. If an antibody response is the goal, it is clearly desirable to direct antigen expression to the endoplasmic reticulum (ER), in which folding and secretion can occur. An appropriate leader (signal) sequence can achieve this. (reviewed in [<a href="#B47" rid="B47" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_321350130">47</a>]). For induction of CTLs, addition of genes encoding molecules such as ubiquitin, aimed to enhance degradation and peptide production in the proteasome, can be effective (reviewed in [<a href="#B85" rid="B85" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872799">85</a>]). Similarly, targeting expression to different subcellular pathways such as the endosome or lysosome can amplify CD4<sup>+</sup>&#x02009;&#x02009;T cell responses [<a href="#B85" rid="B85" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872812">85</a>]. Thus, DNA vaccines can be designed to induce an appropriate effector pathway, including antibody against cell-surface antigens, or CTL response against intracellular antigens expressed only as MHC class I-associated peptides. Since tumor antigens are often weakly immunogenic and the immune repertoire in patients may have been tolerized, the central question is whether DNA vaccines can activate and maintain the high level of immunity required to suppress cancer cell growth. </p><p id="__p41" class="p p-last">The pivotal position of CD4 T helper (Th) cells in helping B cells to produce antibody and control induction and maintenance of CD8 T cells [<a href="#B86" rid="B86" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872764">86</a>] has led some investigators to focus on their importance in responses to DNA vaccination. By selecting genes encoding microbial proteins fused to the tumor antigen sequence, it was possible to activate Th cells and to dramatically amplify immunity against tumor cells    [<a href="#B87" rid="B87" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872771">87</a>]. As discussed in the following section, DNA vaccines offer the opportunity to activate Th cells and transform weak and ineffective immunity to a powerful antitumor attack    [<a href="#B88" rid="B88" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872773">88</a>].</p></div><div id="sec5.2" class="sec"><h3 id="sec5.2title">5.2. Immunomodulatory and Immunoenhancing Molecules</h3><p id="__p42" class="p p-first">Even though specific antibody and CTL responses could be induced in clinical trials with naked DNA vaccines, by the intramuscular or intradermal route, high doses of DNA were necessary to elicit detectable immune responses    [<a href="#B89" rid="B89" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872842">89</a>, <a href="#B90" rid="B90" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872741">90</a>]. Large quantities, that is, 5&#x02013;10&#x02009;mg, are required to induce only modest immunogenicity    [<a href="#B91" rid="B91" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872768">91</a>].</p><p id="__p43">Modifying the microenvironment of the vaccinated site by coadministration of genetic, that is, DNA plasmids coding for immunostimulatory molecules, protein, or chemical adjuvants, improves the low immunogenicity of DNA vaccines [<a href="#B31" rid="B31" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872860">31</a>].</p><p id="__p44">Progress has been made in developing improved techniques for encapsulating plasmid DNA (liposomes, polymers, and microparticles) although few of these formulations have been shown to elicit immune responses that are superior to those elicited by simple intramuscular plasmid DNA, still disappointing in human clinical trials [<a href="#B92" rid="B92" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872848">92</a>].</p><p id="__p45">Considering the ease in design and construction of plasmid DNA used to target a particular neoplasm, biological adjuvants can be tailored and encoded within the same DNA vector as well [<a href="#B35" rid="B35" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872872">35</a>]. A vast array of molecules able to modulate immune responses can be delivered (<a href="/pmc/articles/PMC2846346/table/tab3/" target="table" class="fig-table-link figpopup" rid-figpopup="tab3" rid-ob="ob-tab3" co-legend-rid=""><span>Table 3</span></a>). </p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="tab3"><h3>Table 3</h3><!--caption a7--><div class="caption"><p id="__p105">Adjuvant molecules employed in cancer clinical trials to enhance the immune response.</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139857079250752" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th align="center" colspan="2" rowspan="1"><em>Adjuvant</em></th><th align="center" rowspan="1" colspan="1"><em>Phase</em></th><th align="center" rowspan="1" colspan="1"><em>References</em></th></tr></thead><tbody><tr><td align="left" rowspan="5" colspan="1"><em>Genetic</em></td><td align="left" rowspan="1" colspan="1">cytokines</td><td align="center" rowspan="2" colspan="1">I/II-II</td><td align="center" rowspan="1" colspan="1"><a id="__tag_544253158" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT00019448" ref="reftype=extlink-clinical-trial&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT00019448","term_id":"NCT00019448"}}</span>NCT00019448</a></td></tr><tr><td align="left" rowspan="1" colspan="1">(GM-CSF, IL-12, IL-2)</td><td align="center" rowspan="1" colspan="1">   [<a href="#B56" rid="B56" class=" bibr popnode">56</a>, <a href="#B62" rid="B62" class=" bibr popnode">62</a>]</td></tr><tr><td align="left" rowspan="1" colspan="1">bacterial toxins</td><td align="center" rowspan="2" colspan="1">I/II</td><td align="center" rowspan="2" colspan="1">   [<a href="#B46" rid="B46" class=" bibr popnode">46</a>, <a href="#B47" rid="B47" class=" bibr popnode">47</a>, <a href="#B64" rid="B64" class=" bibr popnode">64</a>, <a href="#B65" rid="B65" class=" bibr popnode">65</a>]</td></tr><tr><td align="left" rowspan="1" colspan="1">(pDOM/tetanus toxin FrC)</td></tr><tr><td align="left" rowspan="1" colspan="1">immunomodulatory molecules (HSP70)</td><td align="center" rowspan="1" colspan="1">I/II</td><td align="center" rowspan="1" colspan="1">[<a href="#B67" rid="B67" class=" bibr popnode">67</a>] </td></tr><tr><td align="center" colspan="4" rowspan="1"><hr /></td></tr><tr><td align="left" rowspan="1" colspan="1"><em>Protein</em></td><td align="left" rowspan="1" colspan="1">cytokines (GM-CSF, IL-2)</td><td align="center" rowspan="1" colspan="1">I/II-II</td><td align="center" rowspan="1" colspan="1">   [<a href="#B58" rid="B58" class=" bibr popnode">58</a>, <a href="#B59" rid="B59" class=" bibr popnode">59</a>, <a href="#B61" rid="B61" class=" bibr popnode">61</a>];</td></tr></tbody></table></div><div id="largeobj_idm139857079250752" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2846346/table/tab3/?report=objectonly">Open in a separate window</a></div></div><p id="__p46">They include chemokines to attract APC [<a href="#B93" rid="B93" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872804">93</a>], activating cytokines    [<a href="#B94" rid="B94" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872747">94</a>, <a href="#B95" rid="B95" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872780">95</a>], costimulatory molecules, APC-targeting antibodies, and molecules to manipulate antigen presentation and/or processing [<a href="#B96" rid="B96" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872756">96</a>].</p><p id="__p47">One of the common cytokines employed in plasmid DNA vaccine is granulocyte&#x02013;macrophage colony&#x02013;stimulating factor (GM-CSF), a molecule able to enhance immune responses by inducing proliferation, maturation, and migration of DCs as well as expansion and differentiation of B and T lymphocytes    [<a href="#B62" rid="B62" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_353274288">62</a>].</p><p id="__p48">In addition to codelivery, DNA vaccines allow fusion of genes encoding activating molecules to the antigen-encoding sequence. This is an advantage, and fusion genes can create single vaccines capable of multiple functions.</p><p id="__p49">Biragyn and colleagues showed that the efficiency of DNA vaccination in vivo could be greatly increased by encoding a fusion protein consisting of scFv fused to a proinflammatory chemokine moiety that facilitates targeting of APCs for chemokine receptor-mediated binding, uptake, and processing of scFv antigen for subsequent presentation to CD4<sup>+</sup> or CD8<sup>+</sup>&#x02009;&#x02009;T cells, or both [<a href="#B63" rid="B63" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_410071761">63</a>]. In two independent models, vaccination with DNA constructs encoding a fusion protein consisting of scFv fused to the monocyte chemotactic protein 3 (MCP-3) or the interferon inducible protein 10 (IP-10a) generated superior protection against a large tumor challenge (20 times the minimum lethal dose), as compared with the best available protein vaccines [<a href="#B63" rid="B63" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_410071762">63</a>].</p><p id="__p50" class="p p-last">Additional strategies to activate effective immunity against poorly immunogenic tumor antigens employ the &#x0201c;DNA fusion genes vaccines&#x0201d; to activate T cell help for antitumor responses. The CD4<sup>+</sup> Th cell, as pivotal cell of the immune response able to induce high levels of immunity and the maintenance of the response, has been extensively studied by Stevenson and coworkers [<a href="#B97" rid="B97" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872761">97</a>]. The requirement for foreign sequences to induce Th for the B-cell response and to help the CTL response has been known for many years    [<a href="#B98" rid="B98" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872806">98</a>, <a href="#B99" rid="B99" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872749">99</a>]. Since Th cells control responses to vaccination, it is quite obvious that self-antigens, which do not contain epitopes likely to be recognized by available Th cells, are incapable of inducing immunity. A strategy to activate Th cells for inducing antitumor immunity is to engage a repertoire against nontolerized antigens. The use of xenogeneic antigen to break tolerance is likely due to the presence of some foreign sequences in the xenogeneic antigen that are able to activate Th cells    [<a href="#B100" rid="B100" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872809">100</a>]. Focusing on the antimicrobial repertoire, the principle has been applied to realize the DNA fusion gene vaccines encoding the tumor antigen linked to an antigen derived from tetanus toxin. Fusion of the Fragment C (FrC) of tetanus toxin amplified the immune response against a range of tumor antigens, leading to suppression of tumor growth    [<a href="#B87" rid="B87" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872816">87</a>]. Clinical trials by using these approaches to breaking self-tolerance for therapeutic purposes in patients with lymphoma and prostate carcinoma are discussed elsewhere.</p></div><div id="sec5.3" class="sec"><h3 id="sec5.3title">5.3. Route of Administration</h3><p id="__p51" class="p p-first">It is increasingly apparent that the immunogenicity of DNA vaccines greatly depends upon the delivery methods used for immunization [<a href="#B101" rid="B101" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872790">101</a>]. </p><p id="__p52">In a melanoma mouse model, DNA vaccination was administered together with intratumoral delivery of antiangiogenic plasmids, encoding angiostatin, and endostatin. Combined melanoma vaccination resulted in 57% tumor-free survival over 90 days after challenge [<a href="#B54" rid="B54" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872772">54</a>]. In a modest proportion of patients with malignant disease, intratumoral injection of DNA led to regression of tumor at distant sites    [<a href="#B102" rid="B102" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872744">102</a>].</p><p id="__p53">The recent studies have confirmed that physical methods are superior over other delivery methods that administer DNA in various chemical solutions    [<a href="#B103" rid="B103" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872769">103</a>, <a href="#B104" rid="B104" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872841">104</a>].</p><p id="__p54">Biolistic gene gun delivery involves adhering naked DNA to gold beads and shooting the particles through a high-pressured instrument. This system delivers DNA directly into skin and Langerhans cells in a highly efficient process. Gene gun immunization has been shown to induce a greater CD8<sup>+</sup>&#x02009;&#x02009;T cell response as well as to require less vaccine to achieve tumor immunity    [<a href="#B51" rid="B51" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872784">51</a>].</p><p id="__p55">A promising strategy is electroporation (EP), which in primates increases not only the level but also the breadth of response    [<a href="#B105" rid="B105" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872802">105</a>], overcoming the difficulty in translating the effectiveness of DNA vaccination from preclinical rodents to large animals, including human subjects    [<a href="#B106" rid="B106" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_321350117">106</a>].</p><p id="__p56">Electroporation-based DNA delivery technology dramatically enhances cellular uptake of DNA vaccines. EP itself works as an adjuvant to enhance the necessary &#x0201c;danger signals&#x0201d; that become detectable by the immune system. The tissue damage caused by the application of EP causes inflammation and recruits DCs, macrophages, and lymphocytes to the injection site    [<a href="#B107" rid="B107" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872827">107</a>, <a href="#B108" rid="B108" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872763">108</a>] inducing significant immune responses, including antibody and T-cell responses. Moreover, it is tolerable without anesthetic and does not induce unwanted immune responses against the delivery mechanism, therefore it can be used for repeat administrations. </p><p id="__p57" class="p p-last">A newly developed intradermal DNA delivery is the tattoo technology. The tattoo device has a cartridge of nine fine metal perforating needle that oscillate at a constant high frequency and puncture the skin, leading to DNA transfer to skin-associated cells. The expression of reporter genes results in robust T-cell responses [<a href="#B109" rid="B109" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_321350102">109</a>]. Recently tattoo-immunization was applied in a phase I study to assess the toxicity and efficacy of inducing tumor-specific T-cell immunity against melanoma [<a href="#B53" rid="B53" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872845">53</a>].</p></div><div id="sec5.4" class="sec"><h3 id="sec5.4title">5.4. Prime-Boost Strategies</h3><p id="__p58" class="p p-first">Vaccination schedules based on combined prime-boost regimens using different vector systems to deliver the desired antigen (i.e., heterologous prime-boost immunization regimen) appear to be a successful improvement in DNA vaccine platform.</p><p id="__p59">Actually, prime-boost regimens have shown promise in eliciting greater immune response in humans compared with DNA vaccination alone [<a href="#B101" rid="B101" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872849">101</a>]. </p><p id="__p60">The DNA-prime-viral vector-boost approach focuses on the induction of T-cell immune responses. In this approach, homologous boost immunization carries the equivalent antigen than the previous immunization. Viral vectors that have been tested as booster vaccine include adenovirus, vaccinia virus, fowlpox    [<a href="#B110" rid="B110" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872843">110</a>, <a href="#B111" rid="B111" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872797">111</a>] as well as recombinant vesicular stomatitis virus    [<a href="#B112" rid="B112" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872765">112</a>]. </p><p id="__p61">Likewise, the DNA-prime-protein-boost approach employs recombinant protein antigens that match with the antigens used in DNA prime immunization    [<a href="#B68" rid="B68" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872858">68</a>, <a href="#B113" rid="B113" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_321350101">113</a>, <a href="#B114" rid="B114" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872786">114</a>]. This strategy aims to develop balanced humoral and cell-mediated immune responses with a focus on eliciting high quality protective antibody responses.</p><p id="__p62">The heterologous prime-boost vaccination regimen exploits the ability of the immune system to generate a large number of secondary antigen-specific T cells. Following a priming immunization, a proportion of the antigen-specific T cell population transforms into antigen-specific memory T cells, which have the ability to expand rapidly upon encounter with the same antigen a second-time round.</p><p id="__p63">Since the priming and boosting vectors are different, this strategy allows for greater expansion of the disease antigen-specific T cell populations [<a href="#B115" rid="B115" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872851">115</a>]. To date, heterologous prime-boost regimens are among the most potent strategies to induce cellular immune responses. Compared to homologous prime-boost approach with the same DNA vaccine, boosting a primary response with a heterologous vector will result in 4&#x02013;10-fold higher T cell responses    [<a href="#B116" rid="B116" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_321350108">116</a>&#x02013;<a href="#B118" rid="B118" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872824">118</a>]. </p><p id="__p64" class="p p-last">On the one end, a combination of DNA vaccines with EP in a homologous prime-boost approach could generate antibody responses comparable to those that are induced by protein in Complete Freund Adjuvant, and also amplified CTL responses    [<a href="#B46" rid="B46" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_321350122">46</a>]. EP may provide a prime-boost combination equivalent to that observed using viral vectors, and it is now undergoing testing in the clinic using a DNA vaccine for patients with prostate cancer. Repeated EP has been accepted by patients without the need for general or local anaesthesia and with no apparent long-term ill effects [<a href="#B47" rid="B47" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_321350096">47</a>].</p></div><div id="sec5.5" class="sec sec-last"><h3 id="sec5.5title">5.5. Strategies to Break the Immunosuppressive Networks</h3><p id="__p65" class="p p-first">Immune suppression is a feature of the tumor microenvironment and a barrier to tumor immune therapy. The microenvironment of tumors is established through the activity of both myeloid and lymphoid regulatory cells, as well as through the production of immune-suppressive factors by malignant cells themselves.</p><p id="__p66">Many tumor-infiltrating macrophages, referred to myeloid-derived suppressor cells (MDSCs), have an immune-suppressive phenotype [<a href="#B119" rid="B119" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872760">119</a>]. These macrophages are abundant in many tumors arising in both humans and mice and can exert powerful anti-inflammatory effects. In addition to MDSCs, regulatory T cells (Tregs) also heavily infiltrate many tumors [<a href="#B120" rid="B120" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872833">120</a>]. These cells, characterized by the expression of the transcription factor FoxP3 as well as CD4 and CD25, play a key role in the regulation of adaptive immunity. Tregs can suppress immune responses through the secretion of suppressive cytokines like TGF-<em>&#x003b2;</em> and IL- 35    [<a href="#B120" rid="B120" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872736">120</a>, <a href="#B121" rid="B121" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872871">121</a>]. Tregs are a potential barrier to developing productive immune therapies for cancer, and they represent an attractive target for enhancing antitumor immunity.</p><p id="__p67">Cancer immunotherapy is designed to specifically target cancer types using components of the immune system. Therefore DNA vaccines are also faced many obstacles that include breaking peripheral T cell tolerance against tumor self-antigens, to elicit appropriate immune reactions, as well as overcoming tumor-derived immunosuppressive networks and evasion tactics. Evasive mechanisms adopted by malignant cells to prevent immune cell function are numerous and lead to the clonal expansion of non-immunogenic tumor cells, by loss of tumor antigen, and to the apoptosis prevention [<a href="#B35" rid="B35" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872767">35</a>].</p><p id="__p68">Tumour cells can downregulate expression of MHC and target antigens and often secrete immunosuppressive molecules to defend themselves against attack [<a href="#B122" rid="B122" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872746">122</a>]. Tumours can create a tolerogenic environment which spreads to draining lymph nodes and can enhance regulatory T-cell activity. The hurdles to successful reversal of tolerance and induction of effective immunity are becoming clear and vaccines must incorporate elements to overcome them [<a href="#B123" rid="B123" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872778">123</a>]. </p><p id="__p69">Furthermore cancer cells secrete soluble factors in the tumor microenviroment, for example, VEGF, IL-10, and TGF-<em>&#x003b2;</em>, that affect the maturation, differentiation, and activity of APCs as DCs [<a href="#B124" rid="B124" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_321350129">124</a>], interfering with immune cells maturation and effector properties. The tumour microenvironment may drive tumour growth and even selectively support a subset of tumour cells, the cancer stem cells (CSCs). </p><p id="__p70">The DNA vaccination platform can be capable of suppressing the progression of already established tumor by targeting those secreted soluble factors in the tumor microenvironment    [<a href="#B125" rid="B125" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872831">125</a>], reversing immunological attenuation mechanisms and improving DNA vaccine potency.</p><p id="__p71">The concept of combining cancer vaccination with angiogenesis inhibition is appealing, due to favorable safety profile of both approaches, as well as possible biological synergies [<a href="#B54" rid="B54" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872859">54</a>]. DNA vaccination in mice against the VEGF receptor, FLK-1, abrogated the tumor vasculature and protected DNA vaccinated animals from tumor challenge in prophylactic approach [<a href="#B126" rid="B126" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_321350116">126</a>]. Expression of the platelet-derived growth factor receptor (PDGFR) in stromal cells directly correlates with advanced stage disease in human colorectal cancer. DNA vaccine against PDGFR<em>&#x003b2;</em> suppressed growth and dissemination of human colorectal cancer cells injected into mice    [<a href="#B127" rid="B127" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872751">127</a>].</p><p id="__p72">In vivo coadministration of plasmids encoding the chemokine macrophage inflammatory protein-1alpha (MIP-1alpha) and the DC-specific growth factor fms-like tyrosine kinase 3 ligand (Flt3L) with the plasmid DNA augments the immunogenicity of the vaccine, mobilizing and activating large numbers of DCs at the site of inoculation    [<a href="#B128" rid="B128" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872825">128</a>].</p><p id="__p73" class="p p-last">Consistent with the concept that most effective cancer therapies are multimodal, combining Treg depletion with active cancer immunotherapeutic interventions is an attractive prospect, supported by abundant data in mice    [<a href="#B129" rid="B129" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872789">129</a>&#x02013;<a href="#B132" rid="B132" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872766">132</a>] and by preliminary human trials    [<a href="#B133" rid="B133" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_321350121">133</a>&#x02013;<a href="#B135" rid="B135" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_321350127">135</a>]. Lastly, additional strategies aimed to altering regulatory T cell function in cancer immunotherapy, including blocking Treg trafficking, differentiation, and/or function and reducing effector cell susceptibility to suppression, have already proven successful in preliminary studies    [<a href="#B136" rid="B136" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_321350131">136</a>&#x02013;<a href="#B138" rid="B138" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872742">138</a>].</p></div></div><div id="sec6" class="tsec sec"><h2 class="head no_bottom_margin" id="sec6title">6. Human Clinical Trials</h2><p id="__p74" class="p p-first">The goals of the various clinical trials were to demonstrate the safety and tolerability of the candidate vaccines, and to explore the efficacy of DNA vaccines in humans. Injection of the plasmid DNA construct is tolerated well in terms of safety in the patient population and rarely involves systemic toxicities. DNA vaccines that are currently being tested do not show relevant levels of integration into host cellular DNA    [<a href="#B139" rid="B139" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872750">139</a>, <a href="#B140" rid="B140" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872861">140</a>]. Besides, preclinical studies in nonhuman primates as well as early studies in humans did not detect increases in antinuclear or anti-DNA antibodies. Participants in human trials of DNA vaccines are followed for possible signs and symptoms of autoimmunity induced by DNA vaccination giving no convincing evidence of autoimmunity developing in association with a DNA vaccine    [<a href="#B40" rid="B40" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872863">40</a>, <a href="#B42" rid="B42" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872775">42</a>, <a href="#B141" rid="B141" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872828">141</a>].</p><p id="__p75">The earliest Phase I clinical trial for a DNA vaccine was of an HIV-1 candidate tested in individuals infected by HIV-1, followed by studies in volunteers who were not infected by HIV-1    [<a href="#B40" rid="B40" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872754">40</a>]. Other prophylactic and therapeutic DNA vaccine trials followed, including trials that tested DNA vaccines against cancer influenza, malaria, hepatitis B, and other HIV-1 candidates    [<a href="#B24" rid="B24" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872862">24</a>, <a href="#B41" rid="B41" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872748">41</a>, <a href="#B42" rid="B42" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872876">42</a>]. These trials demonstrated that the DNA vaccine platform is well tolerated and safe, as no adverse events were reported and all studies went to completion.</p><p id="__p76">The evident safety of DNA vaccines has led to a relaxation of the requirements for approval by both the United States Food and Drug Administration and the national competent regulatory authorities in Europe. This is why many clinical studies tend to melt the first phase with the second phase. Then the issue has become the efficacy rather than toxicity.</p><p id="__p77">Since tumour antigens are generally weakly immunogenic, they often induce a low level of spontaneous immunity or, in other cases, the spontaneous response can lead to tolerance [<a href="#B47" rid="B47" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_321350107">47</a>]. The molecular precision offered by gene-based vaccines, together with the facility to include additional genes to direct and amplify immunity, could lead to an efficient methods to use the immune system against cancer. The inclusion of FrC sequence, or other nonself antigens, activates T-cell help to reverse tolerance and induces high levels of immunity    [<a href="#B47" rid="B47" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_321350105">47</a>, <a href="#B64" rid="B64" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872847">64</a>, <a href="#B65" rid="B65" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_321350123">65</a>]. To further increase immunogenicity of DNA vaccine, the use of molecular adjuvants such as cytokines and immunomodulatory molecules has been extensively employed in clinical trials    [<a href="#B56" rid="B56" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872866">56</a>, <a href="#B58" rid="B58" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_321350106">58</a>&#x02013;<a href="#B63" rid="B63" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_410071763">63</a>, <a href="#B67" rid="B67" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872774">67</a>].</p><p id="__p78">Clinical trials conducted over the last few years have led promising results, particularly when DNA vaccines were used in combination with other form of vaccines, as demonstrated in prostate and liver cancer clinical trials    [<a href="#B58" rid="B58" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_321350115">58</a>&#x02013;<a href="#B60" rid="B60" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872868">60</a>, <a href="#B68" rid="B68" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872801">68</a>]. Delivery of gene-based vaccines by physical methods, that is, electroporation and gene gun, has demonstrated to amplify the immune responses induced by therapeutic vaccines against cancer    [<a href="#B46" rid="B46" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_321350113">46</a>, <a href="#B47" rid="B47" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_321350099">47</a>, <a href="#B64" rid="B64" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872740">64</a>].</p><p id="__p79" class="p">In the following section, an overview of various types of clinical trials will be given to highlight the issue for usage of plasmid DNA in humans.<a href="/pmc/articles/PMC2846346/table/tab4/" target="table" class="fig-table-link figpopup" rid-figpopup="tab4" rid-ob="ob-tab4" co-legend-rid=""><span> Table 4 </span></a>provides a brief summary of clinical trials discussed in this review.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="tab4"><h3>Table 4</h3><!--caption a7--><div class="caption"><p id="__p106">Phases I/II-II clinical trials: key summary.</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139857073109344" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th align="left" rowspan="1" colspan="1">Tumor</th><th align="center" rowspan="1" colspan="1">Study ID</th><th align="center" rowspan="1" colspan="1">Patients no.</th><th align="left" rowspan="1" colspan="1">Objectives</th><th align="center" rowspan="1" colspan="1">Status</th><th align="left" rowspan="1" colspan="1">Response</th><th align="left" rowspan="1" colspan="1">Side effects</th></tr></thead><tbody><tr><td align="left" rowspan="3" colspan="1">Lymphoma</td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Determine the safety,</td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Absence of  toxicity</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="center" rowspan="1" colspan="1">UK-007</td><td align="center" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">dose,  immunogenicity</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="left" rowspan="1" colspan="1">Cellular and/or</td><td rowspan="1" colspan="1"></td></tr><tr><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">humoral responses</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="center" colspan="7" rowspan="1"><hr /></td></tr><tr><td align="left" rowspan="18" colspan="1">Prostate cancer</td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Determine the feasibility</td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">and safety</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">Determine the safety and</td><td align="center" rowspan="1" colspan="1">Open</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td align="center" rowspan="1" colspan="1"><a id="__tag_544253164" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT00859729" ref="reftype=extlink-clinical-trial&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT00859729","term_id":"NCT00859729"}}</span>NCT00859729</a></td><td align="center" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">functionality of  DNA</td><td align="center" rowspan="1" colspan="1">recruiting</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">vaccine delivery system</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">Determine the</td><td align="center" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">Absence of  toxicity</td><td align="left" rowspan="1" colspan="1">Brief and</td></tr><tr><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">feasibility and safety</td><td align="center" rowspan="1" colspan="1">Open</td><td align="left" rowspan="1" colspan="1">CD8+ T-cell</td><td align="left" rowspan="1" colspan="1">acceptable</td></tr><tr><td align="center" rowspan="1" colspan="1">UK-112</td><td align="center" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">Determine the</td><td align="center" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">reactivity against the</td><td align="left" rowspan="1" colspan="1">pain at the</td></tr><tr><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">immunological responses</td><td align="center" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">target peptide</td><td align="left" rowspan="1" colspan="1">injection site</td></tr><tr><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">PAP-specific IFN</td><td rowspan="1" colspan="1"></td></tr><tr><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">gamma-secreting</td><td rowspan="1" colspan="1"></td></tr><tr><td align="center" rowspan="1" colspan="1"><a id="__tag_544253156" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT00582140" ref="reftype=extlink-clinical-trial&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT00582140","term_id":"NCT00582140"}}</span>NCT00582140</a></td><td align="center" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">Determine the safety</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="left" rowspan="1" colspan="1">CD8+ T-cells</td><td rowspan="1" colspan="1"></td></tr><tr><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">(Aug 2009)</td><td align="left" rowspan="1" colspan="1">PAP-specific</td><td rowspan="1" colspan="1"></td></tr><tr><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">CD4+ and/or CD8+</td><td rowspan="1" colspan="1"></td></tr><tr><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">T-cell proliferation</td><td rowspan="1" colspan="1"></td></tr><tr><td align="center" rowspan="1" colspan="1">Bulgarian</td><td align="center" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">Characterize the humoral</td><td align="left" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">Specific humoral</td><td rowspan="1" colspan="1"></td></tr><tr><td align="center" rowspan="1" colspan="1">Drug</td><td align="center" rowspan="1" colspan="1">52</td><td align="left" rowspan="1" colspan="1">immune response</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="left" rowspan="1" colspan="1">immune response</td><td rowspan="1" colspan="1"></td></tr><tr><td align="center" rowspan="1" colspan="1">Agency Register</td><td align="center" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">against PSMA</td><td align="left" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">against PSMA</td><td align="center" rowspan="1" colspan="1"></td></tr><tr><td align="center" colspan="7" rowspan="1"><hr /></td></tr><tr><td align="left" rowspan="9" colspan="1">Melanoma</td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Determine the safety</td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Antigen-specific</td><td align="left" rowspan="5" colspan="1">Grade I/II toxicity</td></tr><tr><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">and tolerability</td><td align="left" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">Immunity</td></tr><tr><td align="center" rowspan="1" colspan="1"><a id="__tag_544253162" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT00033228" ref="reftype=extlink-clinical-trial&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT00033228","term_id":"NCT00033228"}}</span>NCT00033228</a></td><td align="center" rowspan="1" colspan="1">6&#x02013;18</td><td align="left" rowspan="1" colspan="1">Determine the</td><td align="left" rowspan="1" colspan="1">Completed</td><td align="left" rowspan="1" colspan="1">No regression of</td></tr><tr><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">immunological and</td><td align="left" rowspan="1" colspan="1">(July 2009)</td><td align="center" rowspan="1" colspan="1">established disease</td></tr><tr><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">clinical responses</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">Determine the safety</td><td align="left" rowspan="1" colspan="1">Open</td><td align="left" rowspan="1" colspan="1">Immunological</td><td align="center" rowspan="4" colspan="1">Grade I toxicity</td></tr><tr><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">and tolerability</td><td align="left" rowspan="1" colspan="1">Not</td><td align="left" rowspan="1" colspan="1">efficacy</td></tr><tr><td align="center" rowspan="1" colspan="1">NCT00085137</td><td align="center" rowspan="1" colspan="1">3&#x02013;27</td><td align="left" rowspan="1" colspan="1">Determine any</td><td align="left" rowspan="1" colspan="1">Recruiting</td><td align="left" rowspan="1" colspan="1">in terms of</td></tr><tr><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">antitumor response</td><td align="left" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1">T-cell response</td></tr><tr><td align="center" colspan="7" rowspan="1"><hr /></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Determine the feasibility</td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">and toxicity</td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Absence of</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Determine the effect</td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">toxicity</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Determine changes</td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">In the highest-dose</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">in lesion size and</td><td align="center" rowspan="1" colspan="1">Open</td><td align="left" rowspan="1" colspan="1">cohort the number</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">HPV viral load</td><td align="center" rowspan="1" colspan="1">Not</td><td align="left" rowspan="1" colspan="1">of patients with</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">Cervical cancer</td><td align="center" rowspan="1" colspan="1"><a id="__tag_544253163" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT00121173" ref="reftype=extlink-clinical-trial&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT00121173","term_id":"NCT00121173"}}</span>NCT00121173</a></td><td align="center" rowspan="1" colspan="1">150</td><td align="left" rowspan="1" colspan="1">Determine the immune</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="left" rowspan="1" colspan="1">complete histologic</td><td align="left" rowspan="1" colspan="1">Transient</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">responses</td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">regression is</td><td align="left" rowspan="1" colspan="1">injection-site</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Correlate measures of</td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">higher than the</td><td align="left" rowspan="1" colspan="1">discomfort</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">immune response with</td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">unvaccinated cohort,</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">clinical response</td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">but not significant.</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="center" colspan="7" rowspan="1"><hr /></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Determine the dose-</td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">limiting toxicity and</td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">maximum tolerated dose</td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">Liver cancer</td><td align="center" rowspan="1" colspan="1"><a id="__tag_544253159" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT00093548" ref="reftype=extlink-clinical-trial&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT00093548","term_id":"NCT00093548"}}</span>NCT00093548</a></td><td align="center" rowspan="1" colspan="1">3&#x02013;25</td><td align="left" rowspan="1" colspan="1">Determine the optimal</td><td align="center" rowspan="1" colspan="1">Completed</td><td align="left" rowspan="1" colspan="1">Absence of</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">biological dose</td><td align="center" rowspan="1" colspan="1">(Feb 2009)</td><td align="left" rowspan="1" colspan="1">toxicity</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Determine disease-free</td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">survival of patients treated</td><td align="center" rowspan="1" colspan="1">&#x02003;</td><td align="left" rowspan="1" colspan="1">&#x02003;</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="center" colspan="7" rowspan="1"><hr /></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Determine and</td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">characterize</td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1">Breast cancer</td><td align="center" rowspan="1" colspan="1"><a id="__tag_544253161" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT00363012" ref="reftype=extlink-clinical-trial&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT00363012","term_id":"NCT00363012"}}</span>NCT00363012</a></td><td align="center" rowspan="1" colspan="1">56</td><td align="left" rowspan="1" colspan="1">the immunologic</td><td align="center" rowspan="1" colspan="1">Open</td><td align="left" rowspan="1" colspan="1">Absence of</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">memory</td><td align="center" rowspan="1" colspan="1">recruiting</td><td align="left" rowspan="1" colspan="1">toxicity</td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">to the HER2-ICD</td><td align="center" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr></tbody></table></div><div id="largeobj_idm139857073109344" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2846346/table/tab4/?report=objectonly">Open in a separate window</a></div></div><div id="sec6.1" class="sec"><h3 id="sec6.1title">6.1. Lymphoma</h3><p id="__p80" class="p p-first">DNA vaccination is an attractive and effective approach for active therapeutic vaccination against B-cell malignancies given the ease of production compared to Id protein vaccines. </p><p id="__p81">Patient-specific DNA vaccines for therapy of B cell lymphomas and multiple myelomas based on scFv encoding a chimeric immunoglobulin molecule consisting of <em>V</em><sub><em>H</em></sub> and <em>V</em><sub><em>L</em></sub> genes derived from each patients\'s tumor were shown to be effective in animal models    [<a href="#B47" rid="B47" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_321350111">47</a>, <a href="#B73" rid="B73" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872800">73</a>].</p><p id="__p82">The first phase I/II trial of idiotypic vaccination for follicular B-cell lymphoma using a genetic approach [<a href="#B142" rid="B142" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872793">142</a>] was conducted by Hawkins and colleagues. Vaccines encoding individual DNA idiotypic scFv fused to TTFrC were delivered as naked DNA by i.m. injection in patients with follicular lymphoma in clinical remission following chemotherapy, and plasmid DNA were able to develop cellular or/and humoral antiidiotype immune responses  in 38% of patients over a period of several months [<a href="#B47" rid="B47" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_321350126">47</a>].</p><p id="__p83" class="p p-last">In a second study of vaccine therapy for B-cell lymphoma, the patient\'s tumor scFv was linked to the IgG2a and <em>&#x003ba;</em> mouse immunoglobulin heavy- and light-chain constant regions chains, respectively. In this phase, I/II trial patients in remission after chemotherapy received two series of i.m. DNA vaccinations and at the end of the second vaccination, 50% of patients exhibited humoral and/or T-cell anti-Id responses; yet, these were cross-reactive with Id proteins from other patient\'s tumors. Subsequently, a third series of vaccinations was carried out using human GM-CSF DNA mixed with Id DNA: humoral or T-cell responses were boosted in some cases    [<a href="#B56" rid="B56" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872753">56</a>].</p></div><div id="sec6.2" class="sec"><h3 id="sec6.2title">6.2. Prostate Carcinoma</h3><p id="__p84" class="p p-first">After the important insights provided in preclinical studies [<a href="#B49" rid="B49" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_321350124">49</a>], the department of Oncology of the University Hospital of Uppsala is recruiting participants for a phase I/II trial, where intradermal EP (DERMA VAX) will be used as a delivery system. This study will assess the feasibility and safety of vaccination with increasing doses of xenogenic DNA coding for the Rhesus Prostate Specific Antigen (rhPSA), a protein that is 89% homologous to human PSA, administered in patients with relapsed prostate cancer. </p><p id="__p85">A phase I/II, dose escalation, DNA vaccination trial with plasmid DNA, which carries prostate-specific membrane antigen (PSMA), fused to a domain (DOM1) of Fragment C of tetanus toxin, delivered either by i.m. or by i.m. followed by EP, was performed in patients with recurrent prostate cancer. The epitope used in this study, PSMA<sub>27</sub> is a short stretch of 9 amino acids tumor-derived epitope belonging to the PSMA. Preliminary analysis of CD8<sup>+</sup>&#x02009;&#x02009;T-cell reactivity against the prostate-specific membrane antigen target peptide indicated significant responses in 3 out of 3 patients and CD4<sup>+</sup> T-cell responses against the DOM1. These data validated EP as a potent method for stimulating humoral responses induced by DNA vaccination in humans    [<a href="#B46" rid="B46" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_321350110">46</a>, <a href="#B47" rid="B47" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_321350103">47</a>, <a href="#B64" rid="B64" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872737">64</a>].</p><p id="__p86">Results of a phase I/II trial, conducted with DNA vaccine encoding human prostatic acid phosphatase (PAP) coadministered intradermally with GM-CSF, in prostate cancer patients (stage D0) are associated with an increased PSA doubling time (PSADT), 6.5 months pretreatment versus 9.3 months in the 1 year posttreatment    [<a href="#B61" rid="B61" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872835">61</a>]. A longer PSADT is associated with an extremely low risk of death from prostate cancer. Besides, 14% of patients developed PAP-specific IFN gamma-secreting CD8<sup>+</sup>&#x02009;&#x02009;T-cells immediately after the treatment course, and 41% of patients developed PAP-specific CD4<sup>+</sup> and/or CD8<sup>+</sup>&#x02009;&#x02009;T-cell proliferation, confirming the preclinical studies    [<a href="#B143" rid="B143" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872745">143</a>].</p><p id="__p87" class="p p-last">Todorova and colleagues    [<a href="#B58" rid="B58" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_321350114">58</a>] enhanced the DNA vaccine efficacy by heterologous prime-boost regimen in a Phase I/II study. Prostate cancer patients were prime-boosted with alternate injections of recombinant adenoviral vector expressing PSMA and plasmid DNA encoding PSMA and CD86 alongside receiving GM-CSF proteins as adjuvants. After 36-month observation period from the first vaccine injection, 86% of participants developed anti-PSMA antibody.</p></div><div id="sec6.3" class="sec"><h3 id="sec6.3title">6.3. Melanoma</h3><p id="__p88" class="p p-first">DNA vaccine platform is a promising therapeutic approach also for the treatment of malignant melanoma, as demonstrated by already completed and ongoing clinical trials. </p><p id="__p89">In stage IV melanoma patients, a phase I/II pilot study of intranodal delivery of Synchrotope MA2M plasmid DNA vaccine induced both humoral and CTL responses against cells expressing tumor two melanoma-associated antigens    [<a href="#B144" rid="B144" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872735">144</a>]. Synchrotope MA2M plasmid is a bivalent DNA vaccine encoding epitopes for both Melan-A (MART-1) and tyrosinase with potential antineoplastic activity.</p><p id="__p90">The same approach was used in a improved trial conducted with the Synchrovax SEM plasmid DNA vaccine containing a plasmid pSEM that encodes 4 peptide epitope sequences, Melan-A (26&#x02013;35), Melan-A (31&#x02013;96), tyrosinase (1&#x02013;9), and tyrosinase (369&#x02013;377), resulting in antigen-specific immunity even though not induce regression of established disease    [<a href="#B145" rid="B145" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872819">145</a>].</p><p id="__p91" class="p p-last">DNA plasmids encoding the gp100 nonmutated melanoma-melanocyte antigen alone were administered in patients with metastatic melanoma. Rosenberg et al. showed that neither intramuscular nor intradermal injection was capable of raising cellular immune reactivity or a significant incidence of antitumor effects    [<a href="#B57" rid="B57" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872805">57</a>].  Increasing results were obtained in a phase II study with interleukin-2 cytokines as adjuvant used in combination with same vaccination protocols (ClinicalTrials.gov Identifier: <a id="__tag_544253155" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT00019448" ref="reftype=extlink-clinical-trial&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT00019448","term_id":"NCT00019448"}}</span>NCT00019448</a>) and in a phase II trial with human GM-CSF plasmid DNA in conjunction with a multipeptide vaccine encoding gp100 and tyrosinase peptidse    [<a href="#B62" rid="B62" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_353274289">62</a>].</p></div><div id="sec6.4" class="sec"><h3 id="sec6.4title">6.4. Cervical Cancer</h3><p id="__p92" class="p p-first">Current vaccination strategies are based on the induction of neutralizing antibodies against the major and minor capsid proteins, L1 and L2, of human papillomavirus, and Gardasil is only effective against a subset of HPV genotypes    [<a href="#B146" rid="B146" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872820">146</a>]. Further therapeutic interventions for early-stage and late-stage cervical cancers or HPV-related disease are uneffective. </p><p id="__p93">DNA plasmid platform could represent an ideal vaccine against HPV infections since it could generate both humoral immune response to prevent new infections as well as cell-mediated immunity to eliminate established infection    [<a href="#B146" rid="B146" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872837">146</a>].</p><p id="__p94" class="p p-last">A recent phase I/II clinical trial in patients with high-grade squamous intraepithelial lesion associated with HPV16 provided DNA plasmid expressing a mutated nonfunctional E7 incapable of binding retinoblastoma protein, with no transforming activity, linked to HSP70. A signal sequence was also attached to the hybrid antigen which results in secretion of the linked E7 antigen [<a href="#B67" rid="B67" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872781">67</a>]. E7 HPV antigen as well as E6 antigen are essential for transformation and are coexpressed in HPV-associated lesions hence they represent ideal targets for the development of HPV therapeutic vaccines.</p></div><div id="sec6.5" class="sec"><h3 id="sec6.5title">6.5. Liver Cancer</h3><p id="__p95" class="p p-first">In preclinical studies, mice were successfully DNA-based immunized [<a href="#B147" rid="B147" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872792">147</a>].  In a prime-boost approach, coadministration of plasmids DNA encoding murine alpha fetoprotein (AFP) and murine GM-CSF was followed by boosting with an AFP-expressing nonreplicating adenoviral vector    [<a href="#B60" rid="B60" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872808">60</a>] leading to tumor protective immunity.</p><p id="__p96" class="p p-last">The early studies were applied in a phase I/II clinical trial in patients with HLA-A*0201-expressing stage II&#x02013;IVA hepatocellular carcinoma. Vaccine therapy, comprising AFP and sargramostim (GM-CSF) plasmids DNA, followed by AFP adenoviral vector boost determined the dose-limiting toxicity and maximum tolerated dose of adjuvant vaccination (ClinicalTrials.gov Identifier: <a id="__tag_544253157" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT00093548" ref="reftype=extlink-clinical-trial&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT00093548","term_id":"NCT00093548"}}</span>NCT00093548</a>).</p></div><div id="sec6.6" class="sec sec-last"><h3 id="sec6.6title">6.6. Breast Cancer</h3><p id="__p97" class="p p-first">Since HER-2/neu (HER2) oncogenic protein is a tumor antigen in patients with breast and ovarian cancer, several vaccine strategies have been developed and are being evaluated for safety and immunogenicity in phases I and II clinical trials (ClinicalTrials.gov). Patients whose tumors overexpress the antigen have both detectable antibody and T-cell immunity directed against HER2. Likewise preclinical studies suggest that the HER2 protein, particularly the intracellular domain (ICD), is a tumor rejection antigen [<a href="#B148" rid="B148" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872877">148</a>].</p><p id="__p98" class="p p-last">Salazar and colleagues are studying the immune response in patients overexpressessing HER2 epitope who have undergone vaccine therapy in a heterologous prime-boost regimen (ClinicalTrials.gov identifier: <a id="__tag_544253154" class="tag_hotlink" href="https://clinicaltrials.gov/ct2/show/NCT00363012" ref="reftype=extlink-clinical-trial&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CBody&amp;TO=External%7CResource%7CClinical%20Trials%7CClinicalTrials.gov"><span class="tag-json" style="display:none">{"type":"clinical-trial","attrs":{"text":"NCT00363012","term_id":"NCT00363012"}}</span>NCT00363012</a>). After vaccination with a plasmid encoding HER2 ICD in patients with advanced stage HER2 overexpressing breast and ovarian cancers patients receive HER2 ICD protein treatment intradermally at 6 months postvaccination with the pNGVL3-hICD vaccine. The injection site is biopsied and examined for infiltrating T-cell and antigen-presenting cell populations and blood samples are examined for the presence of memory markers to demonstrate the development of HER2 ICD memory immunity.</p></div></div><div id="sec7" class="tsec sec"><h2 class="head no_bottom_margin" id="sec7title">7. Conclusions and Future Directions</h2><p id="__p99" class="p p-first">Plasmid DNA is a new generation biotechnology product that is just beginning to enter the marketplace. Progress in the application of DNA vaccines as an immunization protocol is evident from the increasing number of such vaccines under evaluation in clinical trials and by the recent approval of several DNA vaccine products for veterinary applications.</p><p id="__p100">The goal of DNA vaccination will be the development of effective immunization strategies against previously established tumors. Because of tolerance to tumour antigens, efforts are ongoing to optimize the DNA vaccine technology platform. Strategies to improve antigen expression, inclusion of adjuvants in the formulation, or as immune modulators to improve the immunogenicity, and the use of next-generation delivery methods are under intensive investigation. Current effort to prioritize cancer antigens represents the logical next step in attempting to focus translational efforts on the most promising cancer antigens into vaccines for cancer treatment or prevention. It is likely that these vaccines will have to be combined with other treatment modalities. It has become appreciated that vaccine approaches may enhance subsequent responses to radiotherapy and that certain chemotherapies actually enhance responses to vaccines. Accordingly, several late-stage clinical trials are already evaluating the benefit of vaccination in addition to conventional chemotherapy. One attractive setting is in patients during complete remission after standard adjuvant treatment (chemotherapy, radiotherapy, etc., or a combination) to whom vaccination can be given after immunological recovery    [<a href="#B149" rid="B149" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_96872821">149</a>]. Combining immunotherapy with conventional chemotherapy, antiangiogenic therapy, and other approaches could yield synergistic or additive therapeutic results.</p><p id="__p101" class="p p-last">There is still much to do in terms of optimizing vaccine design, activation and selecting appropriate target antigens, improving immune recruitment, and delivery technology. Nevertheless, in the next years an increasing number of DNA vaccines will enter more advanced phases of human studies, aimed to establish their efficacy as real clinical products. Therapeutic regimens composed of optimal vaccine formulations with combinations of immunotherapy agents and delivery strategies could offer hope to patients suffering from incurable cancer that current standard therapies cannot provide alone.</p></div><div id="idm139857114970576" class="tsec sec"><h2 class="head no_bottom_margin" id="idm139857114970576title">Acknowledgments</h2><div class="sec"><p id="__p102">This work was supported by MUR Grant FIRB 2006 (RBIP0695BB), and by the Italian Banca Marche. D. Fioretti and S. Iurescia. have been supported by MUR Grant FIRB 2006 (RBIP0695BB). Both of them contributed equally to the preparation of this paper.</p></div></div><div id="idm139857114969344" class="tsec sec"><h2 class="head no_bottom_margin" id="idm139857114969344title">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="B1">1. <span class="element-citation">Hoption Cann SA, Van Netten JP, Van Netten C. Dr William Coley and tumour regression: a place in history or in the future. <span><span class="ref-journal"><em>Postgraduate Medical Journal</em>. </span>2003;<span class="ref-vol">79</span>(938):672\xe2\x80\x93680.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1742910/">PMC free article</a>]</span> [<a href="/pubmed/14707241" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Postgraduate+Medical+Journal&amp;title=Dr+William+Coley+and+tumour+regression:+a+place+in+history+or+in+the+future&amp;author=SA+Hoption+Cann&amp;author=JP+Van+Netten&amp;author=C+Van+Netten&amp;volume=79&amp;issue=938&amp;publication_year=2003&amp;pages=672-680&amp;pmid=14707241&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B2">2. <span class="element-citation">Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. <span><span class="ref-journal"><em>Annals of Oncology</em>. </span>2007;<span class="ref-vol">18</span>(3):581\xe2\x80\x93592.</span> [<a href="/pubmed/17287242" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Annals+of+Oncology&amp;title=Estimates+of+the+cancer+incidence+and+mortality+in+Europe+in+2006&amp;author=J+Ferlay&amp;author=P+Autier&amp;author=M+Boniol&amp;author=M+Heanue&amp;author=M+Colombet&amp;volume=18&amp;issue=3&amp;publication_year=2007&amp;pages=581-592&amp;pmid=17287242&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B3">3. <span class="element-citation">Varmus H. The new era in cancer research. <span><span class="ref-journal"><em>Science</em>. </span>2006;<span class="ref-vol">312</span>(5777):1162\xe2\x80\x931165.</span> [<a href="/pubmed/16728627" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=The+new+era+in+cancer+research&amp;author=H+Varmus&amp;volume=312&amp;issue=5777&amp;publication_year=2006&amp;pages=1162-1165&amp;pmid=16728627&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B4">4. <span class="element-citation">Wolff JA, Malone RW, Williams P, et al.  Direct gene transfer into mouse muscle in vivo. <span><span class="ref-journal"><em>Science</em>. </span>1990;<span class="ref-vol">247</span>(4949):1465\xe2\x80\x931468.</span> [<a href="/pubmed/1690918" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Direct+gene+transfer+into+mouse+muscle+in+vivo&amp;author=JA+Wolff&amp;author=RW+Malone&amp;author=P+Williams&amp;volume=247&amp;issue=4949&amp;publication_year=1990&amp;pages=1465-1468&amp;pmid=1690918&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B5">5. <span class="element-citation">Ulmer JB, Donnelly JJ, Parker SE, et al.  Heterologous protection against influenza by injection of DNA encoding a viral protein. <span><span class="ref-journal"><em>Science</em>. </span>1993;<span class="ref-vol">259</span>(5102):1745\xe2\x80\x931749.</span> [<a href="/pubmed/8456302" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Heterologous+protection+against+influenza+by+injection+of+DNA+encoding+a+viral+protein&amp;author=JB+Ulmer&amp;author=JJ+Donnelly&amp;author=SE+Parker&amp;volume=259&amp;issue=5102&amp;publication_year=1993&amp;pages=1745-1749&amp;pmid=8456302&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B6">6. <span class="element-citation">Wang B, Ugen KE, Srikantan V, et al.  Gene inoculation generates immune responses against human immunodeficiency virus type 1. <span><span class="ref-journal"><em>Proceedings of the National Academy of Sciences of the United States of America</em>. </span>1993;<span class="ref-vol">90</span>(9):4156\xe2\x80\x934160.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC46465/">PMC free article</a>]</span> [<a href="/pubmed/8483929" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proceedings+of+the+National+Academy+of+Sciences+of+the+United+States+of+America&amp;title=Gene+inoculation+generates+immune+responses+against+human+immunodeficiency+virus+type+1&amp;author=B+Wang&amp;author=KE+Ugen&amp;author=V+Srikantan&amp;volume=90&amp;issue=9&amp;publication_year=1993&amp;pages=4156-4160&amp;pmid=8483929&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B7">7. <span class="element-citation">Raz E, Carson DA, Parker SE, et al.  Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. <span><span class="ref-journal"><em>Proceedings of the National Academy of Sciences of the United States of America</em>. </span>1994;<span class="ref-vol">91</span>(20):9519\xe2\x80\x939523.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC44844/">PMC free article</a>]</span> [<a href="/pubmed/7937799" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proceedings+of+the+National+Academy+of+Sciences+of+the+United+States+of+America&amp;title=Intradermal+gene+immunization:+the+possible+role+of+DNA+uptake+in+the+induction+of+cellular+immunity+to+viruses&amp;author=E+Raz&amp;author=DA+Carson&amp;author=SE+Parker&amp;volume=91&amp;issue=20&amp;publication_year=1994&amp;pages=9519-9523&amp;pmid=7937799&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B8">8. <span class="element-citation">Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. <span><span class="ref-journal"><em>Annual Review of Immunology</em>. </span>1997;<span class="ref-vol">15</span>:617\xe2\x80\x93648.</span> [<a href="/pubmed/9143702" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Annual+Review+of+Immunology&amp;title=DNA+vaccines&amp;author=JJ+Donnelly&amp;author=JB+Ulmer&amp;author=JW+Shiver&amp;author=MA+Liu&amp;volume=15&amp;publication_year=1997&amp;pages=617-648&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B9">9. <span class="element-citation">Haupt K, Roggendorf M, Mann K. The potential of DNA vaccination against tumor-associated antigens for antitumor therapy. <span><span class="ref-journal"><em>Experimental Biology and Medicine</em>. </span>2002;<span class="ref-vol">227</span>(4):227\xe2\x80\x93237.</span> [<a href="/pubmed/11910045" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Experimental+Biology+and+Medicine&amp;title=The+potential+of+DNA+vaccination+against+tumor-associated+antigens+for+antitumor+therapy&amp;author=K+Haupt&amp;author=M+Roggendorf&amp;author=K+Mann&amp;volume=227&amp;issue=4&amp;publication_year=2002&amp;pages=227-237&amp;pmid=11910045&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B10">10. <span class="element-citation">Yannelli JR, Wroblewski JM. On the road to a tumor cell vaccine: 20 years of cellular immunotherapy. <span><span class="ref-journal"><em>Vaccine</em>. </span>2004;<span class="ref-vol">23</span>(1):97\xe2\x80\x93113.</span> [<a href="/pubmed/15519713" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Vaccine&amp;title=On+the+road+to+a+tumor+cell+vaccine:+20+years+of+cellular+immunotherapy&amp;author=JR+Yannelli&amp;author=JM+Wroblewski&amp;volume=23&amp;issue=1&amp;publication_year=2004&amp;pages=97-113&amp;pmid=15519713&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B11">11. <span class="element-citation">George AJ, Stevenson FK. Prospects for the treatment of B cell tumors using idiotypic vaccination. <span><span class="ref-journal"><em>International Reviews of Immunology</em>. </span>1989;<span class="ref-vol">4</span>(4):271\xe2\x80\x93310.</span> [<a href="/pubmed/2519930" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=International+Reviews+of+Immunology&amp;title=Prospects+for+the+treatment+of+B+cell+tumors+using+idiotypic+vaccination&amp;author=AJ+George&amp;author=FK+Stevenson&amp;volume=4&amp;issue=4&amp;publication_year=1989&amp;pages=271-310&amp;pmid=2519930&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B12">12. <span class="element-citation">Van der Bruggen P, Zhang Y, Chaux P, et al.  Tumor-specific shared antigenic peptides recognized by human T cells. <span><span class="ref-journal"><em>Immunological Reviews</em>. </span>2002;<span class="ref-vol">188</span>:51\xe2\x80\x9364.</span> [<a href="/pubmed/12445281" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Immunological+Reviews&amp;title=Tumor-specific+shared+antigenic+peptides+recognized+by+human+T+cells&amp;author=P+Van+der+Bruggen&amp;author=Y+Zhang&amp;author=P+Chaux&amp;volume=188&amp;publication_year=2002&amp;pages=51-64&amp;pmid=12445281&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B13">13. <span class="element-citation">Stevenson FK, Rice J, Zhu D. Tumor vaccines. <span><span class="ref-journal"><em>Advances in Immunology</em>. </span>2004;<span class="ref-vol">82</span>:49\xe2\x80\x93103.</span> [<a href="/pubmed/14975255" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Advances+in+Immunology&amp;title=Tumor+vaccines&amp;author=FK+Stevenson&amp;author=J+Rice&amp;author=D+Zhu&amp;volume=82&amp;publication_year=2004&amp;pages=49-103&amp;pmid=14975255&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B14">14. <span class="element-citation">Caballero OL, Chen Y-T. Cancer/testis (CT) antigens: potential targets for immunotherapy. <span><span class="ref-journal"><em>Cancer Science</em>. </span>2009;<span class="ref-vol">100</span>(11):2014\xe2\x80\x932021.</span> [<a href="/pubmed/19719775" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Science&amp;title=Cancer/testis+(CT)+antigens:+potential+targets+for+immunotherapy&amp;author=OL+Caballero&amp;author=Y-T+Chen&amp;volume=100&amp;issue=11&amp;publication_year=2009&amp;pages=2014-2021&amp;pmid=19719775&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B15">15. <span class="element-citation">Wang R-F, Rosenberg SA. Human tumor antigens for cancer vaccine development. <span><span class="ref-journal"><em>Immunological Reviews</em>. </span>1999;<span class="ref-vol">170</span>:85\xe2\x80\x93100.</span> [<a href="/pubmed/10566144" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Immunological+Reviews&amp;title=Human+tumor+antigens+for+cancer+vaccine+development&amp;author=R-F+Wang&amp;author=SA+Rosenberg&amp;volume=170&amp;publication_year=1999&amp;pages=85-100&amp;pmid=10566144&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B16">16. <span class="element-citation">Disis ML, Cheever MA. HER-2/neu oncogenic protein: issues in vaccine development. <span><span class="ref-journal"><em>Critical Reviews in Immunology</em>. </span>1998;<span class="ref-vol">18</span>(1-2):37\xe2\x80\x9345.</span> [<a href="/pubmed/9419446" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Critical+Reviews+in+Immunology&amp;title=HER-2/neu+oncogenic+protein:+issues+in+vaccine+development&amp;author=ML+Disis&amp;author=MA+Cheever&amp;volume=18&amp;issue=1-2&amp;publication_year=1998&amp;pages=37-45&amp;pmid=9419446&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B17">17. <span class="element-citation">Berinstein NL. Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review. <span><span class="ref-journal"><em>Journal of Clinical Oncology</em>. </span>2002;<span class="ref-vol">20</span>(8):2197\xe2\x80\x932207.</span> [<a href="/pubmed/11956282" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Clinical+Oncology&amp;title=Carcinoembryonic+antigen+as+a+target+for+therapeutic+anticancer+vaccines:+a+review&amp;author=NL+Berinstein&amp;volume=20&amp;issue=8&amp;publication_year=2002&amp;pages=2197-2207&amp;pmid=11956282&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B18">18. <span class="element-citation">Robbins PF, El-Gamil M, Kawakami Y, Rosenberg SA. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. <span><span class="ref-journal"><em>Cancer Research</em>. </span>1994;<span class="ref-vol">54</span>(12):3124\xe2\x80\x933126.</span> [<a href="/pubmed/8205528" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Research&amp;title=Recognition+of+tyrosinase+by+tumor-infiltrating+lymphocytes+from+a+patient+responding+to+immunotherapy&amp;author=PF+Robbins&amp;author=M+El-Gamil&amp;author=Y+Kawakami&amp;author=SA+Rosenberg&amp;volume=54&amp;issue=12&amp;publication_year=1994&amp;pages=3124-3126&amp;pmid=8205528&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B19">19. <span class="element-citation">Kawakami Y, Eliyahu S, Delgado CH, et al.  Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. <span><span class="ref-journal"><em>Proceedings of the National Academy of Sciences of the United States of America</em>. </span>1994;<span class="ref-vol">91</span>(9):3515\xe2\x80\x933519.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC43610/">PMC free article</a>]</span> [<a href="/pubmed/8170938" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proceedings+of+the+National+Academy+of+Sciences+of+the+United+States+of+America&amp;title=Cloning+of+the+gene+coding+for+a+shared+human+melanoma+antigen+recognized+by+autologous+T+cells+infiltrating+into+tumor&amp;author=Y+Kawakami&amp;author=S+Eliyahu&amp;author=CH+Delgado&amp;volume=91&amp;issue=9&amp;publication_year=1994&amp;pages=3515-3519&amp;pmid=8170938&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B20">20. <span class="element-citation">Kawakami Y, Eliyahu S, Delgado CH, et al.  Identification of a human melanoma antigen recognized by tumor- infiltrating lymphocytes associated with in vivo tumor rejection. <span><span class="ref-journal"><em>Proceedings of the National Academy of Sciences of the United States of America</em>. </span>1994;<span class="ref-vol">91</span>(14):6458\xe2\x80\x936462.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC44221/">PMC free article</a>]</span> [<a href="/pubmed/8022805" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proceedings+of+the+National+Academy+of+Sciences+of+the+United+States+of+America&amp;title=Identification+of+a+human+melanoma+antigen+recognized+by+tumor-+infiltrating+lymphocytes+associated+with+in+vivo+tumor+rejection&amp;author=Y+Kawakami&amp;author=S+Eliyahu&amp;author=CH+Delgado&amp;volume=91&amp;issue=14&amp;publication_year=1994&amp;pages=6458-6462&amp;pmid=8022805&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B21">21. <span class="element-citation">Doehn C, Bohmer T, Kausch I, Sommerauer M, Jocham D. Prostate cancer vaccines: current status and future potential. <span><span class="ref-journal"><em>BioDrugs</em>. </span>2008;<span class="ref-vol">22</span>(2):71\xe2\x80\x9384.</span> [<a href="/pubmed/18345705" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=BioDrugs&amp;title=Prostate+cancer+vaccines:+current+status+and+future+potential&amp;author=C+Doehn&amp;author=T+Bohmer&amp;author=I+Kausch&amp;author=M+Sommerauer&amp;author=D+Jocham&amp;volume=22&amp;issue=2&amp;publication_year=2008&amp;pages=71-84&amp;pmid=18345705&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B22">22. <span class="element-citation">Cheever MA, Allison JP, Ferris AS, et al.  The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research. <span><span class="ref-journal"><em>Clinical Cancer Research</em>. </span>2009;<span class="ref-vol">15</span>(17):5323\xe2\x80\x935337.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC5779623/">PMC free article</a>]</span> [<a href="/pubmed/19723653" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clinical+Cancer+Research&amp;title=The+prioritization+of+cancer+antigens:+a+National+Cancer+Institute+pilot+project+for+the+acceleration+of+translational+research&amp;author=MA+Cheever&amp;author=JP+Allison&amp;author=AS+Ferris&amp;volume=15&amp;issue=17&amp;publication_year=2009&amp;pages=5323-5337&amp;pmid=19723653&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B23">23. <span class="element-citation">Webster RG, Robinson HL. DNA vaccines: a review of developments. <span><span class="ref-journal"><em>BioDrugs</em>. </span>1997;<span class="ref-vol">8</span>(4):273\xe2\x80\x93292.</span> [<a href="/pubmed/18020519" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=BioDrugs&amp;title=DNA+vaccines:+a+review+of+developments&amp;author=RG+Webster&amp;author=HL+Robinson&amp;volume=8&amp;issue=4&amp;publication_year=1997&amp;pages=273-292&amp;pmid=18020519&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B24">24. <span class="element-citation">Liu MA, Ulmer JB. Human clinical trials of plasmid DNA vaccines. <span><span class="ref-journal"><em>Advances in Genetics</em>. </span>2005;<span class="ref-vol">55</span>:25\xe2\x80\x9340.</span> [<a href="/pubmed/16291211" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Advances+in+Genetics&amp;title=Human+clinical+trials+of+plasmid+DNA+vaccines&amp;author=MA+Liu&amp;author=JB+Ulmer&amp;volume=55&amp;publication_year=2005&amp;pages=25-40&amp;pmid=16291211&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B25">25. <span class="element-citation">Porgador A, Irvine KR, Iwasaki A, Barber BH, Restifo NP, Germain RN. Predominant role for directly transfected dendritic cells in antigen presentation to CD8<sup>+</sup> T cells after gene gun immunization. <span><span class="ref-journal"><em>Journal of Experimental Medicine</em>. </span>1998;<span class="ref-vol">188</span>(6):1075\xe2\x80\x931082.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2212529/">PMC free article</a>]</span> [<a href="/pubmed/9743526" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Experimental+Medicine&amp;title=Predominant+role+for+directly+transfected+dendritic+cells+in+antigen+presentation+to+CD8++T+cells+after+gene+gun+immunization&amp;author=A+Porgador&amp;author=KR+Irvine&amp;author=A+Iwasaki&amp;author=BH+Barber&amp;author=NP+Restifo&amp;volume=188&amp;issue=6&amp;publication_year=1998&amp;pages=1075-1082&amp;pmid=9743526&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B26">26. <span class="element-citation">Fu T-M, Ulmer JB, Caulfield MJ, et al.  Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. <span><span class="ref-journal"><em>Molecular Medicine</em>. </span>1997;<span class="ref-vol">3</span>(6):362\xe2\x80\x93371.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2230213/">PMC free article</a>]</span> [<a href="/pubmed/9234241" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Molecular+Medicine&amp;title=Priming+of+cytotoxic+T+lymphocytes+by+DNA+vaccines:+requirement+for+professional+antigen+presenting+cells+and+evidence+for+antigen+transfer+from+myocytes&amp;author=T-M+Fu&amp;author=JB+Ulmer&amp;author=MJ+Caulfield&amp;volume=3&amp;issue=6&amp;publication_year=1997&amp;pages=362-371&amp;pmid=9234241&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B27">27. <span class="element-citation">Torres CAT, Iwasaki A, Barber BH, Robinson HL. Differential dependence on target site tissue for gene gun and intramuscular DNA immunizations. <span><span class="ref-journal"><em>Journal of Immunology</em>. </span>1997;<span class="ref-vol">158</span>(10):4529\xe2\x80\x934532.</span> [<a href="/pubmed/9144463" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Immunology&amp;title=Differential+dependence+on+target+site+tissue+for+gene+gun+and+intramuscular+DNA+immunizations&amp;author=CAT+Torres&amp;author=A+Iwasaki&amp;author=BH+Barber&amp;author=HL+Robinson&amp;volume=158&amp;issue=10&amp;publication_year=1997&amp;pages=4529-4532&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B28">28. <span class="element-citation">Dupuis M, Denis-Mize K, Woo C, et al.  Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice. <span><span class="ref-journal"><em>Journal of Immunology</em>. </span>2000;<span class="ref-vol">165</span>(5):2850\xe2\x80\x932858.</span> [<a href="/pubmed/10946318" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Immunology&amp;title=Distribution+of+DNA+vaccines+determines+their+immunogenicity+after+intramuscular+injection+in+mice&amp;author=M+Dupuis&amp;author=K+Denis-Mize&amp;author=C+Woo&amp;volume=165&amp;issue=5&amp;publication_year=2000&amp;pages=2850-2858&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B29">29. <span class="element-citation">Haddad D, Ramprakash J, Sedegah M, et al.  Plasmid vaccine expressing granulocyte-macrophage colony-stimulating factor attracts infiltrates including immature dendritic cells into injected muscles. <span><span class="ref-journal"><em>Journal of Immunology</em>. </span>2000;<span class="ref-vol">165</span>(7):3772\xe2\x80\x933781.</span> [<a href="/pubmed/11034382" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Immunology&amp;title=Plasmid+vaccine+expressing+granulocyte-macrophage+colony-stimulating+factor+attracts+infiltrates+including+immature+dendritic+cells+into+injected+muscles&amp;author=D+Haddad&amp;author=J+Ramprakash&amp;author=M+Sedegah&amp;volume=165&amp;issue=7&amp;publication_year=2000&amp;pages=3772-3781&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B30">30. <span class="element-citation">Chattergoon MA, Robinson TM, Boyer JD, Weiner DB. Specific immune induction following DNA-based immunization through in vivo transfection and activation of macrophages/antigen-presenting cells. <span><span class="ref-journal"><em>Journal of Immunology</em>. </span>1998;<span class="ref-vol">160</span>(12):5707\xe2\x80\x935718.</span> [<a href="/pubmed/9637479" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Immunology&amp;title=Specific+immune+induction+following+DNA-based+immunization+through+in+vivo+transfection+and+activation+of+macrophages/antigen-presenting+cells&amp;author=MA+Chattergoon&amp;author=TM+Robinson&amp;author=JD+Boyer&amp;author=DB+Weiner&amp;volume=160&amp;issue=12&amp;publication_year=1998&amp;pages=5707-5718&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B31">31. <span class="element-citation">Anderson RJ, Schneider J. Plasmid DNA and viral vector-based vaccines for the treatment of cancer. <span><span class="ref-journal"><em>Vaccine</em>. </span>2007;<span class="ref-vol">25</span>(supplement 2):B24\xe2\x80\x93B34.</span> [<a href="/pubmed/17698262" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Vaccine&amp;title=Plasmid+DNA+and+viral+vector-based+vaccines+for+the+treatment+of+cancer&amp;author=RJ+Anderson&amp;author=J+Schneider&amp;volume=25&amp;issue=supplement+2&amp;publication_year=2007&amp;pages=B24-B34&amp;pmid=17698262&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B32">32. <span class="element-citation">Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization. <span><span class="ref-journal"><em>Annual Review of Immunology</em>. </span>2000;<span class="ref-vol">18</span>:927\xe2\x80\x93974.</span> [<a href="/pubmed/10837079" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Annual+Review+of+Immunology&amp;title=DNA+vaccines:+immunology,+application,+and+optimization&amp;author=S+Gurunathan&amp;author=DM+Klinman&amp;author=RA+Seder&amp;volume=18&amp;publication_year=2000&amp;pages=927-974&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B33">33. <span class="element-citation">Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. <span><span class="ref-journal"><em>Advances in Immunology</em>. </span>2006;<span class="ref-vol">90</span>:51\xe2\x80\x9381.</span> [<a href="/pubmed/16730261" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Advances+in+Immunology&amp;title=Mechanisms+of+immune+evasion+by+tumors&amp;author=CG+Drake&amp;author=E+Jaffee&amp;author=DM+Pardoll&amp;volume=90&amp;publication_year=2006&amp;pages=51-81&amp;pmid=16730261&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B34">34. <span class="element-citation">Seliger B. Strategies of tumor immune evasion. <span><span class="ref-journal"><em>BioDrugs</em>. </span>2005;<span class="ref-vol">19</span>(6):347\xe2\x80\x93354.</span> [<a href="/pubmed/16392887" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=BioDrugs&amp;title=Strategies+of+tumor+immune+evasion&amp;author=B+Seliger&amp;volume=19&amp;issue=6&amp;publication_year=2005&amp;pages=347-354&amp;pmid=16392887&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B35">35. <span class="element-citation">Lowe DB, Shearer MH, Jumper CA, Kennedy RC. Towards progress on DNA vaccines for cancer. <span><span class="ref-journal"><em>Cellular and Molecular Life Sciences</em>. </span>2007;<span class="ref-vol">64</span>(18):2391\xe2\x80\x932403.</span> [<a href="/pubmed/17565444" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cellular+and+Molecular+Life+Sciences&amp;title=Towards+progress+on+DNA+vaccines+for+cancer&amp;author=DB+Lowe&amp;author=MH+Shearer&amp;author=CA+Jumper&amp;author=RC+Kennedy&amp;volume=64&amp;issue=18&amp;publication_year=2007&amp;pages=2391-2403&amp;pmid=17565444&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B36">36. <span class="element-citation">Gregorevic P, Blankinship MJ, Chamberlain JS. Viral vectors for gene transfer to striated muscle. <span><span class="ref-journal"><em>Current Opinion in Molecular Therapeutics</em>. </span>2004;<span class="ref-vol">6</span>(5):491\xe2\x80\x93498.</span> [<a href="/pubmed/15537050" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Current+Opinion+in+Molecular+Therapeutics&amp;title=Viral+vectors+for+gene+transfer+to+striated+muscle&amp;author=P+Gregorevic&amp;author=MJ+Blankinship&amp;author=JS+Chamberlain&amp;volume=6&amp;issue=5&amp;publication_year=2004&amp;pages=491-498&amp;pmid=15537050&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B37">37. <span class="element-citation">Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al.  LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. <span><span class="ref-journal"><em>Science</em>. </span>2003;<span class="ref-vol">302</span>(5644):415\xe2\x80\x93419.</span> [<a href="/pubmed/14564000" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=LMO2-associated+clonal+T+cell+proliferation+in+two+patients+after+gene+therapy+for+SCID-X1&amp;author=S+Hacein-Bey-Abina&amp;author=C+Von+Kalle&amp;author=M+Schmidt&amp;volume=302&amp;issue=5644&amp;publication_year=2003&amp;pages=415-419&amp;pmid=14564000&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B38">38. <span class="element-citation">Fazio VM, Ria F, Franco E, et al.  Immune response at birth, long-term immune memory and 2 years follow-up after in-utero anti-HBV DNA immunization. <span><span class="ref-journal"><em>Gene Therapy</em>. </span>2004;<span class="ref-vol">11</span>(6):544\xe2\x80\x93551.</span> [<a href="/pubmed/14999226" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Gene+Therapy&amp;title=Immune+response+at+birth,+long-term+immune+memory+and+2+years+follow-up+after+in-utero+anti-HBV+DNA+immunization&amp;author=VM+Fazio&amp;author=F+Ria&amp;author=E+Franco&amp;volume=11&amp;issue=6&amp;publication_year=2004&amp;pages=544-551&amp;pmid=14999226&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B39">39. <span class="element-citation">Rinaldi M, Signori E, Rosati P, et al.  Feasibilty of in utero DNA vaccination following naked gene transfer into pig fetal muscle: transgene expression, immunity and safety. <span><span class="ref-journal"><em>Vaccine</em>. </span>2006;<span class="ref-vol">24</span>(21):4586\xe2\x80\x934591.</span> [<a href="/pubmed/16154671" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Vaccine&amp;title=Feasibilty+of+in+utero+DNA+vaccination+following+naked+gene+transfer+into+pig+fetal+muscle:+transgene+expression,+immunity+and+safety&amp;author=M+Rinaldi&amp;author=E+Signori&amp;author=P+Rosati&amp;volume=24&amp;issue=21&amp;publication_year=2006&amp;pages=4586-4591&amp;pmid=16154671&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B40">40. <span class="element-citation">MacGregor RR, Boyer JD, Ugen KE, et al.  First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. <span><span class="ref-journal"><em>Journal of Infectious Diseases</em>. </span>1998;<span class="ref-vol">178</span>(1):92\xe2\x80\x93100.</span> [<a href="/pubmed/9652427" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Infectious+Diseases&amp;title=First+human+trial+of+a+DNA-based+vaccine+for+treatment+of+human+immunodeficiency+virus+type+1+infection:+safety+and+host+response&amp;author=RR+MacGregor&amp;author=JD+Boyer&amp;author=KE+Ugen&amp;volume=178&amp;issue=1&amp;publication_year=1998&amp;pages=92-100&amp;pmid=9652427&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B41">41. <span class="element-citation">Mincheff M, Tchakarov S, Zoubak S, et al.  Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial. <span><span class="ref-journal"><em>European Urology</em>. </span>2000;<span class="ref-vol">38</span>(2):208\xe2\x80\x93217.</span> [<a href="/pubmed/10895014" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=European+Urology&amp;title=Naked+DNA+and+adenoviral+immunizations+for+immunotherapy+of+prostate+cancer:+a+phase+I/II+clinical+trial&amp;author=M+Mincheff&amp;author=S+Tchakarov&amp;author=S+Zoubak&amp;volume=38&amp;issue=2&amp;publication_year=2000&amp;pages=208-217&amp;pmid=10895014&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B42">42. <span class="element-citation">Le TP, Coonan KM, Hedstrom RC, et al.  Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. <span><span class="ref-journal"><em>Vaccine</em>. </span>2000;<span class="ref-vol">18</span>(18):1893\xe2\x80\x931901.</span> [<a href="/pubmed/10699338" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Vaccine&amp;title=Safety,+tolerability+and+humoral+immune+responses+after+intramuscular+administration+of+a+malaria+DNA+vaccine+to+healthy+adult+volunteers&amp;author=TP+Le&amp;author=KM+Coonan&amp;author=RC+Hedstrom&amp;volume=18&amp;issue=18&amp;publication_year=2000&amp;pages=1893-1901&amp;pmid=10699338&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B43">43. <span class="element-citation">Smith HA. Regulation and review of DNA vaccine products. <span><span class="ref-journal"><em>Developments in Biologicals</em>. </span>2000;<span class="ref-vol">104</span>:57\xe2\x80\x9362.</span> [<a href="/pubmed/11713825" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Developments+in+Biologicals&amp;title=Regulation+and+review+of+DNA+vaccine+products&amp;author=HA+Smith&amp;volume=104&amp;publication_year=2000&amp;pages=57-62&amp;pmid=11713825&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B44">44. <span class="element-citation">Cui Z. DNA vaccine. <span><span class="ref-journal"><em>Advances in Genetics</em>. </span>2005;<span class="ref-vol">54</span>:257\xe2\x80\x93289.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7119308/">PMC free article</a>]</span> [<a href="/pubmed/16096015" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Advances+in+Genetics&amp;title=DNA+vaccine&amp;author=Z+Cui&amp;volume=54&amp;publication_year=2005&amp;pages=257-289&amp;pmid=16096015&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B45">45. <span class="element-citation">Wolff J, Lewis DL, Herweijer H, Hegge J, Hagstrom J. Non-viral approaches for gene transfer. <span><span class="ref-journal"><em>Acta Myologica</em>. </span>2005;<span class="ref-vol">24</span>(3):202\xe2\x80\x93208.</span> [<a href="/pubmed/16629054" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Acta+Myologica&amp;title=Non-viral+approaches+for+gene+transfer&amp;author=J+Wolff&amp;author=DL+Lewis&amp;author=H+Herweijer&amp;author=J+Hegge&amp;author=J+Hagstrom&amp;volume=24&amp;issue=3&amp;publication_year=2005&amp;pages=202-208&amp;pmid=16629054&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B46">46. <span class="element-citation">Buchan S, Gr&#x000f8;nevik E, Mathiesen I, King CA, Stevenson FK, Rice J. Electroporation as a &#x0201c;prime/boost&#x0201d; strategy for naked DNA vaccination against a tumor antigen. <span><span class="ref-journal"><em>Journal of Immunology</em>. </span>2005;<span class="ref-vol">174</span>(10):6292\xe2\x80\x936298.</span> [<a href="/pubmed/15879128" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Immunology&amp;title=Electroporation+as+a+&#x0201c;prime/boost&#x0201d;+strategy+for+naked+DNA+vaccination+against+a+tumor+antigen&amp;author=S+Buchan&amp;author=E+Gr&#x000f8;nevik&amp;author=I+Mathiesen&amp;author=CA+King&amp;author=FK+Stevenson&amp;volume=174&amp;issue=10&amp;publication_year=2005&amp;pages=6292-6298&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B47">47. <span class="element-citation">Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. <span><span class="ref-journal"><em>Nature Reviews Cancer</em>. </span>2008;<span class="ref-vol">8</span>(2):108\xe2\x80\x93120.</span> [<a href="/pubmed/18219306" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature+Reviews+Cancer&amp;title=DNA+vaccines:+precision+tools+for+activating+effective+immunity+against+cancer&amp;author=J+Rice&amp;author=CH+Ottensmeier&amp;author=FK+Stevenson&amp;volume=8&amp;issue=2&amp;publication_year=2008&amp;pages=108-120&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B48">48. <span class="element-citation">Rinaldi M, Fioretti D, Iurescia S, et al.  Anti-tumor immunity induced by CDR3-based DNA vaccination in a murine B-cell lymphoma model. <span><span class="ref-journal"><em>Biochemical and Biophysical Research Communications</em>. </span>2008;<span class="ref-vol">370</span>(2):279\xe2\x80\x93284.</span> [<a href="/pubmed/18364239" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biochemical+and+Biophysical+Research+Communications&amp;title=Anti-tumor+immunity+induced+by+CDR3-based+DNA+vaccination+in+a+murine+B-cell+lymphoma+model&amp;author=M+Rinaldi&amp;author=D+Fioretti&amp;author=S+Iurescia&amp;volume=370&amp;issue=2&amp;publication_year=2008&amp;pages=279-284&amp;pmid=18364239&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B49">49. <span class="element-citation">Roos A-K, Eriksson F, Timmons JA, et al.  Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment. <span><span class="ref-journal"><em>PLoS ONE</em>. </span>2009;<span class="ref-vol">4</span>(9, article e7226)</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2748717/">PMC free article</a>]</span> [<a href="/pubmed/19789652" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=PLoS+ONE&amp;title=Skin+electroporation:+effects+on+transgene+expression,+DNA+persistence+and+local+tissue+environment&amp;author=A-K+Roos&amp;author=F+Eriksson&amp;author=JA+Timmons&amp;volume=4&amp;issue=9,+article+e7226&amp;publication_year=2009&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B50">50. <span class="element-citation">Brave A, Hallengard D, Gudmundsdotter L, et al.  Late administration of plasmid DNA by intradermal electroporation efficiently boosts DNA-primed T and B cell responses to carcinoembryonic antigen. <span><span class="ref-journal"><em>Vaccine</em>. </span>2009;<span class="ref-vol">27</span>(28):3692\xe2\x80\x933696.</span> [<a href="/pubmed/19428161" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Vaccine&amp;title=Late+administration+of+plasmid+DNA+by+intradermal+electroporation+efficiently+boosts+DNA-primed+T+and+B+cell+responses+to+carcinoembryonic+antigen&amp;author=A+Brave&amp;author=D+Hallengard&amp;author=L+Gudmundsdotter&amp;volume=27&amp;issue=28&amp;publication_year=2009&amp;pages=3692-3696&amp;pmid=19428161&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B51">51. <span class="element-citation">Trimble C, Lin C-T, Hung C-F, et al.  Comparison of the CD8<sup>+</sup> T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. <span><span class="ref-journal"><em>Vaccine</em>. </span>2003;<span class="ref-vol">21</span>(25-26):4036\xe2\x80\x934042.</span> [<a href="/pubmed/12922140" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Vaccine&amp;title=Comparison+of+the+CD8++T+cell+responses+and+antitumor+effects+generated+by+DNA+vaccine+administered+through+gene+gun,+biojector,+and+syringe&amp;author=C+Trimble&amp;author=C-T+Lin&amp;author=C-F+Hung&amp;volume=21&amp;issue=25-26&amp;publication_year=2003&amp;pages=4036-4042&amp;pmid=12922140&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B52">52. <span class="element-citation">Lou P-J, Cheng W-F, Chung Y-C, Cheng C-Y, Chiu L-H, Young T-H. PMMA particle-mediated DNA vaccine for cervical cancer. <span><span class="ref-journal"><em>Journal of Biomedical Materials Research, Part A</em>. </span>2009;<span class="ref-vol">88</span>(4):849\xe2\x80\x93857.</span> [<a href="/pubmed/18357566" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Biomedical+Materials+Research,+Part+A&amp;title=PMMA+particle-mediated+DNA+vaccine+for+cervical+cancer&amp;author=P-J+Lou&amp;author=W-F+Cheng&amp;author=Y-C+Chung&amp;author=C-Y+Cheng&amp;author=L-H+Chiu&amp;volume=88&amp;issue=4&amp;publication_year=2009&amp;pages=849-857&amp;pmid=18357566&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B53">53. <span class="element-citation">Quaak SGL, van den Berg JH, Toebes M, et al.  GMP production of pDERMATT for vaccination against melanoma in a phase I clinical trial. <span><span class="ref-journal"><em>European Journal of Pharmaceutics and Biopharmaceutics</em>. </span>2008;<span class="ref-vol">70</span>(2):429\xe2\x80\x93438.</span> [<a href="/pubmed/18606527" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=European+Journal+of+Pharmaceutics+and+Biopharmaceutics&amp;title=GMP+production+of+pDERMATT+for+vaccination+against+melanoma+in+a+phase+I+clinical+trial&amp;author=SGL+Quaak&amp;author=JH+van+den+Berg&amp;author=M+Toebes&amp;volume=70&amp;issue=2&amp;publication_year=2008&amp;pages=429-438&amp;pmid=18606527&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B54">54. <span class="element-citation">Chan RC-F, Gutierrez B, Ichim TE, Lin F. Enhancement of DNA cancer vaccine efficacy by combination with anti-angiogenesis in regression of established subcutaneous B16 melanoma. <span><span class="ref-journal"><em>Oncology Reports</em>. </span>2009;<span class="ref-vol">22</span>(5):1197\xe2\x80\x931203.</span> [<a href="/pubmed/19787240" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncology+Reports&amp;title=Enhancement+of+DNA+cancer+vaccine+efficacy+by+combination+with+anti-angiogenesis+in+regression+of+established+subcutaneous+B16+melanoma&amp;author=RC-F+Chan&amp;author=B+Gutierrez&amp;author=TE+Ichim&amp;author=F+Lin&amp;volume=22&amp;issue=5&amp;publication_year=2009&amp;pages=1197-1203&amp;pmid=19787240&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B55">55. <span class="element-citation">Settelen N, Roch O, Bock D, Rooke R, Braun S, Meyer O. Controlled plasmid gene transfer to murine renal carcinoma by hexadecylphosphocholine. <span><span class="ref-journal"><em>Journal of Controlled Release</em>. </span>2004;<span class="ref-vol">94</span>(1):237\xe2\x80\x93244.</span> [<a href="/pubmed/14684287" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Controlled+Release&amp;title=Controlled+plasmid+gene+transfer+to+murine+renal+carcinoma+by+hexadecylphosphocholine&amp;author=N+Settelen&amp;author=O+Roch&amp;author=D+Bock&amp;author=R+Rooke&amp;author=S+Braun&amp;volume=94&amp;issue=1&amp;publication_year=2004&amp;pages=237-244&amp;pmid=14684287&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B56">56. <span class="element-citation">Timmerman JM, Singh G, Hermanson G, et al.  Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. <span><span class="ref-journal"><em>Cancer Research</em>. </span>2002;<span class="ref-vol">62</span>(20):5845\xe2\x80\x935852.</span> [<a href="/pubmed/12384547" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Research&amp;title=Immunogenicity+of+a+plasmid+DNA+vaccine+encoding+chimeric+idiotype+in+patients+with+B-cell+lymphoma&amp;author=JM+Timmerman&amp;author=G+Singh&amp;author=G+Hermanson&amp;volume=62&amp;issue=20&amp;publication_year=2002&amp;pages=5845-5852&amp;pmid=12384547&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B57">57. <span class="element-citation">Rosenberg SA, Yang JC, Sherry RM, et al.  Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. <span><span class="ref-journal"><em>Human Gene Therapy</em>. </span>2003;<span class="ref-vol">14</span>(8):709\xe2\x80\x93714.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2078240/">PMC free article</a>]</span> [<a href="/pubmed/12804135" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Human+Gene+Therapy&amp;title=Inability+to+immunize+patients+with+metastatic+melanoma+using+plasmid+DNA+encoding+the+gp100+melanoma-melanocyte+antigen&amp;author=SA+Rosenberg&amp;author=JC+Yang&amp;author=RM+Sherry&amp;volume=14&amp;issue=8&amp;publication_year=2003&amp;pages=709-714&amp;pmid=12804135&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B58">58. <span class="element-citation">Todorova K, Ignatova I, Tchakarov S, et al.  Humoral immune response in prostate cancer patients after immunization with gene-based vaccines that encode for a protein that is proteasomally degraded. <span><span class="ref-journal"><em>Cancer Immunity</em>. </span>2005;<span class="ref-vol">5</span>:p. 1.</span> [<a href="/pubmed/15641767" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Immunity&amp;title=Humoral+immune+response+in+prostate+cancer+patients+after+immunization+with+gene-based+vaccines+that+encode+for+a+protein+that+is+proteasomally+degraded&amp;author=K+Todorova&amp;author=I+Ignatova&amp;author=S+Tchakarov&amp;volume=5&amp;publication_year=2005&amp;pages=p.+1&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B59">59. <span class="element-citation">Miller AM, Ozenci V, Kiessling R, Pisa P. Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer. <span><span class="ref-journal"><em>Journal of Immunotherapy</em>. </span>2005;<span class="ref-vol">28</span>(4):389\xe2\x80\x93395.</span> [<a href="/pubmed/16000958" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Immunotherapy&amp;title=Immune+monitoring+in+a+phase+1+trial+of+a+PSA+DNA+vaccine+in+patients+with+hormone-refractory+prostate+cancer&amp;author=AM+Miller&amp;author=V+Ozenci&amp;author=R+Kiessling&amp;author=P+Pisa&amp;volume=28&amp;issue=4&amp;publication_year=2005&amp;pages=389-395&amp;pmid=16000958&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B60">60. <span class="element-citation">Meng WS, Butterfield LH, Ribas A, et al.  \n\t\t\t\t\t\t<em>&#x003b1;</em>-fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. <span><span class="ref-journal"><em>Cancer Research</em>. </span>2001;<span class="ref-vol">61</span>(24):8782\xe2\x80\x938786.</span> [<a href="/pubmed/11751399" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Research&amp;title=&#10;&#9;&#9;&#9;&#9;&#9;&#9;&#x003b1;-fetoprotein-specific+tumor+immunity+induced+by+plasmid+prime-adenovirus+boost+genetic+vaccination&amp;author=WS+Meng&amp;author=LH+Butterfield&amp;author=A+Ribas&amp;volume=61&amp;issue=24&amp;publication_year=2001&amp;pages=8782-8786&amp;pmid=11751399&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B61">61. <span class="element-citation">McNeel DG, Dunphy EJ, Davies JG, et al.  Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. <span><span class="ref-journal"><em>Journal of Clinical Oncology</em>. </span>2009;<span class="ref-vol">27</span>(25):4047\xe2\x80\x934054.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2734418/">PMC free article</a>]</span> [<a href="/pubmed/19636017" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Clinical+Oncology&amp;title=Safety+and+immunological+efficacy+of+a+DNA+vaccine+encoding+prostatic+acid+phosphatase+in+patients+with+stage+D0+prostate+cancer&amp;author=DG+McNeel&amp;author=EJ+Dunphy&amp;author=JG+Davies&amp;volume=27&amp;issue=25&amp;publication_year=2009&amp;pages=4047-4054&amp;pmid=19636017&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B62">62. <span class="element-citation">Perales M-A, Yuan J, Powel S, et al.  Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma. <span><span class="ref-journal"><em>Molecular Therapy</em>. </span>2008;<span class="ref-vol">16</span>(12):2022\xe2\x80\x932029.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3909666/">PMC free article</a>]</span> [<a href="/pubmed/18797450" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Molecular+Therapy&amp;title=Phase+I/II+study+of+GM-CSF+DNA+as+an+adjuvant+for+a+multipeptide+cancer+vaccine+in+patients+with+advanced+melanoma&amp;author=M-A+Perales&amp;author=J+Yuan&amp;author=S+Powel&amp;volume=16&amp;issue=12&amp;publication_year=2008&amp;pages=2022-2029&amp;pmid=18797450&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B63">63. <span class="element-citation">Biragyn A, Kwak LW.  <span class="ref-journal"><em>Current Protocols in Immunology</em>.</span> chapter 20. 2002. Models for lymphoma; p. unit 20.6. [<a href="/pubmed/18432878" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?title=Current+Protocols+in+Immunology&amp;author=A+Biragyn&amp;author=LW+Kwak&amp;publication_year=2002&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B64">64. <span class="element-citation">Low L, Mander A, McCann K, et al.  DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. <span><span class="ref-journal"><em>Human Gene Therapy</em>. </span>2009;<span class="ref-vol">20</span>(11):1269\xe2\x80\x931278.</span> [<a href="/pubmed/19619001" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Human+Gene+Therapy&amp;title=DNA+vaccination+with+electroporation+induces+increased+antibody+responses+in+patients+with+prostate+cancer&amp;author=L+Low&amp;author=A+Mander&amp;author=K+McCann&amp;volume=20&amp;issue=11&amp;publication_year=2009&amp;pages=1269-1278&amp;pmid=19619001&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B65">65. <span class="element-citation">Mander A, Chowdhury F, Low L, Ottensmeier CH. Fit for purpose? A case study: validation of immunological endpoint assays for the detection of cellular and humoral responses to anti-tumour DNA fusion vaccines. <span><span class="ref-journal"><em>Cancer Immunology, Immunotherapy</em>. </span>2009;<span class="ref-vol">58</span>(5):789\xe2\x80\x93800.</span> [<a href="/pubmed/19066888" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Immunology,+Immunotherapy&amp;title=Fit+for+purpose?+A+case+study:+validation+of+immunological+endpoint+assays+for+the+detection+of+cellular+and+humoral+responses+to+anti-tumour+DNA+fusion+vaccines&amp;author=A+Mander&amp;author=F+Chowdhury&amp;author=L+Low&amp;author=CH+Ottensmeier&amp;volume=58&amp;issue=5&amp;publication_year=2009&amp;pages=789-800&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B66">66. <span class="element-citation">Takeshita F, Tanaka T, Matsuda T, et al.  Toll-like receptor adaptor molecules enhance DNA-raised adaptive immune responses against influenza and tumors through activation of innate immunity. <span><span class="ref-journal"><em>Journal of Virology</em>. </span>2006;<span class="ref-vol">80</span>(13):6218\xe2\x80\x936224.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1488967/">PMC free article</a>]</span> [<a href="/pubmed/16775309" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Virology&amp;title=Toll-like+receptor+adaptor+molecules+enhance+DNA-raised+adaptive+immune+responses+against+influenza+and+tumors+through+activation+of+innate+immunity&amp;author=F+Takeshita&amp;author=T+Tanaka&amp;author=T+Matsuda&amp;volume=80&amp;issue=13&amp;publication_year=2006&amp;pages=6218-6224&amp;pmid=16775309&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B67">67. <span class="element-citation">Trimble CL, Peng S, Kos F, et al.  A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. <span><span class="ref-journal"><em>Clinical Cancer Research</em>. </span>2009;<span class="ref-vol">15</span>(1):361\xe2\x80\x93367.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2865676/">PMC free article</a>]</span> [<a href="/pubmed/19118066" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clinical+Cancer+Research&amp;title=A+phase+I+trial+of+a+human+papillomavirus+DNA+vaccine+for+HPV16++cervical+intraepithelial+neoplasia+2/3&amp;author=CL+Trimble&amp;author=S+Peng&amp;author=F+Kos&amp;volume=15&amp;issue=1&amp;publication_year=2009&amp;pages=361-367&amp;pmid=19118066&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B68">68. <span class="element-citation">Lu Y, Ouyang K, Fang J, et al.  Improved efficacy of DNA vaccination against prostate carcinoma by boosting with recombinant protein vaccine and by introduction of a novel adjuvant epitope. <span><span class="ref-journal"><em>Vaccine</em>. </span>2009;<span class="ref-vol">27</span>(39):5411\xe2\x80\x935418.</span> [<a href="/pubmed/19616501" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Vaccine&amp;title=Improved+efficacy+of+DNA+vaccination+against+prostate+carcinoma+by+boosting+with+recombinant+protein+vaccine+and+by+introduction+of+a+novel+adjuvant+epitope&amp;author=Y+Lu&amp;author=K+Ouyang&amp;author=J+Fang&amp;volume=27&amp;issue=39&amp;publication_year=2009&amp;pages=5411-5418&amp;pmid=19616501&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B69">69. <span class="element-citation">Smith CL, Dunbar PR, Mirza F, et al.  Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. <span><span class="ref-journal"><em>International Journal of Cancer</em>. </span>2005;<span class="ref-vol">113</span>(2):259\xe2\x80\x93266.</span> [<a href="/pubmed/15386406" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=International+Journal+of+Cancer&amp;title=Recombinant+modified+vaccinia+Ankara+primes+functionally+activated+CTL+specific+for+a+melanoma+tumor+antigen+epitope+in+melanoma+patients+with+a+high+risk+of+disease+recurrence&amp;author=CL+Smith&amp;author=PR+Dunbar&amp;author=F+Mirza&amp;volume=113&amp;issue=2&amp;publication_year=2005&amp;pages=259-266&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B70">70. <span class="element-citation">Montgomery DL, Donnelly JJ, Shiver JW, Liu MA, Ulmer JB. Protein expression in vivo by injection of polynucleotides. <span><span class="ref-journal"><em>Current Opinion in Biotechnology</em>. </span>1994;<span class="ref-vol">5</span>(5):505\xe2\x80\x93510.</span> [<a href="/pubmed/7765464" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Current+Opinion+in+Biotechnology&amp;title=Protein+expression+in+vivo+by+injection+of+polynucleotides&amp;author=DL+Montgomery&amp;author=JJ+Donnelly&amp;author=JW+Shiver&amp;author=MA+Liu&amp;author=JB+Ulmer&amp;volume=5&amp;issue=5&amp;publication_year=1994&amp;pages=505-510&amp;pmid=7765464&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B71">71. <span class="element-citation">Dean DA, Strong DD, Zimmer WE. Nuclear entry of nonviral vectors. <span><span class="ref-journal"><em>Gene Therapy</em>. </span>2005;<span class="ref-vol">12</span>(11):881\xe2\x80\x93890.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4403635/">PMC free article</a>]</span> [<a href="/pubmed/15908994" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Gene+Therapy&amp;title=Nuclear+entry+of+nonviral+vectors&amp;author=DA+Dean&amp;author=DD+Strong&amp;author=WE+Zimmer&amp;volume=12&amp;issue=11&amp;publication_year=2005&amp;pages=881-890&amp;pmid=15908994&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B72">72. <span class="element-citation">Weide B, Garbe C, Rammensee H-G, Pascolo S. Plasmid DNA- and messenger RNA-based anti-cancer vaccination. <span><span class="ref-journal"><em>Immunology Letters</em>. </span>2008;<span class="ref-vol">115</span>(1):33\xe2\x80\x9342.</span> [<a href="/pubmed/18006079" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Immunology+Letters&amp;title=Plasmid+DNA-+and+messenger+RNA-based+anti-cancer+vaccination&amp;author=B+Weide&amp;author=C+Garbe&amp;author=H-G+Rammensee&amp;author=S+Pascolo&amp;volume=115&amp;issue=1&amp;publication_year=2008&amp;pages=33-42&amp;pmid=18006079&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B73">73. <span class="element-citation">Neelapu SS, Kwak LW. Vaccine therapy for B-cell lymphomas: next-generation strategies. <span><span class="ref-journal"><em>Hematology</em>. </span>2007;<span class="ref-vol">2007</span>(1):243\xe2\x80\x93249.</span> [<a href="/pubmed/18024636" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Hematology&amp;title=Vaccine+therapy+for+B-cell+lymphomas:+next-generation+strategies&amp;author=SS+Neelapu&amp;author=LW+Kwak&amp;volume=2007&amp;issue=1&amp;publication_year=2007&amp;pages=243-249&amp;pmid=18024636&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B74">74. <span class="element-citation">Hoebe K, Jiang Z, Tabeta K, et al.  Genetic analysis of innate immunity. <span><span class="ref-journal"><em>Advances in Immunology</em>. </span>2006;<span class="ref-vol">91</span>:175\xe2\x80\x93226.</span> [<a href="/pubmed/16938541" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Advances+in+Immunology&amp;title=Genetic+analysis+of+innate+immunity&amp;author=K+Hoebe&amp;author=Z+Jiang&amp;author=K+Tabeta&amp;volume=91&amp;publication_year=2006&amp;pages=175-226&amp;pmid=16938541&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B75">75. <span class="element-citation">Tudor D, Dubuquoy C, Gaboriau V, Lef&#x000e8;vre F, Charley B, Riffault S. TLR9 pathway is involved in adjuvant effects of plasmid DNA-based vaccines. <span><span class="ref-journal"><em>Vaccine</em>. </span>2005;<span class="ref-vol">23</span>(10):1258\xe2\x80\x931264.</span> [<a href="/pubmed/15652668" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Vaccine&amp;title=TLR9+pathway+is+involved+in+adjuvant+effects+of+plasmid+DNA-based+vaccines&amp;author=D+Tudor&amp;author=C+Dubuquoy&amp;author=V+Gaboriau&amp;author=F+Lef&#x000e8;vre&amp;author=B+Charley&amp;volume=23&amp;issue=10&amp;publication_year=2005&amp;pages=1258-1264&amp;pmid=15652668&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B76">76. <span class="element-citation">Saha S, Takeshita F, Matsuda T, et al.  Blocking of the TLR5 activation domain hampers protective potential of flagellin DNA vaccine. <span><span class="ref-journal"><em>Journal of Immunology</em>. </span>2007;<span class="ref-vol">179</span>(2):1147\xe2\x80\x931154.</span> [<a href="/pubmed/17617608" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Immunology&amp;title=Blocking+of+the+TLR5+activation+domain+hampers+protective+potential+of+flagellin+DNA+vaccine&amp;author=S+Saha&amp;author=F+Takeshita&amp;author=T+Matsuda&amp;volume=179&amp;issue=2&amp;publication_year=2007&amp;pages=1147-1154&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B77">77. <span class="element-citation">Morgan DJ, Kreuwel HTC, Sherman LA. Antigen concentration and precursor frequency determine the rate of CD8<sup>+</sup> T cell tolerance to peripherally expressed antigens. <span><span class="ref-journal"><em>Journal of Immunology</em>. </span>1999;<span class="ref-vol">163</span>(2):723\xe2\x80\x93727.</span> [<a href="/pubmed/10395663" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Immunology&amp;title=Antigen+concentration+and+precursor+frequency+determine+the+rate+of+CD8++T+cell+tolerance+to+peripherally+expressed+antigens&amp;author=DJ+Morgan&amp;author=HTC+Kreuwel&amp;author=LA+Sherman&amp;volume=163&amp;issue=2&amp;publication_year=1999&amp;pages=723-727&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B78">78. <span class="element-citation">Sandberg JK, Franksson L, Sandberg J, et al.  T cell tolerance based on avidity thresholds rather than complete deletion allows maintenance of maximal repertoire diversity. <span><span class="ref-journal"><em>Journal of Immunology</em>. </span>2000;<span class="ref-vol">165</span>(1):25\xe2\x80\x9333.</span> [<a href="/pubmed/10861031" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Immunology&amp;title=T+cell+tolerance+based+on+avidity+thresholds+rather+than+complete+deletion+allows+maintenance+of+maximal+repertoire+diversity&amp;author=JK+Sandberg&amp;author=L+Franksson&amp;author=J+Sandberg&amp;volume=165&amp;issue=1&amp;publication_year=2000&amp;pages=25-33&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B79">79. <span class="element-citation">Berzofsky JA. Epitope selection and design of synthetic vaccines. Molecular approaches to enhancing immunogenicity and cross-reactivity of engineered vaccines. <span><span class="ref-journal"><em>Annals of the New York Academy of Sciences</em>. </span>1993;<span class="ref-vol">690</span>:256\xe2\x80\x93264.</span> [<a href="/pubmed/7690214" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Annals+of+the+New+York+Academy+of+Sciences&amp;title=Epitope+selection+and+design+of+synthetic+vaccines.+Molecular+approaches+to+enhancing+immunogenicity+and+cross-reactivity+of+engineered+vaccines&amp;author=JA+Berzofsky&amp;volume=690&amp;publication_year=1993&amp;pages=256-264&amp;pmid=7690214&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B80">80. <span class="element-citation">Rammensee H-G, Friede T, Stevanovic S. MHC ligands and peptide motifs: first listing. <span><span class="ref-journal"><em>Immunogenetics</em>. </span>1995;<span class="ref-vol">41</span>(4):178\xe2\x80\x93228.</span> [<a href="/pubmed/7890324" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Immunogenetics&amp;title=MHC+ligands+and+peptide+motifs:+first+listing&amp;author=H-G+Rammensee&amp;author=T+Friede&amp;author=S+Stevanovic&amp;volume=41&amp;issue=4&amp;publication_year=1995&amp;pages=178-228&amp;pmid=7890324&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B81">81. <span class="element-citation">Ruppert J, Sidney J, Celis E, Kubo RT, Grey HM, Sette A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. <span><span class="ref-journal"><em>Cell</em>. </span>1993;<span class="ref-vol">74</span>(5):929\xe2\x80\x93937.</span> [<a href="/pubmed/8104103" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=Prominent+role+of+secondary+anchor+residues+in+peptide+binding+to+HLA-A2.1+molecules&amp;author=J+Ruppert&amp;author=J+Sidney&amp;author=E+Celis&amp;author=RT+Kubo&amp;author=HM+Grey&amp;volume=74&amp;issue=5&amp;publication_year=1993&amp;pages=929-937&amp;pmid=8104103&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B82">82. <span class="element-citation">Mok H, Lee S, Wright DW, Crowe JE., Jr. Enhancement of the CD8<sup>+</sup> T cell response to a subdominant epitope of respiratory syncytial virus by deletion of an immunodominant epitope. <span><span class="ref-journal"><em>Vaccine</em>. </span>2008;<span class="ref-vol">26</span>(37):4775\xe2\x80\x934782.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2561208/">PMC free article</a>]</span> [<a href="/pubmed/18662734" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Vaccine&amp;title=Enhancement+of+the+CD8++T+cell+response+to+a+subdominant+epitope+of+respiratory+syncytial+virus+by+deletion+of+an+immunodominant+epitope&amp;author=H+Mok&amp;author=S+Lee&amp;author=DW+Wright&amp;author=JE+Crowe&amp;volume=26&amp;issue=37&amp;publication_year=2008&amp;pages=4775-4782&amp;pmid=18662734&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B83">83. <span class="element-citation">Berzofsky JA, Ahlers JD, Belyakov IM. Strategies for designing and optimizing new generation vaccines. <span><span class="ref-journal"><em>Nature Reviews Immunology</em>. </span>2001;<span class="ref-vol">1</span>(3):209\xe2\x80\x93219.</span> [<a href="/pubmed/11905830" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature+Reviews+Immunology&amp;title=Strategies+for+designing+and+optimizing+new+generation+vaccines&amp;author=JA+Berzofsky&amp;author=JD+Ahlers&amp;author=IM+Belyakov&amp;volume=1&amp;issue=3&amp;publication_year=2001&amp;pages=209-219&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B84">84. <span class="element-citation">Leitner WW, Bergmann-Leitner ES, Hwang LN, Restifo NP. Type I Interferons are essential for the efficacy of replicase-based DNA vaccines. <span><span class="ref-journal"><em>Vaccine</em>. </span>2006;<span class="ref-vol">24</span>(24):5110\xe2\x80\x935118.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1484849/">PMC free article</a>]</span> [<a href="/pubmed/16725231" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Vaccine&amp;title=Type+I+Interferons+are+essential+for+the+efficacy+of+replicase-based+DNA+vaccines&amp;author=WW+Leitner&amp;author=ES+Bergmann-Leitner&amp;author=LN+Hwang&amp;author=NP+Restifo&amp;volume=24&amp;issue=24&amp;publication_year=2006&amp;pages=5110-5118&amp;pmid=16725231&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B85">85. <span class="element-citation">Leifert JA, Rodriguez-Carreno MP, Rodriguez F, Whitton JL. Targeting plasmid-encoded proteins to the antigen presentation pathways. <span><span class="ref-journal"><em>Immunological Reviews</em>. </span>2004;<span class="ref-vol">199</span>:40\xe2\x80\x9353.</span> [<a href="/pubmed/15233725" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Immunological+Reviews&amp;title=Targeting+plasmid-encoded+proteins+to+the+antigen+presentation+pathways&amp;author=JA+Leifert&amp;author=MP+Rodriguez-Carreno&amp;author=F+Rodriguez&amp;author=JL+Whitton&amp;volume=199&amp;publication_year=2004&amp;pages=40-53&amp;pmid=15233725&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B86">86. <span class="element-citation">Janssen EM, Lemmens EE, Wolfe T, Christen U, Von Herrath MG, Schoenberger SP. CD4<sup>+</sup> T cells are required for secondary expansion and memory in CD8<sup>+</sup> T lymphocytes. <span><span class="ref-journal"><em>Nature</em>. </span>2003;<span class="ref-vol">421</span>(6925):852\xe2\x80\x93856.</span> [<a href="/pubmed/12594515" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=CD4++T+cells+are+required+for+secondary+expansion+and+memory+in+CD8++T+lymphocytes&amp;author=EM+Janssen&amp;author=EE+Lemmens&amp;author=T+Wolfe&amp;author=U+Christen&amp;author=MG+Von+Herrath&amp;volume=421&amp;issue=6925&amp;publication_year=2003&amp;pages=852-856&amp;pmid=12594515&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B87">87. <span class="element-citation">Stevenson FK, Rice J, Ottensmeier CH, Thirdborough SM, Zhu D. DNA fusion gene vaccines against cancer: from the laboratory to the clinic. <span><span class="ref-journal"><em>Immunological Reviews</em>. </span>2004;<span class="ref-vol">199</span>:156\xe2\x80\x93180.</span> [<a href="/pubmed/15233733" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Immunological+Reviews&amp;title=DNA+fusion+gene+vaccines+against+cancer:+from+the+laboratory+to+the+clinic&amp;author=FK+Stevenson&amp;author=J+Rice&amp;author=CH+Ottensmeier&amp;author=SM+Thirdborough&amp;author=D+Zhu&amp;volume=199&amp;publication_year=2004&amp;pages=156-180&amp;pmid=15233733&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B88">88. <span class="element-citation">Stevenson FK, Ottensmeier CH, Johnson P, et al.  DNA vaccines to attack cancer. <span><span class="ref-journal"><em>Proceedings of the National Academy of Sciences of the United States of America</em>. </span>2004;<span class="ref-vol">101</span>(supplement 2):14646\xe2\x80\x9314652.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC521995/">PMC free article</a>]</span> [<a href="/pubmed/15292504" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proceedings+of+the+National+Academy+of+Sciences+of+the+United+States+of+America&amp;title=DNA+vaccines+to+attack+cancer&amp;author=FK+Stevenson&amp;author=CH+Ottensmeier&amp;author=P+Johnson&amp;volume=101&amp;issue=supplement+2&amp;publication_year=2004&amp;pages=14646-14652&amp;pmid=15292504&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B89">89. <span class="element-citation">Wang R, Doolan DL, Le TP, et al.  Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. <span><span class="ref-journal"><em>Science</em>. </span>1998;<span class="ref-vol">282</span>(5388):476\xe2\x80\x93480.</span> [<a href="/pubmed/9774275" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Induction+of+antigen-specific+cytotoxic+T+lymphocytes+in+humans+by+a+malaria+DNA+vaccine&amp;author=R+Wang&amp;author=DL+Doolan&amp;author=TP+Le&amp;volume=282&amp;issue=5388&amp;publication_year=1998&amp;pages=476-480&amp;pmid=9774275&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B90">90. <span class="element-citation">Calarota S, Bratt G, Nordlund S, et al.  Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. <span><span class="ref-journal"><em>Lancet</em>. </span>1998;<span class="ref-vol">351</span>(9112):1320\xe2\x80\x931325.</span> [<a href="/pubmed/9643795" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Cellular+cytotoxic+response+induced+by+DNA+vaccination+in+HIV-1-infected+patients&amp;author=S+Calarota&amp;author=G+Bratt&amp;author=S+Nordlund&amp;volume=351&amp;issue=9112&amp;publication_year=1998&amp;pages=1320-1325&amp;pmid=9643795&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B91">91. <span class="element-citation">Graham BS, Koup RA, Roederer M, et al.  Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. <span><span class="ref-journal"><em>Journal of Infectious Diseases</em>. </span>2006;<span class="ref-vol">194</span>(12):1650\xe2\x80\x931660.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2428069/">PMC free article</a>]</span> [<a href="/pubmed/17109336" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Infectious+Diseases&amp;title=Phase+1+safety+and+immunogenicity+evaluation+of+a+multiclade+HIV-1+DNA+candidate+vaccine&amp;author=BS+Graham&amp;author=RA+Koup&amp;author=M+Roederer&amp;volume=194&amp;issue=12&amp;publication_year=2006&amp;pages=1650-1660&amp;pmid=17109336&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B92">92. <span class="element-citation">Greenland JR, Letvin NL. Chemical adjuvants for plasmid DNA vaccines. <span><span class="ref-journal"><em>Vaccine</em>. </span>2007;<span class="ref-vol">25</span>(19):3731\xe2\x80\x933741.</span> [<a href="/pubmed/17350735" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Vaccine&amp;title=Chemical+adjuvants+for+plasmid+DNA+vaccines&amp;author=JR+Greenland&amp;author=NL+Letvin&amp;volume=25&amp;issue=19&amp;publication_year=2007&amp;pages=3731-3741&amp;pmid=17350735&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B93">93. <span class="element-citation">Dell&#x02019;Agnola C, Biragyn A. Clinical utilization of chemokines to combat cancer: the double-edged sword. <span><span class="ref-journal"><em>Expert Review of Vaccines</em>. </span>2007;<span class="ref-vol">6</span>(2):267\xe2\x80\x93283.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2262932/">PMC free article</a>]</span> [<a href="/pubmed/17408375" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Expert+Review+of+Vaccines&amp;title=Clinical+utilization+of+chemokines+to+combat+cancer:+the+double-edged+sword&amp;author=C+Dell&#x02019;Agnola&amp;author=A+Biragyn&amp;volume=6&amp;issue=2&amp;publication_year=2007&amp;pages=267-283&amp;pmid=17408375&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B94">94. <span class="element-citation">Rinaldi M, Ria F, Parrella P, et al.  Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients&#x02019; tumor cells. <span><span class="ref-journal"><em>Cancer Research</em>. </span>2001;<span class="ref-vol">61</span>(4):1555\xe2\x80\x931562.</span> [<a href="/pubmed/11245465" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Research&amp;title=Antibodies+elicited+by+naked+DNA+vaccination+against+the+complementary-determining+region+3+hypervariable+region+of+immunoglobulin+heavy+chain+idiotypic+determinants+of+B-lymphoproliferative+disorders+specifically+react+with+patients&#x02019;+tumor+cells&amp;author=M+Rinaldi&amp;author=F+Ria&amp;author=P+Parrella&amp;volume=61&amp;issue=4&amp;publication_year=2001&amp;pages=1555-1562&amp;pmid=11245465&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B95">95. <span class="element-citation">Calarota SA, Weiner DB. Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants. <span><span class="ref-journal"><em>Immunological Reviews</em>. </span>2004;<span class="ref-vol">199</span>:84\xe2\x80\x9399.</span> [<a href="/pubmed/15233728" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Immunological+Reviews&amp;title=Enhancement+of+human+immunodeficiency+virus+type+1-DNA+vaccine+potency+through+incorporation+of+T-helper+1+molecular+adjuvants&amp;author=SA+Calarota&amp;author=DB+Weiner&amp;volume=199&amp;publication_year=2004&amp;pages=84-99&amp;pmid=15233728&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B96">96. <span class="element-citation">Zhu D, Stevenson FK. DNA gene fusion vaccines against cancer. <span><span class="ref-journal"><em>Current Opinion in Molecular Therapeutics</em>. </span>2002;<span class="ref-vol">4</span>(1):41\xe2\x80\x9348.</span> [<a href="/pubmed/11883694" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Current+Opinion+in+Molecular+Therapeutics&amp;title=DNA+gene+fusion+vaccines+against+cancer&amp;author=D+Zhu&amp;author=FK+Stevenson&amp;volume=4&amp;issue=1&amp;publication_year=2002&amp;pages=41-48&amp;pmid=11883694&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B97">97. <span class="element-citation">Stevenson FK, Rice J. Optimizing cancer immunotherapy trials: back to basics. <span><span class="ref-journal"><em>European Journal of Immunology</em>. </span>2006;<span class="ref-vol">36</span>(5):1070\xe2\x80\x931073.</span> [<a href="/pubmed/16639707" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=European+Journal+of+Immunology&amp;title=Optimizing+cancer+immunotherapy+trials:+back+to+basics&amp;author=FK+Stevenson&amp;author=J+Rice&amp;volume=36&amp;issue=5&amp;publication_year=2006&amp;pages=1070-1073&amp;pmid=16639707&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B98">98. <span class="element-citation">Keene JA, Forman J. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. <span><span class="ref-journal"><em>Journal of Experimental Medicine</em>. </span>1982;<span class="ref-vol">155</span>(3):768\xe2\x80\x93782.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2186611/">PMC free article</a>]</span> [<a href="/pubmed/6801178" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Experimental+Medicine&amp;title=Helper+activity+is+required+for+the+in+vivo+generation+of+cytotoxic+T+lymphocytes&amp;author=JA+Keene&amp;author=J+Forman&amp;volume=155&amp;issue=3&amp;publication_year=1982&amp;pages=768-782&amp;pmid=6801178&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B99">99. <span class="element-citation">Von Herrath MG, Yokoyama M, Dockter J, Oldstone MBA, Whitton JL. CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. <span><span class="ref-journal"><em>Journal of Virology</em>. </span>1996;<span class="ref-vol">70</span>(2):1072\xe2\x80\x931079.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC189913/">PMC free article</a>]</span> [<a href="/pubmed/8551565" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Virology&amp;title=CD4-deficient+mice+have+reduced+levels+of+memory+cytotoxic+T+lymphocytes+after+immunization+and+show+diminished+resistance+to+subsequent+virus+challenge&amp;author=MG+Von+Herrath&amp;author=M+Yokoyama&amp;author=J+Dockter&amp;author=MBA+Oldstone&amp;author=JL+Whitton&amp;volume=70&amp;issue=2&amp;publication_year=1996&amp;pages=1072-1079&amp;pmid=8551565&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B100">100. <span class="element-citation">Elia L, Mennuni C, Storto M, et al.  Genetic vaccines against Ep-CAM break tolerance to self in a limited subset of subjects: initial identification of predictive biomarkers. <span><span class="ref-journal"><em>European Journal of Immunology</em>. </span>2006;<span class="ref-vol">36</span>(5):1337\xe2\x80\x931349.</span> [<a href="/pubmed/16619291" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=European+Journal+of+Immunology&amp;title=Genetic+vaccines+against+Ep-CAM+break+tolerance+to+self+in+a+limited+subset+of+subjects:+initial+identification+of+predictive+biomarkers&amp;author=L+Elia&amp;author=C+Mennuni&amp;author=M+Storto&amp;volume=36&amp;issue=5&amp;publication_year=2006&amp;pages=1337-1349&amp;pmid=16619291&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B101">101. <span class="element-citation">Lu S, Wang S, Grimes-Serrano JM. Current progress of DNA vaccine studies in humans. <span><span class="ref-journal"><em>Expert Review of Vaccines</em>. </span>2008;<span class="ref-vol">7</span>(2):175\xe2\x80\x93191.</span> [<a href="/pubmed/18324888" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Expert+Review+of+Vaccines&amp;title=Current+progress+of+DNA+vaccine+studies+in+humans&amp;author=S+Lu&amp;author=S+Wang&amp;author=JM+Grimes-Serrano&amp;volume=7&amp;issue=2&amp;publication_year=2008&amp;pages=175-191&amp;pmid=18324888&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B102">102. <span class="element-citation">Stopeck AT, Hersh EM, Akporiaye ET, et al.  Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. <span><span class="ref-journal"><em>Journal of Clinical Oncology</em>. </span>1997;<span class="ref-vol">15</span>(1):341\xe2\x80\x93349.</span> [<a href="/pubmed/8996161" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Clinical+Oncology&amp;title=Phase+I+study+of+direct+gene+transfer+of+an+allogeneic+histocompatibility+antigen,+HLA-B7,+in+patients+with+metastatic+melanoma&amp;author=AT+Stopeck&amp;author=EM+Hersh&amp;author=ET+Akporiaye&amp;volume=15&amp;issue=1&amp;publication_year=1997&amp;pages=341-349&amp;pmid=8996161&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B103">103. <span class="element-citation">Drape RJ, Macklin MD, Barr LJ, Jones S, Haynes JR, Dean HJ. Epidermal DNA vaccine for influenza is immunogenic in humans. <span><span class="ref-journal"><em>Vaccine</em>. </span>2006;<span class="ref-vol">24</span>(21):4475\xe2\x80\x934481.</span> [<a href="/pubmed/16150518" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Vaccine&amp;title=Epidermal+DNA+vaccine+for+influenza+is+immunogenic+in+humans&amp;author=RJ+Drape&amp;author=MD+Macklin&amp;author=LJ+Barr&amp;author=S+Jones&amp;author=JR+Haynes&amp;volume=24&amp;issue=21&amp;publication_year=2006&amp;pages=4475-4481&amp;pmid=16150518&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B104">104. <span class="element-citation">Egan MA, Megati S, Roopchand V, et al.  Rational design of a plasmid DNA vaccine capable of eliciting cell-mediated immune responses to multiple HIV antigens in mice. <span><span class="ref-journal"><em>Vaccine</em>. </span>2006;<span class="ref-vol">24</span>(21):4510\xe2\x80\x934523.</span> [<a href="/pubmed/16140439" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Vaccine&amp;title=Rational+design+of+a+plasmid+DNA+vaccine+capable+of+eliciting+cell-mediated+immune+responses+to+multiple+HIV+antigens+in+mice&amp;author=MA+Egan&amp;author=S+Megati&amp;author=V+Roopchand&amp;volume=24&amp;issue=21&amp;publication_year=2006&amp;pages=4510-4523&amp;pmid=16140439&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B105">105. <span class="element-citation">Luckay A, Sidhu MK, Kjeken R, et al.  Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. <span><span class="ref-journal"><em>Journal of Virology</em>. </span>2007;<span class="ref-vol">81</span>(10):5257\xe2\x80\x935269.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1900241/">PMC free article</a>]</span> [<a href="/pubmed/17329330" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Virology&amp;title=Effect+of+plasmid+DNA+vaccine+design+and+in+vivo+electroporation+on+the+resulting+vaccine-specific+immune+responses+in+rhesus+macaques&amp;author=A+Luckay&amp;author=MK+Sidhu&amp;author=R+Kjeken&amp;volume=81&amp;issue=10&amp;publication_year=2007&amp;pages=5257-5269&amp;pmid=17329330&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B106">106. <span class="element-citation">Ahlen G, Soderholm J, Tjelle T, et al.  In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3<sup>+</sup> T cells. <span><span class="ref-journal"><em>Journal of Immunology</em>. </span>2007;<span class="ref-vol">179</span>(7):4741\xe2\x80\x934753.</span> [<a href="/pubmed/17878373" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Immunology&amp;title=In+vivo+electroporation+enhances+the+immunogenicity+of+hepatitis+C+virus+nonstructural+3/4A+DNA+by+increased+local+DNA+uptake,+protein+expression,+inflammation,+and+infiltration+of+CD3++T+cells&amp;author=G+Ahlen&amp;author=J+Soderholm&amp;author=T+Tjelle&amp;volume=179&amp;issue=7&amp;publication_year=2007&amp;pages=4741-4753&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B107">107. <span class="element-citation">Murtaugh MP, Foss DL. Inflammatory cytokines and antigen presenting cell activation. <span><span class="ref-journal"><em>Veterinary Immunology and Immunopathology</em>. </span>2002;<span class="ref-vol">87</span>(3-4):109\xe2\x80\x93121.</span> [<a href="/pubmed/12072225" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Veterinary+Immunology+and+Immunopathology&amp;title=Inflammatory+cytokines+and+antigen+presenting+cell+activation&amp;author=MP+Murtaugh&amp;author=DL+Foss&amp;volume=87&amp;issue=3-4&amp;publication_year=2002&amp;pages=109-121&amp;pmid=12072225&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B108">108. <span class="element-citation">Liu J, Kjeken R, Mathiesen I, Barouch DH. Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation. <span><span class="ref-journal"><em>Journal of Virology</em>. </span>2008;<span class="ref-vol">82</span>(11):5643\xe2\x80\x935649.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2395223/">PMC free article</a>]</span> [<a href="/pubmed/18353952" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Virology&amp;title=Recruitment+of+antigen-presenting+cells+to+the+site+of+inoculation+and+augmentation+of+human+immunodeficiency+virus+type+1+DNA+vaccine+immunogenicity+by+in+vivo+electroporation&amp;author=J+Liu&amp;author=R+Kjeken&amp;author=I+Mathiesen&amp;author=DH+Barouch&amp;volume=82&amp;issue=11&amp;publication_year=2008&amp;pages=5643-5649&amp;pmid=18353952&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B109">109. <span class="element-citation">Bins AD, Jorritsma A, Wolkers MC, et al.  A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. <span><span class="ref-journal"><em>Nature Medicine</em>. </span>2005;<span class="ref-vol">11</span>(8):899\xe2\x80\x93904.</span> [<a href="/pubmed/15965482" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature+Medicine&amp;title=A+rapid+and+potent+DNA+vaccination+strategy+defined+by+in+vivo+monitoring+of+antigen+expression&amp;author=AD+Bins&amp;author=A+Jorritsma&amp;author=MC+Wolkers&amp;volume=11&amp;issue=8&amp;publication_year=2005&amp;pages=899-904&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B110">110. <span class="element-citation">Kelleher AD, Puls RL, Bebbington M, et al.  A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. <span><span class="ref-journal"><em>AIDS</em>. </span>2006;<span class="ref-vol">20</span>(2):294\xe2\x80\x93297.</span> [<a href="/pubmed/16511428" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=AIDS&amp;title=A+randomized,+placebo-controlled+phase+I+trial+of+DNA+prime,+recombinant+fowlpox+virus+boost+prophylactic+vaccine+for+HIV-1&amp;author=AD+Kelleher&amp;author=RL+Puls&amp;author=M+Bebbington&amp;volume=20&amp;issue=2&amp;publication_year=2006&amp;pages=294-297&amp;pmid=16511428&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B111">111. <span class="element-citation">Webster DP, Dunachie S, McConkey S, et al.  Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. <span><span class="ref-journal"><em>Vaccine</em>. </span>2006;<span class="ref-vol">24</span>(15):3026\xe2\x80\x933034.</span> [<a href="/pubmed/16488059" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Vaccine&amp;title=Safety+of+recombinant+fowlpox+strain+FP9+and+modified+vaccinia+virus+Ankara+vaccines+against+liver-stage+P.+falciparum+malaria+in+non-immune+volunteers&amp;author=DP+Webster&amp;author=S+Dunachie&amp;author=S+McConkey&amp;volume=24&amp;issue=15&amp;publication_year=2006&amp;pages=3026-3034&amp;pmid=16488059&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B112">112. <span class="element-citation">Egan MA, Chong SY, Megati S, et al.  Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus. <span><span class="ref-journal"><em>AIDS Research and Human Retroviruses</em>. </span>2005;<span class="ref-vol">21</span>(7):629\xe2\x80\x93643.</span> [<a href="/pubmed/16060834" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=AIDS+Research+and+Human+Retroviruses&amp;title=Priming+with+plasmid+DNAs+expressing+interleukin-12+and+simian+immunodeficiency+virus+gag+enhances+the+immunogenicity+and+efficacy+of+an+experimental+AIDS+vaccine+based+on+recombinant+vesicular+stomatitis+virus&amp;author=MA+Egan&amp;author=SY+Chong&amp;author=S+Megati&amp;volume=21&amp;issue=7&amp;publication_year=2005&amp;pages=629-643&amp;pmid=16060834&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B113">113. <span class="element-citation">Wang R, Epstein J, Charoenvit Y, et al.  Induction in humans of CD8<sup>+</sup> and CD4<sup>+</sup> T cell and antibody responses by sequential immunization with malaria DNA and recombinant protein. <span><span class="ref-journal"><em>Journal of Immunology</em>. </span>2004;<span class="ref-vol">172</span>(9):5561\xe2\x80\x935569.</span> [<a href="/pubmed/15100299" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Immunology&amp;title=Induction+in+humans+of+CD8++and+CD4++T+cell+and+antibody+responses+by+sequential+immunization+with+malaria+DNA+and+recombinant+protein&amp;author=R+Wang&amp;author=J+Epstein&amp;author=Y+Charoenvit&amp;volume=172&amp;issue=9&amp;publication_year=2004&amp;pages=5561-5569&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B114">114. <span class="element-citation">Wang S, Kennedy JS, West K, et al.  Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. <span><span class="ref-journal"><em>Vaccine</em>. </span>2008;<span class="ref-vol">26</span>(8):1098\xe2\x80\x931110.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2288749/">PMC free article</a>]</span> [<a href="/pubmed/18243434" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Vaccine&amp;title=Cross-subtype+antibody+and+cellular+immune+responses+induced+by+a+polyvalent+DNA+prime-protein+boost+HIV-1+vaccine+in+healthy+human+volunteers&amp;author=S+Wang&amp;author=JS+Kennedy&amp;author=K+West&amp;volume=26&amp;issue=8&amp;publication_year=2008&amp;pages=1098-1110&amp;pmid=18243434&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B115">115. <span class="element-citation">Schneider J, Gilbert SC, Hannan CM, et al.  Induction of CD8<sup>+</sup> T cells using heterologous prime-boost immunisation strategies. <span><span class="ref-journal"><em>Immunological Reviews</em>. </span>1999;<span class="ref-vol">170</span>:29\xe2\x80\x9338.</span> [<a href="/pubmed/10566139" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Immunological+Reviews&amp;title=Induction+of+CD8++T+cells+using+heterologous+prime-boost+immunisation+strategies&amp;author=J+Schneider&amp;author=SC+Gilbert&amp;author=CM+Hannan&amp;volume=170&amp;publication_year=1999&amp;pages=29-38&amp;pmid=10566139&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B116">116. <span class="element-citation">Schneider J, Gilbert SC, Blanchard TJ, et al.  Enhanced immunogenicity for CD8<sup>+</sup> T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. <span><span class="ref-journal"><em>Nature Medicine</em>. </span>1998;<span class="ref-vol">4</span>(4):397\xe2\x80\x93402.</span> [<a href="/pubmed/9546783" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature+Medicine&amp;title=Enhanced+immunogenicity+for+CD8++T+cell+induction+and+complete+protective+efficacy+of+malaria+DNA+vaccination+by+boosting+with+modified+vaccinia+virus+Ankara&amp;author=J+Schneider&amp;author=SC+Gilbert&amp;author=TJ+Blanchard&amp;volume=4&amp;issue=4&amp;publication_year=1998&amp;pages=397-402&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B117">117. <span class="element-citation">Estcourt MJ, Ramsay AJ, Brooks A, Thomson SA, Medveckzy CJ, Ramshaw IA. Prime-boost immunization generates a high frequency, high-avidity CD8<sup>+</sup> cytotoxic T lymphocyte population. <span><span class="ref-journal"><em>International Immunology</em>. </span>2002;<span class="ref-vol">14</span>(1):31\xe2\x80\x9337.</span> [<a href="/pubmed/11751749" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=International+Immunology&amp;title=Prime-boost+immunization+generates+a+high+frequency,+high-avidity+CD8++cytotoxic+T+lymphocyte+population&amp;author=MJ+Estcourt&amp;author=AJ+Ramsay&amp;author=A+Brooks&amp;author=SA+Thomson&amp;author=CJ+Medveckzy&amp;volume=14&amp;issue=1&amp;publication_year=2002&amp;pages=31-37&amp;pmid=11751749&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B118">118. <span class="element-citation">Degano P, Schneider J, Hannan CM, Gilbert SC, Hill AVS. Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: enhanced CD8<sup>+</sup> T cell immunogenicity and protective efficacy in the influenza and malaria models. <span><span class="ref-journal"><em>Vaccine</em>. </span>1999;<span class="ref-vol">18</span>(7-8):623\xe2\x80\x93632.</span> [<a href="/pubmed/10547421" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Vaccine&amp;title=Gene+gun+intradermal+DNA+immunization+followed+by+boosting+with+modified+vaccinia+virus+Ankara:+enhanced+CD8++T+cell+immunogenicity+and+protective+efficacy+in+the+influenza+and+malaria+models&amp;author=P+Degano&amp;author=J+Schneider&amp;author=CM+Hannan&amp;author=SC+Gilbert&amp;author=AVS+Hill&amp;volume=18&amp;issue=7-8&amp;publication_year=1999&amp;pages=623-632&amp;pmid=10547421&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B119">119. <span class="element-citation">Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. <span><span class="ref-journal"><em>Journal of Clinical Investigation</em>. </span>2007;<span class="ref-vol">117</span>(5):1155\xe2\x80\x931166.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1857267/">PMC free article</a>]</span> [<a href="/pubmed/17476345" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Clinical+Investigation&amp;title=Altered+macrophage+differentiation+and+immune+dysfunction+in+tumor+development&amp;author=A+Sica&amp;author=V+Bronte&amp;volume=117&amp;issue=5&amp;publication_year=2007&amp;pages=1155-1166&amp;pmid=17476345&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B120">120. <span class="element-citation">Curiel TJ. Tregs and rethinking cancer immunotherapy. <span><span class="ref-journal"><em>Journal of Clinical Investigation</em>. </span>2007;<span class="ref-vol">117</span>(5):1167\xe2\x80\x931174.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1857250/">PMC free article</a>]</span> [<a href="/pubmed/17476346" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Clinical+Investigation&amp;title=Tregs+and+rethinking+cancer+immunotherapy&amp;author=TJ+Curiel&amp;volume=117&amp;issue=5&amp;publication_year=2007&amp;pages=1167-1174&amp;pmid=17476346&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B121">121. <span class="element-citation">Collison LW, Workman CJ, Kuo TT, et al.  The inhibitory cytokine IL-35 contributes to regulatory T-cell function. <span><span class="ref-journal"><em>Nature</em>. </span>2007;<span class="ref-vol">450</span>(7169):566\xe2\x80\x93569.</span> [<a href="/pubmed/18033300" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=The+inhibitory+cytokine+IL-35+contributes+to+regulatory+T-cell+function&amp;author=LW+Collison&amp;author=CJ+Workman&amp;author=TT+Kuo&amp;volume=450&amp;issue=7169&amp;publication_year=2007&amp;pages=566-569&amp;pmid=18033300&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B122">122. <span class="element-citation">Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. <span><span class="ref-journal"><em>Journal of Clinical Investigation</em>. </span>2007;<span class="ref-vol">117</span>(5):1147\xe2\x80\x931154.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1857253/">PMC free article</a>]</span> [<a href="/pubmed/17476344" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Clinical+Investigation&amp;title=Indoleamine+2,3-dioxygenase+and+tumor-induced+tolerance&amp;author=DH+Munn&amp;author=AL+Mellor&amp;volume=117&amp;issue=5&amp;publication_year=2007&amp;pages=1147-1154&amp;pmid=17476344&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B123">123. <span class="element-citation">Emens LA, Reilly RT, Jaffee EM. Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity. <span><span class="ref-journal"><em>Endocrine-Related Cancer</em>. </span>2005;<span class="ref-vol">12</span>(1):1\xe2\x80\x9317.</span> [<a href="/pubmed/15788636" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Endocrine-Related+Cancer&amp;title=Breast+cancer+vaccines:+maximizing+cancer+treatment+by+tapping+into+host+immunity&amp;author=LA+Emens&amp;author=RT+Reilly&amp;author=EM+Jaffee&amp;volume=12&amp;issue=1&amp;publication_year=2005&amp;pages=1-17&amp;pmid=15788636&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B124">124. <span class="element-citation">Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. <span><span class="ref-journal"><em>Nature Reviews Cancer</em>. </span>2005;<span class="ref-vol">5</span>(4):263\xe2\x80\x93274.</span> [<a href="/pubmed/15776005" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature+Reviews+Cancer&amp;title=Immunosuppressive+networks+in+the+tumour+environment+and+their+therapeutic+relevance&amp;author=W+Zou&amp;volume=5&amp;issue=4&amp;publication_year=2005&amp;pages=263-274&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B125">125. <span class="element-citation">Xiang R, Luo Y, Niethammer AG, Reisfeld RA. Oral DNA vaccines target the tumor vasculature and microenvironment and suppress tumor growth and metastasis. <span><span class="ref-journal"><em>Immunological Reviews</em>. </span>2008;<span class="ref-vol">222</span>(1):117\xe2\x80\x93128.</span> [<a href="/pubmed/18363997" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Immunological+Reviews&amp;title=Oral+DNA+vaccines+target+the+tumor+vasculature+and+microenvironment+and+suppress+tumor+growth+and+metastasis&amp;author=R+Xiang&amp;author=Y+Luo&amp;author=AG+Niethammer&amp;author=RA+Reisfeld&amp;volume=222&amp;issue=1&amp;publication_year=2008&amp;pages=117-128&amp;pmid=18363997&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B126">126. <span class="element-citation">Niethammer AG, Xiang R, Becker JC, et al.  A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. <span><span class="ref-journal"><em>Nature Medicine</em>. </span>2002;<span class="ref-vol">8</span>(12):1369\xe2\x80\x931375.</span> [<a href="/pubmed/12415261" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature+Medicine&amp;title=A+DNA+vaccine+against+VEGF+receptor+2+prevents+effective+angiogenesis+and+inhibits+tumor+growth&amp;author=AG+Niethammer&amp;author=R+Xiang&amp;author=JC+Becker&amp;volume=8&amp;issue=12&amp;publication_year=2002&amp;pages=1369-1375&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B127">127. <span class="element-citation">Kaplan CD, Kruger JA, Zhou H, Luo Y, Xiang R, Reisfeld RA. A novel DNA vaccine encoding PDGFR<em>&#x003b2;</em> suppresses growth and dissemination of murine colon, lung and breast carcinoma. <span><span class="ref-journal"><em>Vaccine</em>. </span>2006;<span class="ref-vol">24</span>(47-48):6994\xe2\x80\x937002.</span> [<a href="/pubmed/17050049" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Vaccine&amp;title=A+novel+DNA+vaccine+encoding+PDGFR&#x003b2;+suppresses+growth+and+dissemination+of+murine+colon,+lung+and+breast+carcinoma&amp;author=CD+Kaplan&amp;author=JA+Kruger&amp;author=H+Zhou&amp;author=Y+Luo&amp;author=R+Xiang&amp;volume=24&amp;issue=47-48&amp;publication_year=2006&amp;pages=6994-7002&amp;pmid=17050049&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B128">128. <span class="element-citation">Sumida SM, McKay PF, Truitt DM, et al.  Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines. <span><span class="ref-journal"><em>Journal of Clinical Investigation</em>. </span>2004;<span class="ref-vol">114</span>(9):1334\xe2\x80\x931342.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC524232/">PMC free article</a>]</span> [<a href="/pubmed/15520866" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Clinical+Investigation&amp;title=Recruitment+and+expansion+of+dendritic+cells+in+vivo+potentiate+the+immunogenicity+of+plasmid+DNA+vaccines&amp;author=SM+Sumida&amp;author=PF+McKay&amp;author=DM+Truitt&amp;volume=114&amp;issue=9&amp;publication_year=2004&amp;pages=1334-1342&amp;pmid=15520866&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B129">129. <span class="element-citation">Steitz J, Bruck J, Lenz J, Knop J, Tuting T. Depletion of CD25<sup>+</sup>CD4<sup>+</sup> T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon <em>&#x003b1;</em>-induced, CD8<sup>+</sup> T-cell-dependent immune defense of B16 melanoma. <span><span class="ref-journal"><em>Cancer Research</em>. </span>2001;<span class="ref-vol">61</span>(24):8643\xe2\x80\x938646.</span> [<a href="/pubmed/11751377" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Research&amp;title=Depletion+of+CD25+CD4++T+cells+and+treatment+with+tyrosinase-related+protein+2-transduced+dendritic+cells+enhance+the+interferon+&#x003b1;-induced,+CD8++T-cell-dependent+immune+defense+of+B16+melanoma&amp;author=J+Steitz&amp;author=J+Bruck&amp;author=J+Lenz&amp;author=J+Knop&amp;author=T+Tuting&amp;volume=61&amp;issue=24&amp;publication_year=2001&amp;pages=8643-8646&amp;pmid=11751377&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B130">130. <span class="element-citation">Sutmuller RPM, Van Duivenvoorde LM, Van Elsas A, et al.  Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25<sup>+</sup> regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. <span><span class="ref-journal"><em>Journal of Experimental Medicine</em>. </span>2001;<span class="ref-vol">194</span>(6):823\xe2\x80\x93832.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2195955/">PMC free article</a>]</span> [<a href="/pubmed/11560997" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Experimental+Medicine&amp;title=Synergism+of+cytotoxic+T+lymphocyte-associated+antigen+4+blockade+and+depletion+of+CD25++regulatory+T+cells+in+antitumor+therapy+reveals+alternative+pathways+for+suppression+of+autoreactive+cytotoxic+T+lymphocyte+responses&amp;author=RPM+Sutmuller&amp;author=LM+Van+Duivenvoorde&amp;author=A+Van+Elsas&amp;volume=194&amp;issue=6&amp;publication_year=2001&amp;pages=823-832&amp;pmid=11560997&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B131">131. <span class="element-citation">Grauer OM, Nierkens S, Bennink E, et al.  CD4<sup>+</sup>FoxP3<sup>+</sup> regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglionia immune responses in vivo. <span><span class="ref-journal"><em>International Journal of Cancer</em>. </span>2007;<span class="ref-vol">121</span>(1):95\xe2\x80\x93105.</span> [<a href="/pubmed/17315190" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=International+Journal+of+Cancer&amp;title=CD4+FoxP3++regulatory+T+cells+gradually+accumulate+in+gliomas+during+tumor+growth+and+efficiently+suppress+antiglionia+immune+responses+in+vivo&amp;author=OM+Grauer&amp;author=S+Nierkens&amp;author=E+Bennink&amp;volume=121&amp;issue=1&amp;publication_year=2007&amp;pages=95-105&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B132">132. <span class="element-citation">Chen A, Liu S, Park D, Kang Y, Zheng G. Depleting intratumoral CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells via FasL protein transfer enhances the therapeutic efficacy of adoptive T cell transfer. <span><span class="ref-journal"><em>Cancer Research</em>. </span>2007;<span class="ref-vol">67</span>(3):1291\xe2\x80\x931298.</span> [<a href="/pubmed/17283166" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Research&amp;title=Depleting+intratumoral+CD4+CD25++regulatory+T+cells+via+FasL+protein+transfer+enhances+the+therapeutic+efficacy+of+adoptive+T+cell+transfer&amp;author=A+Chen&amp;author=S+Liu&amp;author=D+Park&amp;author=Y+Kang&amp;author=G+Zheng&amp;volume=67&amp;issue=3&amp;publication_year=2007&amp;pages=1291-1298&amp;pmid=17283166&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B133">133. <span class="element-citation">Knutson KL, Dang Y, Lu H, et al.  IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. <span><span class="ref-journal"><em>Journal of Immunology</em>. </span>2006;<span class="ref-vol">177</span>(1):84\xe2\x80\x9391.</span> [<a href="/pubmed/16785502" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Immunology&amp;title=IL-2+immunotoxin+therapy+modulates+tumor-associated+regulatory+T+cells+and+leads+to+lasting+immune-mediated+rejection+of+breast+cancers+in+neu-transgenic+mice&amp;author=KL+Knutson&amp;author=Y+Dang&amp;author=H+Lu&amp;volume=177&amp;issue=1&amp;publication_year=2006&amp;pages=84-91&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B134">134. <span class="element-citation">Dannull J, Su Z, Rizzieri D, et al.  Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. <span><span class="ref-journal"><em>Journal of Clinical Investigation</em>. </span>2005;<span class="ref-vol">115</span>(12):3623\xe2\x80\x933633.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1288834/">PMC free article</a>]</span> [<a href="/pubmed/16308572" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Clinical+Investigation&amp;title=Enhancement+of+vaccine-mediated+antitumor+immunity+in+cancer+patients+after+depletion+of+regulatory+T+cells&amp;author=J+Dannull&amp;author=Z+Su&amp;author=D+Rizzieri&amp;volume=115&amp;issue=12&amp;publication_year=2005&amp;pages=3623-3633&amp;pmid=16308572&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B135">135. <span class="element-citation">Mahnke K, Schonfeld K, Fondel S, et al.  Depletion of CD4<sup>+</sup>CD25<sup>+</sup> human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. <span><span class="ref-journal"><em>International Journal of Cancer</em>. </span>2007;<span class="ref-vol">120</span>(12):2723\xe2\x80\x932733.</span> [<a href="/pubmed/17315189" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=International+Journal+of+Cancer&amp;title=Depletion+of+CD4+CD25++human+regulatory+T+cells+in+vivo:+kinetics+of+Treg+depletion+and+alterations+in+immune+functions+in+vivo+and+in+vitro&amp;author=K+Mahnke&amp;author=K+Schonfeld&amp;author=S+Fondel&amp;volume=120&amp;issue=12&amp;publication_year=2007&amp;pages=2723-2733&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B136">136. <span class="element-citation">Curiel TJ, Coukos G, Zou L, et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. <span><span class="ref-journal"><em>Nature Medicine</em>. </span>2004;<span class="ref-vol">10</span>(9):942\xe2\x80\x93949.</span> [<a href="/pubmed/15322536" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature+Medicine&amp;title=Specific+recruitment+of+regulatory+T+cells+in+ovarian+carcinoma+fosters+immune+privilege+and+predicts+reduced+survival&amp;author=TJ+Curiel&amp;author=G+Coukos&amp;author=L+Zou&amp;volume=10&amp;issue=9&amp;publication_year=2004&amp;pages=942-949&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B137">137. <span class="element-citation">Li B, Lalani AS, Harding TC, et al.  Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. <span><span class="ref-journal"><em>Clinical Cancer Research</em>. </span>2006;<span class="ref-vol">12</span>(22):6808\xe2\x80\x936816.</span> [<a href="/pubmed/17121902" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clinical+Cancer+Research&amp;title=Vascular+endothelial+growth+factor+blockade+reduces+intratumoral+regulatory+T+cells+and+enhances+the+efficacy+of+a+GM-CSF-secreting+cancer+immunotherapy&amp;author=B+Li&amp;author=AS+Lalani&amp;author=TC+Harding&amp;volume=12&amp;issue=22&amp;publication_year=2006&amp;pages=6808-6816&amp;pmid=17121902&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B138">138. <span class="element-citation">Ruter J, Barnett BG, Kryczek I, et al.  Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines. <span><span class="ref-journal"><em>Frontiers in Bioscience</em>. </span>2009;<span class="ref-vol">14</span>:1761\xe2\x80\x931770.</span> [<a href="/pubmed/19273160" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Frontiers+in+Bioscience&amp;title=Altering+regulatory+T+cell+function+in+cancer+immunotherapy:+a+novel+means+to+boost+the+efficacy+of+cancer+vaccines&amp;author=J+Ruter&amp;author=BG+Barnett&amp;author=I+Kryczek&amp;volume=14&amp;publication_year=2009&amp;pages=1761-1770&amp;pmid=19273160&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B139">139. <span class="element-citation">Ledwith BJ, Manam S, Troilo PJ, et al.  Plasmid DNA vaccines: investigation of integration into host cellular DNA following intramuscular injection in mice. <span><span class="ref-journal"><em>Intervirology</em>. </span>2000;<span class="ref-vol">43</span>(4&#x02013;6):258\xe2\x80\x93272.</span> [<a href="/pubmed/11251381" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Intervirology&amp;title=Plasmid+DNA+vaccines:+investigation+of+integration+into+host+cellular+DNA+following+intramuscular+injection+in+mice&amp;author=BJ+Ledwith&amp;author=S+Manam&amp;author=PJ+Troilo&amp;volume=43&amp;issue=4&#x02013;6&amp;publication_year=2000&amp;pages=258-272&amp;pmid=11251381&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B140">140. <span class="element-citation">Sheets RL, Stein J, Manetz TS, et al.  Biodistribution of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar, without integration, despite differing plasmid backbones or gene inserts. <span><span class="ref-journal"><em>Toxicological Sciences</em>. </span>2006;<span class="ref-vol">91</span>(2):610\xe2\x80\x93619.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2377020/">PMC free article</a>]</span> [<a href="/pubmed/16569729" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Toxicological+Sciences&amp;title=Biodistribution+of+DNA+plasmid+vaccines+against+HIV-1,+Ebola,+Severe+Acute+Respiratory+Syndrome,+or+West+Nile+virus+is+similar,+without+integration,+despite+differing+plasmid+backbones+or+gene+inserts&amp;author=RL+Sheets&amp;author=J+Stein&amp;author=TS+Manetz&amp;volume=91&amp;issue=2&amp;publication_year=2006&amp;pages=610-619&amp;pmid=16569729&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B141">141. <span class="element-citation">Bagarazzi ML, Boyer JD, Javadian MA, et al.  Safety and immunogenicity of intramuscular and intravaginal delivery of HIV-1 DNA constructs to infant chimpanzees. <span><span class="ref-journal"><em>Journal of Medical Primatology</em>. </span>1997;<span class="ref-vol">26</span>(1-2):27\xe2\x80\x9333.</span> [<a href="/pubmed/9271186" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Medical+Primatology&amp;title=Safety+and+immunogenicity+of+intramuscular+and+intravaginal+delivery+of+HIV-1+DNA+constructs+to+infant+chimpanzees&amp;author=ML+Bagarazzi&amp;author=JD+Boyer&amp;author=MA+Javadian&amp;volume=26&amp;issue=1-2&amp;publication_year=1997&amp;pages=27-33&amp;pmid=9271186&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B142">142. <span class="element-citation">Hawkins RE, Zhu D, Ovecka M, et al.  Idiotypic vaccination against human B-cell lymphoma. Rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines. <span><span class="ref-journal"><em>Blood</em>. </span>1994;<span class="ref-vol">83</span>(11):3279\xe2\x80\x933288.</span> [<a href="/pubmed/8193363" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Idiotypic+vaccination+against+human+B-cell+lymphoma.+Rescue+of+variable+region+gene+sequences+from+biopsy+material+for+assembly+as+single-chain+Fv+personal+vaccines&amp;author=RE+Hawkins&amp;author=D+Zhu&amp;author=M+Ovecka&amp;volume=83&amp;issue=11&amp;publication_year=1994&amp;pages=3279-3288&amp;pmid=8193363&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B143">143. <span class="element-citation">Johnson LE, Frye TP, Arnot AR, et al.  Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP) <span><span class="ref-journal"><em>Vaccine</em>. </span>2006;<span class="ref-vol">24</span>(3):293\xe2\x80\x93303.</span> [<a href="/pubmed/16115700" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Vaccine&amp;title=Safety+and+immunological+efficacy+of+a+prostate+cancer+plasmid+DNA+vaccine+encoding+prostatic+acid+phosphatase+(PAP)&amp;author=LE+Johnson&amp;author=TP+Frye&amp;author=AR+Arnot&amp;volume=24&amp;issue=3&amp;publication_year=2006&amp;pages=293-303&amp;pmid=16115700&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B144">144. <span class="element-citation">Tagawa ST, Lee P, Snively J, et al.  Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma. <span><span class="ref-journal"><em>Cancer</em>. </span>2003;<span class="ref-vol">98</span>(1):144\xe2\x80\x93154.</span> [<a href="/pubmed/12833467" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=Phase+I+study+of+intranodal+delivery+of+a+plasmid+DNA+vaccine+for+patients+with+Stage+IV+melanoma&amp;author=ST+Tagawa&amp;author=P+Lee&amp;author=J+Snively&amp;volume=98&amp;issue=1&amp;publication_year=2003&amp;pages=144-154&amp;pmid=12833467&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B145">145. <span class="element-citation">Weber J, Boswell W, Smith J, et al.  Phase 1 trial of intranodal injection of a melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma. <span><span class="ref-journal"><em>Journal of Immunotherapy</em>. </span>2008;<span class="ref-vol">31</span>(2):215\xe2\x80\x93223.</span> [<a href="/pubmed/18481391" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Immunotherapy&amp;title=Phase+1+trial+of+intranodal+injection+of+a+melan-A/MART-1+DNA+plasmid+vaccine+in+patients+with+stage+IV+melanoma&amp;author=J+Weber&amp;author=W+Boswell&amp;author=J+Smith&amp;volume=31&amp;issue=2&amp;publication_year=2008&amp;pages=215-223&amp;pmid=18481391&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B146">146. <span class="element-citation">Kim D, Gambhira R, Karanam B, et al.  Generation and characterization of a preventive and therapeutic HPV DNA vaccine. <span><span class="ref-journal"><em>Vaccine</em>. </span>2008;<span class="ref-vol">26</span>(3):351\xe2\x80\x93360.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2258233/">PMC free article</a>]</span> [<a href="/pubmed/18096279" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Vaccine&amp;title=Generation+and+characterization+of+a+preventive+and+therapeutic+HPV+DNA+vaccine&amp;author=D+Kim&amp;author=R+Gambhira&amp;author=B+Karanam&amp;volume=26&amp;issue=3&amp;publication_year=2008&amp;pages=351-360&amp;pmid=18096279&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B147">147. <span class="element-citation">Rinaldi M, Iurescia S, Fioretti D, Ponzetto A, Carloni G. Strategies for successful vaccination against hepatocellular carcinoma. <span><span class="ref-journal"><em>International Journal of Immunopathology and Pharmacology</em>. </span>2009;<span class="ref-vol">22</span>(2):269\xe2\x80\x93277.</span> [<a href="/pubmed/19505380" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=International+Journal+of+Immunopathology+and+Pharmacology&amp;title=Strategies+for+successful+vaccination+against+hepatocellular+carcinoma&amp;author=M+Rinaldi&amp;author=S+Iurescia&amp;author=D+Fioretti&amp;author=A+Ponzetto&amp;author=G+Carloni&amp;volume=22&amp;issue=2&amp;publication_year=2009&amp;pages=269-277&amp;pmid=19505380&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B148">148. <span class="element-citation">Disis ML, Schiffman K, Guthrie K, et al.  Effect of dose on immune response in patients vaccinated with an HER-2/neu intracellular domain protein-based vaccine. <span><span class="ref-journal"><em>Journal of Clinical Oncology</em>. </span>2004;<span class="ref-vol">22</span>(10):1916\xe2\x80\x931925.</span> [<a href="/pubmed/15143085" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Journal+of+Clinical+Oncology&amp;title=Effect+of+dose+on+immune+response+in+patients+vaccinated+with+an+HER-2/neu+intracellular+domain+protein-based+vaccine&amp;author=ML+Disis&amp;author=K+Schiffman&amp;author=K+Guthrie&amp;volume=22&amp;issue=10&amp;publication_year=2004&amp;pages=1916-1925&amp;pmid=15143085&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="B149">149. <span class="element-citation">Coleman S, Clayton A, Mason MD, Jasani B, Adams M, Tabi Z. Recovery of CD8<sup>+</sup> T-cell function during systemic chemotherapy in advanced ovarian cancer. <span><span class="ref-journal"><em>Cancer Research</em>. </span>2005;<span class="ref-vol">65</span>(15):7000\xe2\x80\x937006.</span> [<a href="/pubmed/16061686" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Research&amp;title=Recovery+of+CD8++T-cell+function+during+systemic+chemotherapy+in+advanced+ovarian+cancer&amp;author=S+Coleman&amp;author=A+Clayton&amp;author=MD+Mason&amp;author=B+Jasani&amp;author=M+Adams&amp;volume=65&amp;issue=15&amp;publication_year=2005&amp;pages=7000-7006&amp;pmid=16061686&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2846346&amp;issue-id=181617&amp;journal-id=94&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div></div></div></div><!--post-content--><div class="courtesy-note whole_rhythm small"><hr />Articles from <span class="acknowledgment-journal-title">Journal of Biomedicine and Biotechnology</span> are provided here courtesy of <strong>Hindawi Limited</strong></div></div>\n            \n            \n        \n            \n        </div>\n        <!-- Book content -->\n    </div>\n    \n    <div id="rightcolumn" class="four_col col last">\n        <!-- Custom content above discovery portlets -->\n        <div class="col6">\n            \n        </div>\n        \n        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><div class="format-menu"><h2>Formats:</h2><ul><li class="selected">Article</li> | <li><a href="/pmc/articles/PMC2846346/?report=reader">PubReader</a></li> | <li class="epub-link"><a href="/pmc/articles/PMC2846346/epub/">ePub (beta)</a></li> | <li><a href="/pmc/articles/PMC2846346/pdf/JBB2010-174378.pdf">PDF (619K)</a></li> | <li><a href="#" data-citationid="PMC2846346" class="citationexporter ctxp">Citation</a></li></ul></div></div><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="share-buttons"><h2>Share</h2><ul><li class="facebook"><a href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2846346%2F"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047626" alt="Share on Facebook" />\n                             Facebook\n                        </a></li><li class="twitter"><a href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2846346%2F&amp;text=DNA%20Vaccines%3A%20Developing%20New%20Strategies%20against%20Cancer"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047627" alt="Share on Twitter" />\n                             Twitter\n                        </a></li><li class="gplus"><a href="https://plus.google.com/share?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2846346%2F"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047628" alt="Share on Google Plus" />\n                             Google+\n                        </a></li></ul></div>\n        \n        <div id="ajax-portlets" data-pmid="20368780" data-aiid="2846346" data-aid="2846346" data-iid="181617" data-domainid="94" data-domain="jbb" data-accid="PMC2846346" data-md5="1732b36fe40b1faef4ecf840a541bb12"></div>\n                \n        <!-- Custom content below discovery portlets -->\n        <div class="col7">\n            \n        </div>\n    </div>\n</div>\n\n<!-- Custom content after all -->\n<div class="col8">\n    \n</div>\n<div class="col9">\n    \n</div>\n\n<script src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>\n<script>\n    (function($){\n        $(\'.skiplink\').each(function(i, item){\n            var href = $($(item).attr(\'href\'));\n            href.attr(\'tabindex\', \'-1\').addClass(\'skiptarget\'); // ensure the target can receive focus\n            $(item).on(\'click\', function(event){\n                event.preventDefault();\n                $.scrollTo(href, 0, {\n                    onAfter: function(){\n                        href.focus();\n                    }\n                });\n            });\n        });\n    })(jQuery);\n</script>\n\n\n\n<div id="body-link-poppers"></div>\n                        </div>\n                        <div class="bottom">\n                            \n                            <div id="NCBIFooter_dynamic">\n    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>\n    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2020-04-17T20:35:12-04:00&amp;Snapshot=%2Fprojects%2FPMC%2FPMCViewer@4.46&amp;Host=ptpmc101&amp;ncbi_phid=8A1A129CE9A405F10000000004F604F1&amp;ncbi_session=8A1A129CE9A4B3F1_1270SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2846346%2F&amp;Db=pmc&amp;folderID=132&amp;Ncbi_App=pmc&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>\n    \n</div>\n\n                            <div class="footer" id="footer">\n    \n    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>\n    <div id="external-disclaimer" class="offscreen_noflow">\n        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.\n    </div>    \n    <div id="ncbifooter" class="contact_info">      \n        <div id="footer-contents-right">\n            <div id="nlm_thumb_logo">\n                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>\n            </div>\n            <div id="nih_thumb_logo">\n                <a href="https://www.nih.gov" title="NIH">NIH</a>\n            </div>\n            <div id="hhs_thumb_logo">\n                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>\n            </div>\n            <div id="usagov_thumb_logo">\n                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>\n            </div>         \n        </div>\n        \n        <div id="footer-contents-left">\n            <p class="address vcard">\n                <span class="url">\n                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for\n                        Biotechnology Information</a>,\n                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>\n                <span class="adr">\n                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>\n                    <span class="region">MD</span>, <span class="postal-code">20894</span>\n                    <span class="country-name">USA</span>\n                </span>\n            </p>\n            \n            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>\n        </div>\n    </div>\n    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    \n    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>\n</div>\n                        </div>\n                    </div>\n                    <!--/.page-->\n                </div>\n                <!--/.wrap-->\n            </div><!-- /.twelve_col -->\n        </div>\n        <!-- /.grid -->\n\n        <span class="PAFAppResources"></span>\n        \n        <!-- BESelector tab -->\n        \n        \n        \n        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=jbb&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC2846346/&amp;ncbi_app=pmc" /></noscript>\n        \n        \n        <!-- usually for JS scripts at page bottom -->\n        <!--<component id="PageFixtures" label="styles"></component>-->\n    \n\n<!-- 8A1A129CE9A4B3F1_1270SID /projects/PMC/PMCViewer@4.46 ptpmc101 v4.1.r585844 Mon, May 06 2019 02:53:16 -->\n\n<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/js/3879255/4121861/3818874/4168176/3821238/4117325/4087685/4072593/4076480/3921943/4105668/4065628.js" snapshot="pmc"></script></body>\n</html>'